INHIBITEX, INC.

The selling stockholders identified in this prospectus are offering for sale from time to time up to 8,810,581 shares of our Common Stock, $0.01 par value per share. The selling stockholders have indicated that sales of their shares of such Common Stock may be made by the methods described in the section entitled “Plan of Distribution” in this prospectus.

The selling stockholders acquired their shares from us in a private placement that closed on November 10, 2004 and is more fully described on page 74 of this prospectus under the heading “Selling Stockholders.”

Our Common Stock is quoted on the Nasdaq National Market under the symbol “INHX”. On April 11, 2005, the last reported sale price for our Common Stock was $7.74.

Investing in our stock involves a high degree of risk. See “Risk Factors” on Page 3 for information that should be considered by prospective investors.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

Neither the delivery of this prospectus, nor any sale of the shares, shall create any implication that the information in this prospectus is correct after the date hereof.

This prospectus is not an offer to or solicitation of any person in any jurisdiction in which such offer or solicitation is illegal.

Inhibitex®, MSCRAMM®, Veronate® and Aurexis® are registered trademarks of Inhibitex, Inc. MSCRAMM is an acronym for Microbial Surface Components Recognizing Adhesive Matrix Molecules.

PROSPECTUS SUMMARY

This summary does not contain all of the information you should consider before investing in our common stock. Prior to deciding to invest in our common stock, you should read this entire prospectus carefully, including the section entitled “Risk Factors” and our financial statements and the related notes to those financial statements that appear elsewhere in this prospectus. Unless otherwise specified, references in this prospectus to “Inhibitex,” the “Company,” “we,” “our” and “us” refer to Inhibitex, Inc.

Our Business

We are a biopharmaceutical company committed to the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections. We currently have two product candidates in late-stage clinical development and three product candidates in preclinical development. Our product candidates have been developed based on our expertise in MSCRAMM proteins for which we own or have licensed numerous patents and patent applications. MSCRAMM proteins are located on the surface of pathogenic organisms, such as bacteria and fungi, and play a prominent role in the process of infection. These proteins enable organisms to initiate and maintain an infection by adhering to specific sites on human tissue or implanted medical devices. Our antibody-based product candidates are designed to bind to specific MSCRAMM proteins, thereby preventing infections or reducing their severity. We believe that our antibody-based product candidates that utilize MSCRAMM proteins may provide a number of advantages over existing anti-infective therapies, including: the ability to be used prophylactically in patients where the preventive use of antibiotics is not appropriate or recommended; improved patient outcomes by reducing the incidence of secondary site infections, relapse rates, mortality and length of hospital stay; a lower likelihood of inducing patterns of drug resistance due to their mechanisms of action; and fewer side effects.

In May 2004, we commenced enrollment in a 2,000 patient Phase III clinical trial for Veronate, our lead product candidate, which we are developing for the prevention of hospital-associated infections in premature, very low birth weight, or VLBW, infants. The primary endpoint of this trial is the reduction in the frequency of S. aureus infections in VLBW infants weighing 500 to 1,250 grams. We anticipate that this trial will be fully enrolled by the end of 2005, with related data being available in the first half of 2006. Veronate has been granted Fast Track and Orphan Drug status by the FDA.

Our second product candidate, Aurexis, is currently being evaluated in a 60 patient Phase II clinical trial as a first-line, or initial, therapy in combination with antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients. The Phase II trial is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of Aurexis. We have completed the enrollment of this trial and expect to have the related data in the second quarter of 2005. We have also initiated a Phase I clinical trial of Aurexis in patients with end stage renal disease, and plan to initiate an additional clinical trial in patients with cystic fibrosis. We may also initiate additional clinical trials in patients who are undergoing cardiac surgery or in other indications in the future. Aurexis has also been granted Fast Track status by the FDA.

We have retained all worldwide rights to both Veronate and Aurexis and intend to commercialize Veronate, and potentially Aurexis, in the United States by establishing a specialized, hospital-based sales force. We currently do not have any commercialization capabilities, and it is possible that we may never be able to successfully commercialize any of our product candidates. Further, we have neither received regulatory approval for, nor derived any commercial revenues from, either of these product candidates.

We currently have three other product candidates in preclinical development, all of which are based on the use of MSCRAMM proteins. One of these candidates targets hospital-associated enterococcal infections and is the subject of a joint development agreement with Dyax Corp., and another is a human staphylococcal vaccine being developed by Wyeth that is the subject of a worldwide license and collaboration agreement.

Our Strategy

Our goal is to become a leading biopharmaceutical company that discovers, develops and commercializes novel, antibody-based products to prevent and treat serious bacterial and fungal infections in the hospital setting. In order to achieve this goal, we are focused on the following key strategies:

• complete the ongoing Phase III clinical trial and obtain regulatory approval for Veronate;

• advance the development of Aurexis, in one or more indications, and our other preclinical product candidates;

• establish a specialized, hospital-based sales force in the United States to sell Veronate and potentially our other product candidates;

• utilize our expertise in MSCRAMM proteins to discover and develop additional first-in-class product candidates; and

• expand our product portfolio through in-licensing and acquisitions.

Risks Affecting Us

We are subject to a number of risks that you should be aware of before you decide to purchase our common stock. These risks, which are discussed more fully in “Risk Factors,” include, but are not limited to, our significant dependence on the successful development and commercialization of our lead product candidate Veronate, the untested nature of our MSCRAMM approach, our need to comply with extensive governmental regulations in order to obtain approval to further develop and market our product candidates, our ability to protect our intellectual property rights and operate without infringing upon the intellectual property rights of others, our reliance on third-party vendors, suppliers and contract manufacturers, the potential for our clinical trials to fail to demonstrate therapeutic efficacy, and our expected need to raise additional capital in the future to support our operations.

Corporate Information

We were incorporated in Delaware in May 1994. Our principal executive offices are located at 1165 Sanctuary Parkway, Suite 400, Alpharetta, Georgia 30004. Our telephone number is (678) 746-1100. Our website is www.inhibitex.com. Information contained on our website is not incorporated by reference into and does not constitute part of this prospectus.

If you purchase our common stock, you will be taking on a high degree of financial risk. In deciding whether to purchase our common stock, you should carefully consider the following discussion of risks, together with the other information contained in this prospectus. The occurrence of any of the following risks could materially harm our business and financial condition and our ability to raise additional capital in the future. In that event, the market price of our common stock could decline and you could lose part or all of your investment.

Since our inception, we have invested a significant portion of our time and financial resources on the development of Veronate. We anticipate that in the near-term, our ability to generate significant product revenues will depend on the successful development and commercialization of Veronate. We believe we will need to raise additional funds before we can advance Veronate through the regulatory review and approval process and commercialization.

If the data from our ongoing Phase III clinical trial for Veronate are not satisfactory, we will not be able to proceed with the filing of a Biologic License Application, or BLA, for Veronate, or we may be forced to narrow the indication for which we seek marketing approval or perform additional Phase III trials. If we believe the results of our ongoing, or if necessary, an additional Phase III trial are satisfactory and we file a BLA for Veronate, the FDA may not accept our filing, may request additional information, require additional clinical trials, limit the approved use of such product or ultimately not grant marketing approval for Veronate. Veronate has been granted Fast Track status by the FDA. Fast Track status may qualify Veronate for expedited review by the FDA, but does not assure such an expedited review. Fast Track status may be withdrawn if the FDA believes that such status is no longer supported by data from our clinical development program. If we are not successful in commercializing Veronate, or are significantly delayed in doing so, our business will be materially harmed and we may need to curtail or cease operations.

All of our product candidates, including Veronate and Aurexis, target various MSCRAMM proteins. The use of MSCRAMM proteins to develop antibody-based products is an untested approach. These proteins have not yet been used by us or others to successfully develop any approved drugs. We may fail to produce an approved drug that targets MSCRAMM proteins, which could materially harm our business. If Phase III clinical trial results for Veronate are unsatisfactory, this may cast doubt on the viability of our MSCRAMM protein approach and our entire portfolio of product candidates.

You must evaluate us in light of the uncertainties and complexities present in a development stage biopharmaceutical company. In order to receive regulatory approval for the commercialization of our product candidates, we must conduct extensive clinical trials to demonstrate their safety and efficacy. Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Delays, or clinical setbacks or failures may occur at any time. If the enrollment of patients in our clinical trials is delayed or proceeds at a slower pace than expected, our clinical trials will take longer, and cost more, to complete.

The results of preclinical studies and prior clinical trials of our product candidates may not predict the results of later-stage clinical trials. Product candidates in later stages of clinical development may fail to

Our product candidates are subject to extensive and rigorous domestic and foreign government regulation. The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical products. Our product candidates are also subject to similar extensive regulation by foreign governments. We must provide the FDA and foreign regulatory authorities, if applicable, with clinical data that appropriately demonstrate our product candidates’ safety and efficacy in humans before they can be approved for the targeted indications. None of our product candidates has been approved for sale in the United States or any foreign market, and we cannot predict whether regulatory approval will be obtained for any product candidate that we are developing or plan to develop. The regulatory review and approval process can take many years, is dependent upon the type, complexity, and novelty of, and need for the product, requires the expenditure of substantial resources, involves post-marketing surveillance, and may involve ongoing requirements for post-marketing studies. In addition, we may encounter delays in or fail to gain regulatory approval for our product candidates, based upon additional governmental regulation resulting from future legislative or administrative action or changes in FDA policy or interpretation during the period of product development. Delays or failures in obtaining regulatory approvals may:


•	adversely affect our ability to commercialize any product candidates that we develop;

•	diminish any competitive advantages that we may have or attain; and

•	adversely affect revenues or receipt of royalties from the sale of our products.

Furthermore, any required regulatory approvals, if granted, may be withdrawn later. If we fail to comply with applicable FDA and other regulatory requirements at any time, we may be subject to restrictions, including:


•	delays in clinical trials or commercialization;

•	refusal by the FDA to review pending applications or supplements to approved applications;

•	product recalls or seizures;

•	suspension of manufacturing;

•	withdrawals of previously approved marketing applications; and

•	fines, civil penalties and criminal prosecutions.

The ability to market a pharmaceutical product outside of the United States is contingent upon receiving marketing authorization from the respective foreign regulatory authorities. Foreign regulatory approval processes typically include many, if not all, of the risks associated with the FDA as described above and may include additional risks.

We have limited experience in conducting and managing large clinical trials. We rely on third parties, including clinical research organizations, outside consultants and principal investigators to assist us in managing, monitoring and conducting our clinical trials. We rely on these vendors and individuals to assist in the recruitment of sites and patients for participation in our clinical trials, to maintain positive relations with the clinical sites and to ensure that these sites are conducting our trials in compliance with the protocol, our instructions and applicable regulations. If these third parties fail to perform satisfactorily or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the clinical trials for our product candidates may be delayed or unsuccessful. Furthermore, the FDA may inspect some of the clinical sites participating in our clinical trials, or our third party vendors’ sites, to determine if our clinical trials are being conducted according to current good clinical practices. If the FDA determines that our third-party vendors are not in compliance with applicable regulations, we may be required to delay, repeat or terminate such clinical trials. Any delay, repetition or termination of our clinical trials could materially harm our business.

We purchase plasma, which contains the specific antibodies needed to manufacture Veronate, from DCI Management Group, Inc., or DCI, under a long-term supply contract. While we have also recently entered into a long-term supply arrangement with one other supplier to provide us with plasma for the commercialization of Veronate we expect in the near-term to depend on DCI for the majority of this critical raw material. Although our agreement with this other supplier is intended to reduce our reliance on one supplier, in the event that DCI is not able to supply us pursuant to our contract with them, particularly in the near term, it may be difficult for us to find a sufficient supply of plasma from other vendors on commercially acceptable terms without undue delays, which could adversely impact our cost, as well as our ability, to manufacture Veronate on a timely basis.

The collection and testing of plasma, including screening procedures for plasma donors, is subject to extensive and strict regulation by the FDA and other foreign regulatory authorities. In the event that DCI, or any other existing or future supplier, fails to comply with these stringent regulations, it could be precluded from shipping us an adequate supply of plasma, which could adversely impact our ability to manufacture Veronate on a timely basis, if at all.

We do not own or operate any manufacturing facilities. We have contracted with third-party manufacturers to make our product candidates for our clinical trials. We also intend to rely on third-party contract manufacturers, at least for the foreseeable future, to manufacture our products if and when they are approved for sale. Our reliance on third-party contract manufacturers exposes us to a number of risks, any of which could delay or prevent the completion of our clinical trials, the regulatory approval or commercialization of our product candidates, result in higher costs, or deprive us of potential product revenues. Some of these risks include:


•	Each of our current product candidates is, and will likely continue to be, made by a single third-party contract manufacturer. We do not have alternate manufacturing plans for our product candidates at this


	time. It may be difficult or impossible for us to find alternative manufacturers on commercially acceptable terms, if at all.

•	Changing our current or future manufacturers may be difficult for us, as the number of potential contract manufacturers that would be able to make our products is limited and a change may interrupt our ability to continue with our clinical trials or supply our products to the marketplace if we obtain approval for a product candidate. In accordance with FDA-mandated current good manufacturing practices, or cGMPs, changing manufacturers will require re-validation of the manufacturing processes and procedures and may require further clinical trials, which may be costly and time consuming.

•	Our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business.

•	The manufacture of biologic products requires meeting numerous and strict safety, quality and regulatory standards. Our contract manufacturers may not produce our product candidates according to their own standards, our specifications, cGMP requirements or may otherwise manufacture material that we or the FDA may deem unusable in our clinical trials or commercially.

•	Our manufacturers’ plants may be closed as a result of a natural disaster.

•	To date, our product candidates have been manufactured in small quantities for preclinical studies and clinical trials. If we are unable to increase the manufacturing scale of, or increase the capacity for, our product candidates, their regulatory approval or commercial launch may be delayed; we may experience a shortage in supply, or the cost to manufacture our products may adversely affect the profitability of our products. We cannot assure you that we can find alternative manufacturers acceptable to us who can do so.

Drug manufacturers are subject to ongoing periodic inspections by the FDA, the United States Drug Enforcement Administration, or DEA, and corresponding state and foreign agencies to ensure strict compliance with cGMPs, other government regulations and corresponding foreign standards. While we are obligated to audit their performance, we do not have control over our third-party manufacturers’ compliance with these regulations and standards. Failure by our third-party manufacturers, or us, to comply with applicable regulations could result in sanctions being imposed on us or the drug manufacturer from the production of other third-party product. These sanctions include fines, injunctions, civil penalties, failure of the government to grant pre-market approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.

In December 2001, we entered into a ten-year contract manufacturing agreement with Nabi Biopharmaceuticals, Inc., or Nabi, to be our contract manufacturer for Veronate. Nabi is a publicly-held company that discovers, develops, manufactures and markets antibody-based products. Nabi has antibody based product candidates currently being evaluated in various stages of clinical trials that are directed towards preventing staphylococcal infections, one of which could potentially compete with Veronate, if approved. Nabi’s other antibody-based product candidate could potentially compete with our staphylococcal vaccine that is the subject of our worldwide license and collaboration agreement with Wyeth. Under our agreement with Nabi, we may not be able to engage any other third party to manufacture Veronate until our agreement with Nabi is terminated. If we fail to maintain or renew our manufacturing agreement with Nabi, the development and commercialization of Veronate could be delayed or adversely affected.

Since inception through December 31, 2004, we have incurred a cumulative deficit of approximately $103.0 million. Our losses to date have resulted principally from:


•	costs related to our research programs and the preclinical development of our product candidates; and

•	general and administrative costs relating to our operations.

We anticipate incurring substantial and increasing losses for the foreseeable future as we further develop our product candidates, particularly Veronate, which will require us to conduct significant research and laboratory testing, conduct clinical trials, as well as seek regulatory approvals. In addition, we intend to establish a hospital-based sales force in the United States to market and sell Veronate, and potentially Aurexis and our other product candidates. We also expect that our general and administrative expenses will increase as we add additional personnel to support our operations. We cannot assure you that we will ever become profitable.

We expect that our need for additional capital will be substantial and the extent of this need will depend on many factors, some of which are beyond our control, including:


•	the successful and continued development of our product candidates in preclinical and clinical testing;

•	the establishment of marketing and sales capabilities and the costs to commercialize our product candidates;

•	the costs associated with protecting and expanding our patent and other intellectual property rights;

•	future payments, if any, received or made under existing or possible future collaborative arrangements;

•	the timing of regulatory approvals needed to market our product candidates;

•	market acceptance of our products; and

•	the need to acquire licenses to new products or compounds.

We anticipate that our existing cash, cash equivalents and short-term investments will enable us to operate for a period of approximately 21 months. We have no committed sources of additional capital. We cannot assure you that funds will be available to us in the future on favorable terms, if at all. If adequate funds are not available to us on terms that we find acceptable, or at all, we may be required to delay, reduce the scope of, or eliminate research and development efforts or clinical trials on any or all of our product candidates. We may also be forced to curtail or restructure our operations, obtain funds by entering into arrangements with collaborators on unattractive terms or relinquish rights to certain technologies or product candidates that we would not otherwise relinquish in order to continue independent operations.

We expect to enter into and rely on collaborations with third parties to develop and/or commercialize our product candidates outside of the United States and in certain circumstances, in the United States. If we do so, such collaborators may not perform as agreed, fail to comply with strict regulations or elect to delay or terminate their efforts in developing or commercializing our product candidates. We currently have collaborations with Dyax Corp. to jointly develop a monoclonal antibody that targets MSCRAMM proteins on enterococci and with Wyeth to develop a vaccine to prevent staphylococcal infections in humans. We believe these collaborations are necessary for us to fund research and development activities, provide a suitable manufacturer, obtain regulatory approvals and to successfully commercialize any product candidates that result form these collaborations. We cannot assure you that any product candidates will

Our success depends in part on our ability to attract and retain highly qualified management and personnel and academic scientists and clinicians as advisors or consultants. We are currently dependent upon the efforts of our executive officers, each of whom is party to an employment agreement with us. In order to pursue our product development and commercialization strategies, we will need to attract and hire additional personnel with experience in a number of disciplines, including clinical testing, government regulation, manufacturing, sales and marketing, drug reimbursement and information systems. Although we have not had material difficulties in attracting and retaining key personnel in the past, we may not be able to continue to attract and retain such personnel on acceptable terms, if at all. If we lose any key employees, or are unable to attract and retain qualified personnel or advisors, our business may be harmed.

The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Our current and potential competitors generally include, among others, major multinational pharmaceutical companies, biotechnology firms, universities and other research institutions. In particular, we are aware that Nabi, Biosynexus, Inc., and NeuTec PLC are developing protein-based product candidates, including antibodies, enzymes and peptides, for the prevention and treatment of staphylococcal infections. These companies have commenced clinical trials for these product candidates. Some of these companies and institutions, either alone or together with their collaborators, have substantially greater financial resources and larger research and development staffs than we do. In addition, many of these competitors, either alone or together with their collaborators, have significantly greater experience than we do in discovering, developing, manufacturing and marketing products. Developments by others may render our product candidates or technologies obsolete or noncompetitive.

We face, and will continue to face, intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions, for attracting investigators and sites capable of conducting our clinical trials and for licenses of proprietary technology. These competitors, either alone or with their collaborators, may succeed in developing technologies or products that are more effective, less expensive or easier to administer than ours. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals for their drug candidates more rapidly than we can. Companies that complete clinical trials, obtain required regulatory approvals and commercialize their drugs before their competitors may achieve a significant competitive advantage, including certain patent and FDA marketing exclusivity rights that could delay the ability of competitors to market certain products. We cannot assure you that product candidates resulting from our research and development efforts, or from joint efforts with our collaborators, will be able to compete successfully with our competitors’ existing products or products under development.

Our lead product candidate, Veronate, has been granted Orphan Drug status by the FDA for the reduction of nosocomial bacteremia caused by staphylococci in very low birth weight, or VLBW, infants. We believe that several of our other product candidates may also target Orphan Drug indications, which are indications where the intended patient population in the United States is less than 200,000 individuals. Orphan Drug status in the United States is intended to provide, subject to certain limited exceptions,

Even if we successfully develop our product candidates and obtain the requisite regulatory approvals to sell them in the future, they may not gain market acceptance or utilization among physicians and patients, or reimbursement and support from third-party payers. The degree of market acceptance for any product that we commercialize will depend on a number of factors, including:


•	the product’s potential advantages over existing or alternative therapies;

•	the actual or perceived safety of similar classes of products;

•	the effectiveness of our sales, marketing and distribution capabilities; and

•	the scope of the product label approved by the FDA.

There can be no assurance that hospitals or physicians will choose to administer our products to their intended patient population. If our products do not achieve meaningful market acceptance or if the market for our products proves to be smaller than anticipated, we may not generate significant revenues or ever become profitable.


•	obtain patents or rights to patents and maintain their validity;

•	protect our trade secrets;

•	operate without infringing upon the proprietary rights of others; and

•	prevent others from infringing on our proprietary rights or patents.

We will be able to protect our proprietary intellectual property rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biopharmaceutical companies involves complex legal and factual questions, and, therefore, we cannot predict with certainty whether we will be able to ultimately enforce our patents or proprietary rights. Any patents that we own or licenses we have rights to may be challenged, invalidated or circumvented, and may not provide us with the protection against competitors that we anticipate. Accordingly, we may be forced to engage in costly and time consuming litigation in order to protect our intellectual property rights. Our pending patent applications, or those we may file or license from third parties in the future, may not result in patents being issued. Until a patent is issued, the claims covered by the patent may be narrowed or removed entirely and therefore we may not obtain adequate patent protection. As a result, we may face unanticipated competition, or conclude that without patent rights the risk of bringing product candidates to the market is too great, thus adversely affecting our operating results. Because of the extensive time required for the development, testing and regulatory review of a product candidate, it is possible that before any of our product candidates can be approved for sale and commercialized, our relevant patent rights may expire or remain in force for only a short period following commercialization. Patent expiration could adversely affect our ability to protect future product development and, consequently, our operating results and financial position. Also, patent rights may not provide us with adequate proprietary protection or competitive

In addition to patents, we rely on trade secrets and proprietary know-how. We seek to protect these, in part, through confidentiality and non-disclosure agreements. These agreements may not provide meaningful protection or adequate remedies for our technology in the event of unauthorized use or disclosure of confidential and proprietary information. Failure to protect our trade secrets and proprietary know-how could seriously impair our competitive position and harm our business. We may become involved in costly litigation in order to enforce patent rights or protect trade secrets or know-how that we own or license.

Our commercial success depends in part on our ability to operate without infringing the patents and other proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. The defense and prosecution of intellectual property claims, United States Patent and Trademark Office interference proceedings and related legal and administrative proceedings in the United States and internationally involve complex legal and factual questions. As a result, such proceedings are lengthy, costly and time-consuming and their outcome is uncertain. We may become involved in litigation in order to determine the enforceability, scope and validity of the proprietary rights of others.

Scientific research has been conducted for many years in the areas in which we have focused our research and development efforts, which has resulted in third parties having a number of issued patents and still-pending patent applications. Patent applications in the United States are, in most cases, maintained in secrecy until the patent is issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made. Therefore, patent applications relating to products similar to our product candidates may have already been filed by others without our knowledge. In the event an infringement claim is brought against us, we may be required to pay substantial legal and other expenses to defend such a claim and, if we are unsuccessful in defending the claim, we may be prevented from pursuing related product development and commercialization and may be subject to damage awards.

If we become involved in any patent litigation, interference or other administrative proceedings, we will incur substantial expense, and the efforts of our technical and management personnel will be significantly diverted. A detrimental outcome of such litigation or proceedings may expose us to loss of our proprietary position or to significant liabilities, or require us to seek licenses that may not be available from third parties on commercially acceptable terms, if at all. We may be restricted or prevented from developing, manufacturing and selling our product candidates in the event of an adverse determination in a judicial or administrative proceeding or if we fail to obtain necessary licenses.

Our current and future product candidates may be covered by third-party patents or other intellectual property rights, in which case we would need to obtain a license or sublicense to these rights in order to develop or commercialize them. Any required licenses may not be available to us on acceptable terms, if at all. If we do not obtain any required licenses or sublicenses, we could encounter delays in the development of our product candidates or be prevented from manufacturing and commercializing our products. If it is determined that we have infringed an issued patent, we could be compelled to pay significant damages, including punitive damages. In cases where we have in-licensed intellectual property, our failure to comply with the terms and conditions of such agreements could harm our business.

Biosynexus, Inc. filed suit against us in January 2003 in the Superior Court of Fulton County, Georgia, alleging the misappropriation of trade secrets, which we purportedly received through a large, nationally recognized third-party contract research organization and utilized in the design of clinical trials for Veronate. In its suit, Biosynexus is seeking injunctive relief as well as financial damages. As described under “Competition,” we believe Biosynexus is developing a monoclonal antibody against staphylococcal organisms for use in the pediatric market. In July 2003, the court denied Biosynexus’ request for injunctive

We intend to sell Veronate, and possibly Aurexis, through our own hospital-based sales force in the United States and establish relationships with other companies to commercialize them in other countries around the world. We currently have no internal sales and marketing capabilities, or an infrastructure to support such activities, and have no experience in the commercialization of hospital-based pharmaceutical products. Therefore, our future profitability will depend in part on our ability to develop a capable hospital-based sales force and suitable marketing capabilities. The development of our own hospital-based sales force and marketing capabilities will result in us incurring significant costs before the time that we may generate significant revenues. We may not be able to attract and retain qualified marketing or sales personnel, or be able to establish an effective hospital-based sales force. To the extent that we enter into marketing and sales arrangements with other companies to sell, promote or market our products in the United States or abroad, our product revenues will depend on their efforts, which may not be successful.

Hospital-based products are typically distributed through third-party distributors rather than directly through the organization conducting the sale and marketing of the product. Our ability to accurately forecast our sales will be directly linked to the quality and timeliness of inventory information provided by these third-party distributors.

In both the United States and foreign markets, our product revenues will depend principally upon the reimbursement rates established by third-party payers for our products. Such third-party payers include government health administration authorities, managed-care providers, private health insurers and other organizations. These third-party payers are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status, if any, of newly approved drugs or pharmaceutical products. We may need to conduct post-marketing clinical trials in order to demonstrate the cost-effectiveness of our products. Such studies may require us to commit a significant amount of management time and financial and other resources. We cannot assure you that our products will be reimbursed in part or at all by any of these third-party payers.

Domestic and foreign governments continue to propose and pass legislation designed to reduce the cost of healthcare, including drugs. In some foreign markets, governments control prescription drugs’ pricing and profitability. In the United States, we expect that there will continue to be federal and state proposals to implement similar governmental control. In addition, increasing emphasis on managed care in the United States will continue to put pressure on the pricing of pharmaceutical products. Cost control initiatives could decrease the price that we receive for any products in the future, which would limit our revenues and profitability. Accordingly, legislation and regulations affecting the pricing of pharmaceutical products may change before our product candidates are approved for sale, which could further limit or eliminate reimbursement rates for our products.

Veronate, our lead product candidate, is an immune globulin. Immune globulins contain antibodies derived from human plasma, which is a component of blood. Certain pathogenic organisms and impurities are found in blood. While the collection, testing, processing, manufacture, and storage of immune globulins like Veronate are designed to eliminate harmful pathogens or other impurities, we cannot assure you that this will prevent transmission of both known and unknown pathogens or impurities to patients being treated with Veronate. If Veronate were known to have transmitted any harmful pathogens or impurities, approval of Veronate may be delayed, suspended or withdrawn, we could be forced to recall the product, and we may be subject to product liability claims. Further, if public concern arises that any blood product other than Veronate may transmit a disease, approval for Veronate may be delayed or withdrawn, or the use of Veronate may be reduced or limited due to these concerns.

The use of any of our product candidates in clinical trials and the sale of any approved products may expose us to product liability claims. We currently have product liability insurance coverage for our clinical trials in the amount of $5.0 million. In the event any of our product candidates are approved for sale by the FDA, we anticipate that we will need to increase our product liability coverage. Such insurance coverage may not protect us against any or all of the product liability claims which may be brought against us in the future. We may not be able to acquire or maintain adequate such insurance coverage at a commercially reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim brought successfully against us. Defending any product liability claim or claims could require us to expend significant financial and managerial resources, which could have an adverse effect on our business.

Until we have successfully developed and commercialized a product candidate, we expect that substantially all of our revenues will result from payments under collaborative arrangements. To date, these payments have been in the form of up-front license and research and development support payments. We may not be able to generate additional revenues under existing or future collaborative agreements. Furthermore, payments potentially due to us under our existing and any future collaborative arrangements, including any milestone and up-front payments, are subject to significant fluctuation in both timing and amount, or may never be paid. Therefore, our historical and current revenues may not be indicative of our ability to continue to achieve additional payment-generating milestones. In addition, our supply and manufacturing agreements with respect to Veronate and Aurexis require us to purchase certain minimum amounts that we may not need and therefore may be uneconomic to us. As of December 31, 2004, our minimum purchase commitments amounted to an aggregate of $18.3 million, assuming the relevant agreements are not cancelled or terminated by us. We expect that our operating results will vary significantly from quarter to quarter and year to year as a result of the timing of our research and development efforts, the execution or termination of collaborative arrangements, the initiation, success or failure of clinical trials, the timing of the manufacture of our product candidates, or other development related factors. Accordingly, our revenues and results of operations for any period may not be comparable to the revenues or results of operations for any other period.

If we successfully advance our product candidates through clinical development and regulatory approvals, we will need to add or expand research and clinical development, regulatory, manufacturing, information technology and marketing and sales capabilities or contract with third parties to provide these capabilities for us. If our operations expand we will need to hire additional personnel and add corporate functions that we currently do not have. Our ability to manage our operations and growth will require us to continue to improve our operational, financial and management controls, information technology and reporting systems, and procedures. We may not be able to implement such improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.

Our research and manufacturing activities involve the controlled use of certain hazardous materials and medical waste. Notwithstanding the regulations controlling the use of these materials and the safety procedures we undertake, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of an accident or environmental discharge or exposure, we may be held liable for any resulting damages, which may exceed our financial resources.

The market price of our common stock has been highly volatile since we completed our initial public offering in June 2004. The market price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors and events, including but not limited to:


•	disclosure of our or our competitors’ clinical trial data;

•	the approval or commercialization of new products by us or our competitors and the disclosure thereof;

•	announcements of scientific innovations by us or our competitors;

•	rumors relating to us or our competitors;

•	public concern about the safety of our product candidates, products or similar classes of products;

•	litigation to which we may become subject;

•	actual or anticipated variations in our annual and quarterly operating results;

•	changes in general conditions or trends in the biotechnology and pharmaceutical industries;

•	changes in drug reimbursement rates or policies;

•	announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•	new regulatory legislation adopted in the United States or abroad;

•	our failure to achieve or meet equity research analysts’ expectations or their estimates of our business, or a change in their recommendations concerning our company, the value of our common stock or our industry in general;

•	termination or delay in any of our existing or future collaborative arrangements;

•	future sales of equity or debt securities, including large block trades;

In addition, the stock market in general, and the Nasdaq National Market and the market for biotechnology stocks in particular, have historically experienced significant price and volume fluctuations. Volatility in the market price for a particular company’s stock has often been unrelated or disproportionate to the operating performance of that company. Market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Due to this volatility, you may be unable to sell your shares of common stock at or above the price you paid.

We expect that we will need to raise additional capital in the future. We may not be able to do so on favorable terms, if at all. Additional equity financings we may undertake may be dilutive to the holders of our common stock or cause the price of our common stock to decline. If we obtain funds through a credit facility or through the issuance of debt or preferred securities, these securities would have rights senior to your rights as a common stockholder. If we cannot obtain sufficient capital on commercially acceptable terms, we will not be able to fully carry out our business strategy.

The sale of a significant number of these shares of our common stock, or the perception that such sales could occur, particularly with respect to our directors, executive officers, and other insiders, or their affiliates, could materially and adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities at a price deemed appropriate.

As of February 28, 2005, our directors and executive officers, together with their affiliates, beneficially owned, in the aggregate, approximately 59.8% of our outstanding shares of common stock. To the extent these stockholders sell all of their shares covered by this prospectus they would still own, in the aggregate, approximately 51.0% of our outstanding shares of common stock. As a result, these stockholders, acting together, would have the ability to delay or prevent a change in control that may be favored by other stockholders and otherwise exercise significant influence over all corporate actions requiring stockholder approval, irrespective of how our other stockholders may vote, including:


•	the election of directors;

•	any amendment of our certificate of incorporation or bylaws;

•	the approval of some mergers and other significant corporate transactions, including a sale of substantially all of our assets; or

•	the defeat of any non-negotiated takeover attempt that might otherwise benefit the public stockholders.

Provisions of our amended and restated certificate of incorporation, bylaws and the laws of Delaware, the state we are incorporated in, may discourage, delay or prevent a change in control of us or a change in management that stockholders may consider favorable. These provisions:


•	establish a classified, or staggered, board of directors, so that not all members of our board may be elected at one time;

•	set limitations on the removal of directors;


•	limit who may call a special meeting of stockholders;

•	establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at stockholder meetings;

•	prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and

•	provide our board of directors the ability to designate the terms of and issue new series of preferred stock without stockholder approval.

These provisions could discourage proxy contests and make it more difficult for you and other stockholders to remove and elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock.

This prospectus contains forward-looking statements. These forward-looking statements are principally contained in the sections entitled “Prospectus Summary,” “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “forecast,” “potential,” “likely” or “possible”, as well as the negative of such expressions, and similar expressions intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to:


•	our ability to discover and develop novel therapies to prevent or treat serious, life threatening infections based on our expertise in MSCRAMM proteins;

•	the potential advantages of using antibody-based products over existing therapies;

•	the ability of antibodies that target MSCRAMM proteins to reduce the incidence and severity of bacterial and fungal infections;

•	the ability of Veronate to reduce the number of hospital-associated infections caused by S. aureus and candida, and reduce overall mortality in very low birth weight infants;

•	potential future revenue from collaborative research agreements;

•	our ability to generate product-related revenue in the future;

•	the potential volatility of our quarterly and annual operating results;

•	the potential to discover, develop or commercialize any product candidates resulting from existing or future collaborations, including those with Dyax and Wyeth;

•	the number of sites we intend to utilize in our ongoing clinical trials;

•	the anticipated length of time to fully enroll and generate data from our Phase III Veronate trial;

•	successful results from the ongoing Phase III trial for Veronate being sufficient to support a BLA submission for Veronate;

•	the availability of suitable alternative sources of plasma for the manufacture of Veronate;

•	the anticipated time frame to generate data from our Phase II Aurexis trial;

•	our potential initiation of additional clinical trials for Aurexis in other indications;

•	our intention to apply for Fast Track and Orphan Drug status for our other product candidates;

•	our plans to establish a specialized hospital-based sales force and commercialize our product candidates, particularly Veronate, in the United States;

•	our plans to establish partnerships or collaborations with other entities to develop and commercialize our product candidates in other countries;

•	the potential benefits of Fast Track and Orphan Drug status;

•	increases in our research and development expenses, general and administrative expenses and operating losses in the future;

•	the impact that adoption of SFAS No. 123(R) may have on our results of operations;

•	our future financing requirements and how we expect to fund them;


•	the number of months that our current cash, cash equivalents and short-term investments will allow us to operate; and

•	timing of occupancy into a new facility.

These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties including, without limitation: that the preceding preclinical and clinical results related to our antibody-based products, including Veronate and Aurexis, are not reflective of future results; Wyeth terminating our license and collaborative research agreement; our ability to contract with a sufficient number of clinical trial sites to perform our clinical trials; the rate at which investigators at such sites can recruit patients into our clinical trials; our ongoing or future clinical trials not demonstrating the appropriate safety and efficacy of our product candidates; our ability to secure and our use of third-party contract clinical research organizations, raw material suppliers and manufacturers, who may not fulfill their contractual obligations or otherwise perform satisfactorily in the future; manufacturing and maintaining sufficient quantities of clinical trial material on hand to complete our clinical trials; our failure to obtain regulatory approval to continue our clinical trials or to market our product candidates; our ability to protect and maintain our proprietary intellectual property rights from unauthorized use by others; our successful development of a marketing, sales and corporate infrastructure capable of supporting the commercialization of Veronate; our ability to attract suitable organizations to collaborate on the development and commercialization of our product candidates, particularly outside of the United States; that no viable product candidates result from the collaborations with Wyeth or Dyax or that product candidates from these collaborations do not demonstrate any therapeutic benefit or an acceptable safety profile in clinical trials; our collaborators do not fulfill their obligations under the our agreements with them in the future; the condition of the financial equity markets and our ability to raise sufficient funding in such markets; our ability to manage our current cash reserves as planned; changes in related governmental laws and regulations; changes in general economic business or competitive conditions; and other statements contained elsewhere in this prospectus and risk factors described in or referred to in greater detail in the “Risk Factors” section of this prospectus.

There may be events in the future that we are unable to predict accurately, or over which we have no control. Before you purchase our common stock, you should read this prospectus and the documents that we reference in this prospectus and have been filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. Our business, financial condition, results of operations, and prospects may change. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. We qualify all of the information presented in this prospectus, and particularly our forward-looking statements, by these cautionary statements.

You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with different information. This prospectus is not an offer to sell, nor is it seeking an offer to buy, securities in any state where the offer or sale is not permitted. The information in this prospectus is complete and accurate as of the date on the front cover, but the information may have changed since that date.

We will not receive any of the proceeds from the sale of the shares being offered pursuant to this prospectus. However, in the event that all of the warrants to purchase up to 2,033,211 shares of common stock, which were issued in connection with the private placement that we closed on November 10, 2004, are exercised for cash, we will receive proceeds of $24,042,720. See “Selling Stockholders” and “Plan of

We believe we will need to raise additional funds before we file a BLA for Veronate, and complete a Phase III clinical trial for Aurexis.

Our common stock has been traded on the Nasdaq National Market under the symbol “INHX” since June 4, 2004. Prior to that time, there was no public market for the common stock. The following table sets forth the range of high and low sale prices for the common stock for each completed fiscal quarter since June 4, 2004.

On April 11, 2005, the last reported sale price of our common stock on the Nasdaq National Market was $7.74 per share. The number of record holders as of March 31, 2005 was 141, including multiple beneficial holders at depositories, banks and brokers included as a single holder in the single “street” name of each respective depository, bank or broker.

We have never paid or declared any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the growth and development of our business and we do not expect to pay any cash dividends on our common stock in the foreseeable future.

The following selected financial data should be read in conjunction with, and are qualified by reference to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our Financial Statements and related Notes included elsewhere in this prospectus. The statement of operations data for the years ended December 31, 2002, 2003 and 2004 and the balance sheet data as of December 31, 2003 and 2004 are derived from our audited financial statements, which are included elsewhere in this prospectus. The statements of operations data for the years ended December 31, 2000 and 2001, and the balance sheet data as of December 31, 2000, 2001, and 2002 are derived from our audited financial statements that are not included in this prospectus. The selected financial data for the period from inception on May 13, 1994 through December 31, 2004 were derived from our audited financial statements.


(1)	See Note 3 of Notes to Financial Statements for a description of the method used to compute pro forma basic and diluted net loss per common share and number of shares used in computing pro forma basic and diluted net loss per common share.

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this prospectus. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors,” “Special Note on Forward-Looking Statements” and elsewhere in this prospectus. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.

We are a biopharmaceutical company committed to the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious bacterial and fungal infections. We currently have two product candidates in late-stage clinical development. Veronate, our lead product candidate, is the subject of a 2,000 patient Phase III clinical trial, for which we initiated enrollment in May 2004. We are developing Veronate for the prevention of hospital-associated infections in premature, very low birth weight, or VLBW, infants. In February 2004, we completed a 512 patient Phase II clinical trial of Veronate. Veronate has been granted Fast Track and Orphan Drug status by the FDA. Our second product candidate, Aurexis, is currently being evaluated in a 60 patient Phase II clinical trial as a first-line therapy, in combination with antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients. We recently completed the enrollment phase of this trial. In addition, we have three preclinical product candidates that are being developed to prevent and treat serious infections.

We are a development stage company that has generated significant losses since our inception in May 1994. We expect to incur substantial and increasing losses for at least the next several years as we continue the development of our product candidates, particularly Veronate and Aurexis, continue our other research and development activities and establish a commercial infrastructure. We currently do not have any commercialization capabilities, and it is possible that we may never successfully commercialize any of our product candidates.

To date, we have devoted substantially all of our efforts towards research and development activities related to the research and development of our product candidates, which are based on our expertise in MSCRAMM proteins. As of December 31, 2004 we had an accumulated deficit of $103.0 million, which includes non-cash expenses of $16.4 million related to the accrual of cumulative preferred stock dividends and the accretion to the redemption value of redeemable convertible preferred stock and $650,000 related to the amortization of deferred stock compensation. We anticipate that our quarterly and annual results of operations will fluctuate due to several factors, including progress made in our research and development efforts, the timing and outcome of regulatory approvals, if any, and payments made or received pursuant to existing or future licensing or collaboration agreements. Therefore, meaningful predictions of our future operations are difficult to make.

Revenue. Since our inception, we have not generated any revenue from the sale of products and do not expect product-related revenues until we obtain regulatory approval for and commercialize a product candidate. Currently, our revenues represent the amortization of an up-front license fee, quarterly research and development support payments we have received in connection with a license and collaboration agreement with Wyeth. If our development efforts result in regulatory approval and the successful commercialization of any of our product candidates, we expect the majority of our future revenues will result from product sales. In addition, in the future we may generate revenues from up-front or milestone payments in connection with collaborative or strategic relationships and royalties resulting from the licensing of our intellectual property.

Research and Development Expense. Research and development expense consists of the expenses incurred in discovering, developing, testing and manufacturing our product candidates. These costs consist primarily of professional fees paid to third-party service providers in conjunction with treating patients enrolled in our clinical trials and monitoring, accumulating and evaluating the related data, salaries and personnel-related expenses, the cost of raw materials, contract manufacturing services, supplies used in clinical trials and research and development activities, consulting, license and sponsored research fees paid to third parties, and facilities costs. We charge all research and development expenses to operations as incurred.

The following table summarizes our research and development expenses for the years ended December 31, 2002, 2003 and 2004. Direct external costs represent significant expenses paid to third parties that specifically relate to our product candidates in clinical development, such as payments to contract research organizations that monitor, accumulate and analyze data from our clinical trials, investigators who treat the patients enrolled in our clinical trials, and the cost of manufacturing clinical trial material. All remaining research and development expenses not tracked to a specific clinical product development program, such as salaries, supplies and other overhead costs, are included in unallocated costs and overhead. Research and development spending for past periods is not indicative of spending in future periods.

We expect our research and development costs to increase in the future. In the near-term, we expect to expend a greater portion of our resources on the development of our two most advanced product candidates, Veronate and Aurexis, than on the development of our preclinical product candidates due to the number of patients we expect to enroll in the clinical trials for these product candidates and the related cost of manufacturing clinical trial materials. Due to the progress and timing of clinical trials, such expenditures are likely to be uneven in future periods. Although we are currently focused primarily on advancing Veronate through an ongoing Phase III clinical trial, and Aurexis through Phase I and Phase II clinical trials, we will make determinations as to how much funding to direct to these programs on an on-going basis in response to their scientific, clinical and regulatory success. From inception through December 31, 2004, we have incurred approximately $75.0 million in research and development expenses.

The successful development of our product candidates is highly uncertain. We cannot reasonably estimate the nature, timing and cost of the efforts necessary to complete the development of, or the period in which material net cash inflows are expected to commence from, any of our product candidates due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:


•	the scope, rate of progress and cost of our clinical trials and other research and development programs;

•	future clinical trial results;

•	the terms and timing of any collaborative, licensing and other arrangements that we may establish;

•	the cost and timing of regulatory approvals;

•	the cost of establishing clinical and commercial supplies of our product candidates; and

•	the effect of competing technological and market developments.

The failure to complete the development of our product candidates in a timely manner could have a material adverse effect on our operations, financial position, and liquidity. A discussion of the risks and uncertainties associated with completing our projects on schedule, or at all, and some of the consequences of failing to do so, are set forth in the “Risk Factors” section of this prospectus.

General and Administrative Expense. General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance, accounting, information technology, business development and human resource functions. Other significant costs include professional fees for legal, accounting, market research and other consulting services, as well as insurance premiums. We expect our general and administrative expenses to increase as we add personnel, continue to comply with the reporting obligations and regulations applicable to publicly-held companies and establish an infrastructure in anticipation of the commercialization of our product candidates, particularly Veronate. From inception through December 31, 2004, we have incurred approximately $16.3 million in general and administrative expenses.

Interest and Other Income (Expense), net. Interest income consists of interest earned on our cash, cash equivalents and short-term investments. Interest expense consists of interest incurred on capital leases and notes payable. Other income and expense consists of the proceeds from the sale of excess raw materials and the gain or loss on the disposal of equipment.

Dividends and Accretion to Redemption Value of Redeemable Preferred Stock. Until the completion of our IPO, or initial public offering in June 2004, when all then-outstanding preferred stock and related dividends were converted into common stock, we accrued for an 8% cumulative annual dividend payable on our Series C Redeemable Convertible Preferred Stock, or Series C, and on our Series D Redeemable Convertible Preferred Stock, or Series D. In addition, since our redeemable preferred stock had been discounted to reflect the value of attached warrants, we accreted, or increased, the book value of our redeemable preferred stock to equal its redemption value by the earliest redemption date. This accretion had the impact of reducing stockholders’ equity and increasing the net loss per share attributable to common stockholders.

This discussion and analysis of our current financial condition and historical results of operations is based on our audited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and judgments with respect to the selection and application of accounting policies that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. We base our estimates on historical experience and various other assumptions that we believe are reasonable under the circumstances at the time, the results of which form the basis for making judgments about the carrying values of certain assets and liabilities. Actual future results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies are important in understanding our financial statements:

Revenue Recognition. We recognize revenue primarily under licensing and other collaborative research and development agreements as we perform services or meet contractual obligations. Accordingly, up-front, non-refundable license fees under agreements where we have an ongoing research and development commitment are amortized, on a straight-line basis, over the term of our ongoing obligations under the agreement. Revenues received for ongoing research and development activities under collaborative arrangements are recognized as the research and development activities are performed pursuant to the terms of the related agreements. In the event we receive milestone payments in the future, we will recognize such payments when all of the terms of such milestone are achieved. Our revenue recognition policies are in compliance with the Securities and Exchange Commission’s, or SEC’s, Staff Accounting Bulletin, or SAB, No. 101, Revenue Recognition in Financial Statements, and SAB No. 104, Revenue

Accrued Expenses. The preparation of our financial statements requires us to estimate expenses that we believe we have incurred, but for which we have not yet received invoices from our vendors. This process involves identifying services and activities that have been performed by third-party vendors on our behalf and estimating the level to which they have been performed and the associated costs incurred for such service as of each balance sheet date. Examples of expenses for which we accrue based on estimates include fees for services such as those provided by certain clinical research and data management organizations and investigators in conjunction with clinical trials and fees owed to our contract manufacturers in conjunction with the manufacture of materials for our clinical trials.

In connection with these service-related fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual levels of services incurred by such service providers. In order to estimate costs incurred to date, but not yet invoiced, we analyze the progress of the clinical trial and related activities, invoices received and budgeted costs when evaluating the adequacy of the accrued liability for these related costs. The majority of our service providers invoice us monthly in arrears for services performed or based upon meeting pre-determined milestones. In the event that we are not notified of or we do not identify certain costs that have been incurred, or we underestimate or overestimate the level or costs of services performed, our reported expenses for such period might be too low or too high. We must sometimes estimate the date on which certain services commence and the level or costs of services performed on or before a given date. We make these estimates based upon the facts and circumstances known to us at the time and in accordance with generally accepted accounting principles.

Stock-Based Compensation. We have elected to follow Accounting Principles Board, or APB, Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations, in accounting for our stock-based compensation plans, rather than the alternative fair value accounting method provided for under Statement of Financial Accounting Standards, or SFAS, No. 123, Accounting for Stock-Based Compensation. Accordingly, we have not recorded stock-based compensation expense related to stock options issued to employees if the exercise prices of the options are equal to or greater than the fair value of the underlying common stock on the date of grant. In the notes to our financial statements we provide pro forma disclosures in accordance with SFAS No. 123 and related pronouncements. We continue to follow this method until July 1, 2005 with adoption of FASB Statement No. 123 (revised 2004), Share-Based Payment.

Prior to our IPO in June 2004, the determination of the fair value of our common stock for purposes of stock option grants involved significant judgment on our part because our shares were not publicly traded. In determining the fair value of our common stock from time to time, our board of directors considered the price at which we sold shares of convertible preferred stock to investors, comparative values of public companies discounted for the risk and limited liquidity provided for in our shares of common stock, prior valuations of our common stock and the impact of events or milestones that had occurred since. Upon the completion of our IPO, the determination of the fair market value of our common stock is based upon the trading price of our common stock.

On December 16, 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123 (revised 2004), Share-Based Payment (“SFAS 123(R)”), which is a revision of SFAS No. 123, 123(R) supersedes APB Opinion No. 25, and amends SFAS No. 95, Statement of Cash Flows. Generally, the approach in SFAS 123(R) is similar to the approach described in SFAS 123. However, SFAS 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on fair values. Pro forma disclosure is no longer an alternative.

SFAS 123(R) must be adopted no later than July 1, 2005. Early adoption will be permitted in periods in which financial statements have not yet been issued. We expect to adopt SFAS 123(R) on July 1, 2005. We anticipate that adoption of this statement could have a material effect on our results of operations.

Currently we use the Black-Scholes formula to estimate the value of stock options granted to employees and expects to continue to use this acceptable option valuation model upon the required adoption of SFAS 123(R) on July 1, 2005. Because SFAS 123(R) must be applied not only to new awards but to previously granted awards that are not fully vested on the effective date, compensation cost for some previously granted awards that were not recognized under SFAS 123 will be recognized under SFAS 123(R). However had we adopted SFAS 123(R) in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net loss and net loss per share in Note 2 to our financial statements. SFAS 123(R) also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after adoption.

Revenue. Revenue decreased to $650,000 in 2004 from $1,096,000 in 2003. This decrease of $446,000, or 41%, resulted from a $146,000 reduction in collaborative research and development support fees from Wyeth and the receipt of a FDA grant of $300,000 in 2003. The collaborative research and development support fees we receive from Wyeth are based on the number of our employees that support the related program, which during the second half of 2003, were reduced to the minimum annual level. We do not expect this amount to decrease any further in the future, however as product development progresses Inhibitex’s revenue may decline further.

Research and Development Expense. Research and development expense increased to $22.6 million in 2004 from $19.0 million in 2003. This increase of $3.6 million, or 19%, resulted primarily from increases in clinical trials and manufacturing-related costs, personnel-related salaries and expenses, and license fees and other expenses associated with intellectual patents of $2,449,000, $725,000, and $427,000, respectively. Clinical trial costs increased due to the payments associated with the completion of enrollment in the Aurexis Phase II trial, and the ongoing enrollment in the Veronate Phase III trial. In addition, manufacturing-related costs increased primarily due to $355,000 of additional purchases of the raw material and manufacturing expenses related to Veronate, and $383,000 of process development and manufacturing expenses related to Aurexis. Personnel-related salaries and expenses increased due to the hiring of additional personnel required to support our two ongoing clinical trials, and increased salaries and relocation expenses. License fees and other expenses increased partly due to legal fees associated with maintaining and obtaining intellectual property and patents, and prosecution and maintenance of patents that had been historically been paid by a third-party partner for which, as of June 2004, we are responsible for on an ongoing basis. License fees also increased due to our in-licensing of additional patent rights related to one of our MSCRAMM targets.

The following table summarizes the components of our research and development expense for 2004 and 2003.

General and Administrative Expense. General and administrative expense decreased to $4.0 million in 2004 from $4.6 million in 2003. This decrease of $0.6 million, or 13%, resulted from a decrease in litigation-related legal fees of approximately $1.1 million, which was offset, in part, by an increase in personnel-related salaries and expenses of approximately $225,000 associated with in headcount, an increase in directors’ and officers’ insurance premiums and directors’ fees of $121,000 and $68,000, respectively, and an increase of $186,000 for franchise taxes and general office expenses related to our initial public offering. Our directors’ and officers’ insurance premiums increased significantly due to our IPO in June 2004. Directors’ fees increased largely due to our adoption of retainers for all non-officer directors subsequent to our IPO in June 2004.

Amortization of Deferred Stock Compensation. Amortization of deferred stock compensation increased to $473,000 in 2004 from $176,000 in 2003. This increase of $297,000, or 169%, was the result of amortization related to $938,000 of deferred stock compensation recorded in 2004, and the full effect in 2004 of amortization related to $981,000 of deferred stock compensation that we recorded pursuant to stock options granted during 2003. Of the amortization expense for 2004, $259,000 related to employees in general and administrative positions while $214,000 related to employees engaged in research and development activities. Of the amortization expense for 2003, $96,000 related to employees in general and administrative positions while $80,000 related to employees engaged in research and development activities.

Interest and Other Income (Expense), net. Interest and other income (expense), net, increased to $533,000 in 2004 from $319,000 in 2003. This increase of $213,000, or 67%, was due to an increase in interest income of $417,000, which was the result of generally higher average cash balances and to a lesser extent, higher interest rates, in 2004 as compared to 2003. This increase in interest and other income was offset in part by an increase in interest expense of $37,000, which was principally the result of the $2.5 million we borrowed in June 2003 under our credit facility; and a decrease of $167,000 in other income related to the sale of excess plasma in 2003.

Dividends and Accretion to Redemption Value of Redeemable Preferred Stock. Dividends on preferred stock and accretion to redemption value of redeemable preferred stock decreased to $2.8 million in 2004 from $6.2 million in 2003. This decrease of $3.4 million, or 55%, resulted from dividends and the accretion to redemption value being recorded in 2004 only through June 9, 2004, the closing date of our IPO, when all of the related redeemable preferred stock was converted to common stock. Dividends and accretion to redemption value were recorded for all of 2003, during which the related redeemable preferred stock was outstanding.

Revenue. Revenue increased to $1.1 million in 2003 from $900,000 in 2002. This increase of $196,000, or 22%, resulted from a $300,000 grant received from the FDA in 2003, offset, in part, by a reduction in quarterly collaborative research and development support fees of $104,000 from Wyeth. The FDA grant was a one year grant covering the period September 30, 2003 through September 29, 2004. The collaborative research and development support fees from Wyeth are based on the number of our employees that support the program, which was reduced in 2003 to the minimum annual level.

Research and Development Expense. Research and development expense increased to $19.0 million in 2003 from $15.6 million in 2002. This increase of $3.4 million, or 22%, resulted from expenditures related to the clinical development of our two most advanced product candidates, Veronate and Aurexis. During 2003, we enrolled substantially all 512 patients in a Phase II clinical trial for Veronate and we initiated and completed a 19 patient Phase I clinical trial for Aurexis. During 2002, we initiated and completed a 36 patient Phase I clinical trial for Veronate. Approximately $2.0 million of this increase represented direct clinical trial related costs, including fees paid to third-party vendors that performed clinical monitoring, data accumulation, statistical analysis and evaluation for our clinical trials, as well as costs associated with the manufacture of clinical trial materials. The other significant factor contributing to the increase in 2003 was additional license fees of approximately $540,000 paid to several third parties to secure intellectual property rights related to the manufacture of Aurexis. The remainder of the increase was related to a number of items, including an increase in personnel-related salaries and expenses, sponsored research payments to support our clinical trials and other research and development programs, and an increase in facility-related costs. The following table summarizes the components of our research and development expenses for 2003 and 2002.

General and Administrative Expense. General and administrative expense increased to $4.6 million in 2003 from $3.3 million in 2002. This increase of $1.3 million, or 39%, resulted from increased legal fees of $1.4 million related to the Biosynexus litigation. This increase was offset, in part, by $305,000 of costs incurred during 2002 for certain marketing studies that were not conducted in 2003. The remainder of the increase was primarily related to increases in personnel-related salaries and expenses, and the hiring of additional personnel.

Amortization of Deferred Stock Compensation. Amortization of deferred stock compensation increased to $176,000 in 2003 from $0 in 2002. This increase was the result of amortization related to $981,000 of deferred stock compensation that we recorded pursuant to stock options granted during the first nine months of 2003. Of the amortization expense for 2003, $96,000 related to employees in general and administrative positions while $80,000 related to employees engaged in research and development activities.

Interest and Other Income (Expense), net. Interest and other income (expense), net, decreased to $319,000 in 2003 from $430,000 in 2002. This decrease of $111,000, or 26%, resulted from a decrease in interest income of $343,000, an increase in interest expense of $83,000 and an increase in other income of $315,000 primarily due to the sale of unusable raw materials. The decrease in interest income was primarily due to reduced yields on investments resulting from lower interest rates and lower average cash and cash equivalent balances in 2003.

Dividends and Accretion to Redemption Value of Redeemable Preferred Stock. Dividends and accretion to redemption value of redeemable preferred stock increased to $6.2 million in 2003 from $5.6 million in 2002. This increase of $600,000, or 11%, resulted from the accrual of cumulative dividends and the accretion to redemption value associated with our Series D preferred stock. Our Series D financing was completed in February 2002. Accordingly, 2003 reflected the full-year effect of these items.

Since inception in May 1994 through December 31, 2004, we have funded our operations primarily with $173.2 million in gross proceeds raised from a series of five private equity financings, our IPO in June 2004, and a PIPE financing, or private placement of public equity, in November 2004 as follows:

From inception through December 31, 2004, we have also borrowed a total of $5.0 million under notes payable, a credit facility with a commercial bank and capital leases, and received approximately $5.8 million in license fees, collaborative research payments and grants, of which $1.2 million and $1.0 million were recorded as deferred revenue as of December 31, 2003 and December 31, 2004, respectively.

At December 31, 2004, cash, cash equivalents and short-term investments were $87.2 million and we held no investments with a maturity greater than 12 months. Our cash, cash equivalents and short-term investments are generally held in a variety of interest-bearing instruments, consisting of United States government agency securities, high-grade corporate bonds, municipal bonds, asset-backed securities, commercial paper and money market accounts.

For the year ended December 31, 2004, cash and cash equivalents increased by $44.9 million, from $26.6 million to $71.6 million. This increase resulted primarily from net proceeds we received in connection with our IPO in June 2004 and the PIPE financing in November 2004, offset in part by cash used for operating activities, capital expenditures and the repayment of capital lease obligations and notes payable.

Net cash used in operating activities was $21.5 million in 2004, primarily reflecting a net loss in 2004 of $25.9 million, which was partially offset by non-cash charges of $1.5 million and a net increase in current liabilities over current assets of $2.9 million. Our net loss was largely the result of funding our ongoing clinical trials associated with Veronate and Aurexis, research and development activities, and ongoing general and administrative expenses. The net increase in current liabilities over current assets reflected an increase in accounts payable and accrued liabilities of $3.6 million resulting from an increase in accounts payable associated with manufacturing-related expenses, clinical trial expenses, and the development of our new facilities, and an increase in accrued expenses associated with clinical trial expenses, manufacturing-related expenses, personnel-related expenses, and filing expenses related to our PIPE financing. This was offset by an increase in prepaid expenses and receivables of $526,000 associated with our manufacturing agreement with Lonza, and interest receivable from our short-term investments.

We used approximately $15.9 million of cash for investing activities during 2004, which consisted of net purchases of short-term investments of $14.3 million and the purchase of laboratory and computer equipment and software of $1.6 million.

We received net cash of $82.3 million from financing activities during 2004, which consisted of $34.0 million in net proceeds from our IPO; $47.7 million in net proceeds from our PIPE transaction; an additional $1.7 million we received from a subscription receivable related to the issuance of convertible preferred stock and warrants in connection with our Series E financing at the end of 2003, and; $256,000 from the exercise of stock options, offset by payments on our capital leases and promissory notes for $1.3 million.

For the year ended December 31, 2003, cash and cash equivalents decreased by $2.0 million. This decrease resulted primarily from our operating loss and principal payments on capital lease obligations and notes payable, which was mostly offset by proceeds received from the issuance of convertible preferred stock and warrants and a credit facility. Net cash used in operating activities was $21.6 million for the year ended December 31, 2003, primarily reflecting the net loss for the year of $22.3 million, adjusted for non-cash charges including depreciation and amortization of $768,000, and the amortization of deferred stock compensation of $176,000. This net loss was largely the result of conducting clinical trials, manufacturing clinical trial material and research and development activities related to our lead product candidates, and ongoing general and administrative expenses. We used approximately $720,000 for investing activities in 2003, which consisted of purchases of property and equipment of $176,000 and net purchases of marketable securities of $544,000. We received $20.3 million from financing activities during 2003 which consisted of $18.5 million related to the issuance of convertible preferred stock and warrants in connection with our Series E financing and $2.5 million in proceeds from a credit facility, offset by the repayment of capital lease obligations and notes payable of $710,000. In addition, in 2003, we financed the purchase of $421,000 of equipment under capital leases.

Our future funding requirements are difficult to determine and will depend on a number of factors, including the timing and costs involved in conducting clinical trials; obtaining regulatory approvals for our product candidates, if ever; the number of new product candidates we may advance into clinical development; future payments received or made under existing or future license or collaboration agreements; our ability and the time and cost it takes for us to develop, if ever, a corporate infrastructure to commercialize our products; the cost of filing, prosecuting and enforcing patent and other intellectual property claims; and the need to acquire additional licenses to or acquire new products or compounds. We may also need additional funds for possible future strategic acquisitions of businesses, products or technologies complementary to our business, although none are currently anticipated.

Based upon our current business and operating plans, we believe that our existing cash, cash equivalents and short-term investments of $87.2 million as of December 31, 2004 will enable us to operate for a period of approximately 21 months. We currently do not have any commitments for future funding, nor do we anticipate that we will generate revenue from the sale of any products for a number of years. Therefore, in order to meet our anticipated liquidity needs beyond 21 months, we will need to raise additional capital. We expect to continue to fund our operations primarily through the sale of additional common stock or other equity securities and to a lesser extent, strategic collaborations or debt financing. These funds may not be available to us on acceptable terms, if at all, and our failure to raise such funds could have a material adverse impact on our business strategy, plans, financial condition and results of operations. If adequate funds are not available to us in the future, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs, delay or curtail our clinical trial or commercialization efforts or obtain funds through collaborative arrangements that may require us to relinquish rights to certain product candidates that we might otherwise choose to develop or commercialize independently. Additional equity financings may be dilutive to holders of our common stock and debt financing, if available, may involve significant payment obligations and restrictive covenants that restrict how we operate our business.

Our material contractual obligations relate primarily to a credit facility and notes payable, capital leases, facility leases and certain minimum purchase obligations we have under third-party supply and manufacturing agreements.

The following table summarizes our contractual obligations as of December 31, 2004 and the effect such obligations are expected to have on our liquidity and cash flows in future periods.

(1)

Reflects our minimum purchase obligations, in the form of termination fees and cancellation penalties, assuming the related supply and manufacturing agreements are terminated by us as of the date of this table. If not terminated, our expected purchase commitments under these agreements would be approximately $14.2 million in total; $7.3 million for the period of less than one year, and $6.9 million for the period 1-3 years, from the date of this table.

In December 2003, we entered into an agreement to lease a new facility in Alpharetta, Georgia to be built to our specifications. We anticipate that we will occupy this new facility in the second quarter of 2005. Upon the completion of the facility, we expect that our expense including minimum lease obligations and the amortization of leasehold improvements paid by the lessor for this facility will approximate $1.0 million per annum for the lease term of ten years. We have not taken possession of or control the physical use of the property until January 2005. The table above includes these estimated operating lease obligations.

The contractual obligations outlined in the table above do not include several potential future milestone obligations we may be subject to in the future under a number of our licensing and collaborative agreements. The aggregate amount of our milestone obligations is approximately $9.0 million. Our milestone obligations are primarily due upon either the submission of a Biologics License Application, or BLA, and/or the marketing approval of Aurexis. At this time, due to the uncertainties associated with the clinical development of Aurexis, we cannot determine when these events may occur, if at all. Further, the license and collaboration agreements to which these milestone obligations relate are cancelable by us without further financial obligations upon not more than 90 days written notice in the event we choose to terminate any of the license agreements for any reason.

Our primary exposure to market risk relates to changes in interest rates on our cash, cash equivalents, and short-term investments. The objective of our investment activities is to preserve principal. To achieve this objective, we invest in highly liquid and high-quality investment grade debt instruments of financial institutions, corporations and United States government securities with a weighted average maturity of no longer than 12 months. Due to the relatively short-term nature of these investments, we believe that we are not subject to any material market risk exposure, and as a result, the estimated fair value of our cash, cash equivalents and short-term investments approximates their principal amounts. If market interest rates were to increase immediately and uniformly by 10% from levels at December 31, 2004, we estimate that the fair value of our investment portfolio would decline by an immaterial amount. We do not have any foreign currency or other derivative financial instruments and we do not have significant interest rate risk associated with our debt obligations. We have the ability to hold any of our fixed income investments until

The majority of our assets are monetary, consisting of cash, cash equivalents and short-term investments. Because of their liquidity, these assets are not generally directly affected by inflation. We also believe that we have significant intangible assets in the value of our technology and product candidates. In accordance with generally accepted accounting principles, we have not recorded the value of any intellectual property or intangible assets that we have developed on our balance sheet. Due to the nature of these intangible assets, we do not believe they are affected by inflation. Because we intend to retain and continue to use our equipment, furniture and fixtures and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources.

We are a biopharmaceutical company committed to the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections. We currently have two product candidates in late-stage clinical development. In February 2004, we completed a 512 patient Phase II clinical trial for our lead product candidate, Veronate, which we are developing for the prevention of hospital-associated infections in premature, very low birth weight, or VLBW, infants. In May 2004, we initiated enrollment in a Phase III clinical trial for Veronate. Veronate has been granted Fast Track and Orphan Drug status by the FDA. Our second product candidate, Aurexis, is currently being evaluated in a 60 patient Phase II clinical trial as a first-line therapy, in combination with antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus,bloodstream infections in hospitalized patients. We completed the enrollment of this trial in December 2004. Aurexis has also been granted Fast Track status by the FDA. In addition to Veronate and Aurexis, we have three other preclinical product candidates that are being developed to prevent or treat serious bacteria or fungal infections.

All of our product candidates have been developed based on our expertise in MSCRAMM proteins, for which we own or have licensed numerous patents and patent applications. The development of our product candidates are based on the discovery that MSCRAMM proteins found on the surface of pathogenic organisms play a prominent role in the process of infection. We have demonstrated that antibodies that bind to these MSCRAMM proteins can prevent or reduce the severity of infections by interfering with the attachment of the pathogenic organisms to human tissue or implanted medical devices. We believe our expertise in MSCRAMM proteins and the antibodies that target them will enable us to discover additional novel therapies, as well as to identify, license or acquire products that prevent and treat life-threatening infections.

We have retained all worldwide rights to Veronate and Aurexis. We intend to commercialize Veronate in the United States by establishing a specialized, hospital-based sales force. In markets outside the United States, we intend to enter into collaborations to develop and commercialize our product candidates, including Veronate. While we plan to establish a worldwide collaboration for Aurexis, we intend to retain co-promotion rights to Aurexis in the United States. We currently do not have any commercialization capabilities, and it is possible that we may never be able to successfully commercialize any of our product candidates. We have neither received regulatory approval for, nor derived any commercial revenues from, any of our product candidates.

Hospital-associated infections generally refer to infections that patients acquire while being treated or cared for in a hospital setting and include, among others, pneumonia, endocarditis and bloodstream infections, or bacteremia. These infections are for the most part caused by bacterial or fungal organisms that are present in the hospital. Most healthy individuals generally are not susceptible to these organisms, but immunocompromised persons, such as VLBW infants and the elderly, or persons who have had surgical procedures or have in-dwelling catheters or medical devices, are particularly vulnerable. According to the Centers for Disease Control, or CDC, the most prevalent organisms causing hospital-associated infections in the United States are bacterial organisms such as S. aureus, Staphylococcus epidermidis, or S. epidermidis, enterococcal species and fungal organisms such as candida species.

Based on data from the CDC and Decision Resources, a market research firm, there are an estimated six million hospital-associated infections worldwide each year, the vast majority of which are caused by bacteria and fungi. The CDC estimates that approximately two million hospital-associated infections occur in the United States each year, which are implicated in approximately 90,000 deaths per annum. According to the CDC, these infections also result in an estimated $5.0 billion in healthcare costs annually in the United States.

Antibiotics are the predominant agents used to treat hospital-associated infections. Antibiotics are small molecule compounds whose primary mechanisms of action are killing or inhibiting the growth of bacteria. Antibiotics commonly used to treat hospital-associated infections include methicillin and vancomycin. Many bacteria have become increasingly resistant, or unresponsive, to antibiotics, leading to an increase in the incidence of antibiotic-resistant infections. Drug resistance is the result of bacteria undergoing a biochemical mutation that circumvents the mechanisms of action that generally allow antibiotics to work. Some of the most virulent organisms that demonstrate significant patterns of antibiotic resistance include methicillin-resistant S. aureus, or MRSA, and vancomycin-resistant enterococci, or VRE. In light of increasing antibiotic resistance, we believe there is a significant unmet medical need for novel anti-infective therapies that can prevent or treat these serious, life-threatening infections.

We believe there is a substantial opportunity to utilize our expertise in MSCRAMM proteins to discover, develop and commercialize novel antibody-based products that address the increasing prevalence of life-threatening hospital-associated infections and the lack of effective therapies currently available to treat these infections.

The human immune system normally protects the body against a variety of infections and other illnesses by recognizing, neutralizing and eliminating pathogens and malignant cells from the body. One of the primary functions of the immune system is the production of antibodies. Antibodies are soluble proteins found in the plasma portion of whole blood capable of recognizing and binding to pathogens that are potentially harmful to the human body. Antibodies recognize and attach, or bind to antigens, examples of which include MSCRAMM proteins present on the surface of bacteria and fungi. In order for an effective immune response to occur without harming normal cells, the immune system generates antibodies that recognize and bind tightly to one specific antigen. Once an antibody binds to its targeted antigen, it triggers the cellular components of the immune system to clear the pathogen from the body.

We have identified antibodies that specifically bind to a number of different MSCRAMM proteins located on the surface of certain pathogenic organisms. MSCRAMM proteins enable organisms to initiate and maintain an infection by adhering to specific binding sites within human tissue or to implanted or in-dwelling materials, such as orthopedic implants, catheters and vascular grafts. We believe that antibodies that target MSCRAMM proteins can reduce the incidence and severity of bacterial and fungal infections through two important biological mechanisms of action. First, by binding to the MSCRAMM proteins, these antibodies inhibit or block the invading organism from attaching to tissue or implanted or in-dwelling medical devices. Second, these antibodies can cover or coat the invading organism, identifying it for clearance by other cellular components of the immune system through a process commonly referred to as opsoniszation.

We believe that antibody-based products developed utilizing our expertise in MSCRAMM proteins may provide the following advantages over existing anti-infective therapies:


•	the ability to be used prophylactically in patients where the preventive use of antibiotics is not appropriate or recommended;

•	improve patient outcomes by reducing the incidence of secondary site infections, relapse rates, mortality and length of hospital stay;

•	a lower likelihood of inducing patterns of drug resistance due to their novel mechanisms of action; and

•	fewer side effects.

Veronate is an immune globulin product candidate that contains concentrated amounts of human antibodies that target specific MSCRAMM proteins found on the surface of staphylococci. We are developing Veronate for the prevention of hospital-associated infections in VLBW infants that occur after the second day of life. Infections that occur after the second day of life are generally referred to by neonatologists as late-onset sepsis. In May 2004 we initiated enrollment in a 2,000 patient Phase III clinical trial of Veronate. Based on our Phase II clinical trial results, we believe that Veronate can reduce the number of hospital-associated infections caused by S. aureus and candida organisms in VLBW infants. Further, we believe the prophylactic use of Veronate may also reduce the overall mortality rate in VLBW infants in part, because infections caused by S. aureus and candida organisms are associated with an increased risk of death among these infants.

Veronate has been granted Fast Track status by the FDA. Fast Track status may allow for a priority review by the FDA and is afforded to those proposed products that the FDA believes address life-threatening and unmet medical needs. Also, as permitted by FDA regulations governing Fast Track status, we intend to submit a “rolling” BLA for Veronate. A BLA is the application that must be submitted to, accepted and approved by the FDA before a biologic product can be marketed or sold in the United States. A “rolling” submission allows for a BLA to be filed in separate, completed sections over a period of time during the drug’s clinical development period. By utilizing this rolling submission, we intend to file the chemistry, manufacturing and controls, or CMC, section of the BLA for Veronate by the end of 2005. We may also file other sections of the BLA for Veronate prior to the completion of its ongoing Phase III clinical trial. In addition, we anticipate requesting a priority review for this BLA. If the FDA accepts our request for a priority review, the length of time it takes for Veronate to proceed through the FDA approval process may be shortened. We cannot assure you that we will receive approval for a rolling BLA submission; we will be granted a priority review; the duration of the approval process for Veronate will be reduced; or Veronate will be approved by the FDA.

Veronate has also been granted Orphan Drug status for the reduction of nosocomial bacteremia caused by staphylococci in VLBW infants, which may provide for market exclusivity for seven years from the date of FDA approval in certain circumstances.

According to the National Center for Health Statistics, in 2002 there were 58,544 VLBW infants born in the United States. The term VLBW infants refers to those infants that weigh less than 1,500 grams at

VLBW infants are highly susceptible to infection while in the NICU, given the intensity of the medical care they receive, the duration of their hospitalization, and the use of intravenous catheters to deliver nutritional fluids and medication. Various studies indicate that 30-50% of VLBW infants weighing 1,250 grams or less at birth will develop at least up to one hospital-associated infection. There is an inverse relationship between a VLBW infant’s birth weight and the risk of acquiring a hospital-associated infection.

According to a retrospective study conducted by the Neonatal Institute of Child Health and Human Development, or NICHD, covering the calendar years 2000-2002 the mortality rate among VLBW infants who acquire a hospital-associated infection caused by S. aureus or candida is approximately 17% and 34%, respectively, as compared to 7% for those VLBW infants who do not develop any hospital-associated infection. In addition to associated mortality, several studies indicate that VLBW infants that develop a hospital-associated infection stay, on average, 19 additional days in the hospital when compared to those that do not acquire an infection. A recent study conducted by the NICHD also indicated that those VLBW infants that acquire an infection during their stay in the NICU, also experience significant impairment in their neurological development, including cerebral palsy and mental development as compared to those that did not acquire an infection.

Phase III. Veronate is the subject of an ongoing Phase III clinical trial that we initiated in May 2004. This 2,000 patient trial is a multi-center, placebo controlled, double-blind study and is substantially the same in design as the Phase II trial we completed for Veronate in 2004. Patients will be randomized equally into one of two arms: Veronate at a dose of 750 mg/kg or placebo, both administered intravenously. The primary endpoint of this trial is the reduction in the frequency of S. aureus infections in VLBW infants weighing 500-1,250 grams, the same patient population evaluated in our Phase II clinical trial. The design of the trial provides a 90% power to detect a 50% reduction in the frequency of S. aureus infections among infants randomized to receive Veronate compared to those that receive placebo based on 6% infection rate. Secondary endpoints of this Phase III trial include the reduction in the frequency of candidemia, coagulase-negative staphylococcal, or CoNS, infections, from staphylococcal infections and all-cause mortality. If the primary endpoint is achieved, we believe this trial will be sufficient for the submission of a BLA for Veronate.

In January 2005, an independent Data Safety Monitoring Board met to review safety and other data available from the first 500 patients enrolled in this trial and unanimously recommended that the trial proceed as designed without modification. As of March 21, 2005 we have enrolled 962 patients in this trial.

We anticipate that the trial will be conducted in 90-100 neonatal intensive care units in the United States and Canada, approximately 45 of which participated in our Phase II trial for Veronate. We anticipate that full enrollment in this trial will be completed in the fourth quarter of 2005, with data available in the second quarter of 2006. The results of the Phase III trial may not confirm the Phase II results.

Phase II. In February 2004, we completed a 512 patient, multi-center, randomized, double-blind, placebo-controlled Phase II clinical trial of Veronate for the prevention of hospital-associated infections in VLBW infants weighing 500 to 1,250 grams at birth. This trial was designed to evaluate the safety, dosing and preliminary efficacy of Veronate in this patient population. Infants in this trial were initially randomized by birth weight to receive one of four intravenous treatments: placebo or Veronate at a dose of 250mg/kg, 500mg/kg or 750mg/kg. This trial was conducted at 53 different NICUs across the United States, and no single site accounted for more than 7% of the subjects.

The results of the Phase II clinical trial demonstrated that Veronate was generally safe and well tolerated among treated VLBW infants. The most common adverse events, which occurred with similar frequency among those infants who received placebo and those who were administered Veronate, included low serum sodium, metabolic acidosis, food intolerance, high blood glucose, low blood platelets and low blood pressure. There were no dose related trends observed for adverse events, severe adverse events or morbidities associated with prematurity. Nine infants experienced 14 adverse events possibly related to Veronate, including low heart rate, apnea, fast heart rate, diaper rash, jaundice, low blood glucose, high blood glucose, high blood pressure and abdominal distention. Only 4 of 1,280 infusions were discontinued or interrupted due to adverse events possibly related to Veronate.

The preliminary efficacy findings from this trial comparing Veronate at a dose of 750 mg/kg to placebo were:


•	a 63% reduction in the frequency of infection due to S. aureus;

•	a 67% reduction in the frequency of infection due to candida; and

•	a 36% reduction in mortality.

These results were not statistically significant. The Phase II trial was not powered or designed to demonstrate statistically significant differences among the treatment arms in measures of efficacy.

Phase I. In 2002, we conducted a Phase I dose-escalating clinical trial of Veronate in 36 VLBW infants weighing 500 to 1,250 grams at birth. Two cohorts of 18 infants each were studied. One cohort received 500mg/kg of Veronate and the second cohort received 750mg/kg, both intravenously. The infants were monitored for a period of 70 days subsequent to their first infusion. Results from this trial indicated that Veronate was generally safe and well tolerated in VLBW infants.

Aurexis is a humanized monoclonal antibody currently in a Phase II clinical trial for evaluation as a first-line therapy, in combination with antibiotics, for the treatment of serious, life-threatening S. aureus bloodstream infections in hospitalized patients. This trial was initiated in February 2004, and the enrollment phase of the trial was completed in December 2004. We have also completed enrollment in a Phase I trial of Aurexis in patients with end stage renal disease. We anticipate initiating a Phase II clinical trial of Aurexis in patients with cystic fibrosis in the second quarter of 2005, and may initiate additional clinical trials of Aurexis in other patient populations in the future. Aurexis has been granted Fast Track designation by the FDA. Aurexis and Veronate target the same MSCRAMM protein on S. aureus.

S. aureus is one of the leading causes of hospital-associated infections. Based on data compiled by Decision Resources, Inc., a market research firm, there were an estimated one million hospital-associated S. aureus infections worldwide in 2002, of which approximately 225,000 occurred in the United States. Of the estimated 225,000 S. aureus infections that occurred in the United States, we estimate, based on data compiled by Decision Resources, Inc., that approximately 50,000 were bloodstream infections.

According to the CDC and other sources, the percentage of hospital-associated S. aureus infections in intensive care units in the United States caused by methicillin-resistant S. aureus, or MRSA, doubled between 1994 and 2002, increasing from 30% to nearly 60%. MRSA refer to organisms that are resistant to a class of antibiotics regarded as the first-line treatment for staphylococcal infections. The mortality rate for bloodstream infections associated with MRSA infections are approximately 35%, as compared to the mortality rate associated with methicillin-susceptible S. aureus bloodstream infections of approximately 20%. Studies indicate that patients that acquire a MRSA bloodstream infection, as compared to those that do not, require, on average, an additional 12 days in an intensive care unit, at an average cost of more than $27,000.

We are developing Aurexis to be used adjunctively as a first-line therapy to treat S. aureus bloodstream infections, independent of which antibiotic is prescribed for treatment. We also believe that the degree to which the medical community will adopt the use of Aurexis will be based on its ability to reduce the incidence of infection-associated mortality, the relapse rate associated with these infections, the frequency of related secondary site infections, and the number of days that patients with such infections stay in the hospital.

Phase II. We are currently conducting a 60 patient, multi-center, randomized, double-blind, placebo-controlled Phase II clinical trial for Aurexis, for which we completed the enrollment in December 2004. Patients with documented S. aureus bloodstream infections were randomized to receive antibiotic therapy in combination with either Aurexis, at 20 mg/kg, or placebo. Both Aurexis and the placebo were administered intravenously as a single dose. In this trial, standard of care antibiotic therapy was selected by the individual investigators. Subjects were followed for 57 days, or until early termination from the trial.


•	the safety of a single administration of Aurexis;

•	the pharmacokinetics of a single dose of Aurexis; and

•	the preliminary efficacy of a single dose of Aurexis.

The follow-up period for all patients in this trial has been completed and we expect to have data available during the second quarter of 2005. Results of this Phase II trial may not confirm the Phase I safety and pharmacokinetic results.

Phase I. We recently completed enrollment in an eight patient Phase I trial of Aurexis to evaluate its safety and pharmacokinetics in patients with end stage renal disease, or ESRD. The objective of this trial is to assess the suitability of including these patients in future clinical trials of Aurexis for the treatment of documented S. aureus bloodstream infections. We anticipate that data from this trial will be available during the second quarter of 2005.

In 2003, we completed an open-label, randomized, dose-escalating Phase I clinical trial in 19 healthy volunteers to assess the safety of Aurexis and determine dose-related pharmacokinetics. Patients were intravenously administered four dose levels of Aurexis at 2, 5, 10, or 20 mg/kg. The volunteers were monitored for a period of 56 days subsequent to the administration of the drug. Safety was monitored by physical examinations, clinical and laboratory tests, and adverse experience assessments. Results from this trial indicate that Aurexis was well tolerated by the healthy volunteers. The following adverse events were noted among participants: headache, low white blood cell count, gastro esophageal reflux and red rash. None of these adverse events was severe or believed to be definitely related to Aurexis. No other safety issues were identified and no dose reached the protocol-specified definition of maximum tolerated dose. Pharmacokinetic analysis demonstrated that doses of 10mg/kg or greater achieved plasma levels of Aurexis associated with therapeutic efficacy in preclinical animal models. The half life of Aurexis was determined to be approximately 21 days. We selected the 20mg/kg dose for our Phase II trial of Aurexis.

Preclinical Results. We have conducted a number of preclinical studies in animals to assess both the safety and efficacy of Aurexis. These studies include using Aurexis both prophylactically as a monotherapy to prevent, and in combination with vancomycin to treat, MRSA infections. In these studies, no safety or toxicity issues were observed. These studies demonstrated that when used prophylactically, a single dose of Aurexis administered intravenously provided statistically significant levels of protection against MRSA infections as compared to the control. The therapeutic administration of Aurexis intravenously, in combination with vancomycin, significantly enhanced the clearance of MRSA from the animals’ critical organs as compared to vancomycin alone. We believe that the preclinical models that yielded these results are generally viewed by the scientific community as supportive and appropriate for assessing the biological activity of anti-infective product candidates in humans.

In addition to Veronate and Aurexis, we currently have three product candidates in preclinical development, all of which are based on the use of MSCRAMM proteins.

Enterococci account for approximately 8% of all hospital-associated infections and have been reported as the second most common cause of nosocomial endocarditis in the United States. In the United States, greater than 24% of confirmed enterococcal infections reported in the June 2000 report of the hospitals included in the National Nosocomial Infectious Surveillance System were caused by vancomycin-resistant enterococci, or VRE. In these same hospitals, the reported incidence of VRE strains increased by 40% from 1994 to 1998. We have identified and characterized MSCRAMM protein targets expressed by enterococci and we have generated monoclonal antibodies that recognize these targets. In October 2004, we entered into an agreement with Dyax Corp. to collaborate on the discovery, development, and commercialization of fully human monoclonal antibodies against MSCRAMM proteins on enterococci. Under the terms of the agreement, we and Dyax will jointly develop product candidates that may be identified during the collaboration and will share in the costs to develop any resulting product candidates and the commercialization rights and profits from any marketed products.

Candida albicans, or C. albicans, is the causative organism of the majority of invasive fungal infections in an expanding population of immunosuppressed or immunocompromised patients such as those undergoing chemotherapy, those with organ transplants or those with AIDS. We have identified and characterized MSCRAMM proteins on the surface of C. albicans and we have generated monoclonal antibodies that target these proteins.

There are a number of patient groups, including approximately 300,000 end stage renal disease patients in the United States, patients receiving chronic long-term care, and patients undergoing certain elective surgeries, who are at risk of acquiring a staphylococcal infection. For these high-risk groups, we believe an active vaccine that can enhance immunity against staphylococcal organisms may be a less costly and preferred mode of therapy. We have entered into a license and collaboration agreement with Wyeth to develop human vaccines against staphylococcal organisms.

Complete the Phase III Trial and Obtain Regulatory Approval for Veronate. We are focused on completing the clinical and regulatory development of Veronate. We intend to complete the ongoing Phase III clinical trial evaluating Veronate for the prevention of hospital-associated infections in VLBW infants. If data from this trial are supportive, we intend to proceed with the filing of a BLA for Veronate. Veronate has been granted Fast Track status, which may allow for an expedited review by the FDA.

Advance the Development of Aurexis and Our Preclinical Product Candidates. We are developing Aurexis as a first-line therapy for the treatment of serious S. aureus infections in combination with antibiotics. Aurexis is currently being evaluated in a Phase II clinical trial in patients with S. aureus bloodstream infections and a Phase I trial in patients with end stage renal disease and we intend to evaluate it in other indications in the future. We are also advancing the development of our preclinical product candidates focused on enterococcal and candida monoclonal antibodies.

Establish a Specialized, Hospital-Based Sales Force in the United States. We have retained all worldwide rights for Veronate and Aurexis. We intend to establish a specialized hospital-based sales force of approximately 50 individuals to promote Veronate, and potentially Aurexis, in the United States. We believe that the vast majority of the potential demand for Veronate in the United States exists in approximately 1,000 hospitals that operate NICUs. As a result, we believe a relatively small sales force can effectively address this market. While we intend to enter into a worldwide collaboration to further develop and commercialize Aurexis, we plan to leverage our hospital-based sales force by retaining certain co-promotion rights to Aurexis in the United States. In markets outside of the United States, we currently plan to establish partnerships with other companies to commercialize any products we may successfully develop.

Utilize Our Expertise in MSCRAMM Proteins to Discover and Develop Additional First-in-Class Products. Our goal is to be the first to market antibody-based products to prevent and treat specific bacterial and fungal infections. We have used our expertise in MSCRAMM proteins to discover and develop Veronate, Aurexis and certain preclinical candidates that may represent first-in-class products. We believe that first-in-class drugs capture superior market share and have competitive advantages over drugs subsequently introduced. We will continue to devote resources to the discovery and development of product candidates that originate from our expertise in MSCRAMM proteins.

Expand Our Product Portfolio through In-Licensing and Acquisitions. We intend to capitalize upon our expertise in MSCRAMM proteins, antibody development, commercialization and infectious diseases to in-license or acquire selected product candidates in various stages of development. We will also evaluate opportunities to leverage our sales force by in-licensing or acquiring and promoting additional therapeutics which target the hospital-based market.

According to data compiled by the American Hospital Association, there are approximately 5,000 hospitals in the United States; however, we believe that the vast majority of the demand for Veronate will occur in approximately 1,000 hospitals where there are NICUs equipped to handle the special needs of VLBW infants. Furthermore, approximately 80% of the NICU beds in the United States are concentrated in approximately 500 of these hospitals. We believe that a specialized, hospital-based sales force of approximately 50 qualified individuals can effectively promote and sell Veronate in this market. We have retained all worldwide rights to Veronate and intend to establish such a sales force and create a commercial infrastructure capable of supporting the independent commercialization of Veronate in the United States.

We have also retained worldwide rights to Aurexis and one of our product candidates in preclinical development. While we plan to establish a worldwide collaboration to develop and commercialize Aurexis, we intend to retain certain co-promotion rights to Aurexis in the United States. Assuming Veronate is approved for sale by the FDA and we successfully develop a hospital-based sales force, we may promote or co-promote our other product candidates, if approved for sale, in the United States through this sales force. The 1,000 hospitals that contain NICUs also account for 45% of all hospital beds in the United States, therefore we believe our sales force will be able to effectively market Aurexis and our other product candidates in these hospitals. We anticipate partnering or collaborating with other companies to develop and commercialize our product candidates in countries and regions outside of the United States.

Raw Materials. Veronate is an immune globulin product candidate derived from human plasma. Accordingly, the critical raw material used in the manufacture of Veronate is plasma that contains a sufficient concentration of certain naturally occurring antibodies that specifically target MSCRAMM proteins. This plasma is collected at FDA-approved donor centers in the United States. The qualification of donors, the collection process, and the general operation of donor centers are highly regulated by the FDA and other domestic and foreign regulatory bodies. Further, this plasma is required to be tested for

In 2002, we entered into a ten-year supply agreement with DCI Management Group, Inc., or DCI. Pursuant to this supply agreement, no later than 90 days prior to each calendar-year end, we and DCI must agree on the quantity of plasma that we intend to purchase, and they will provide, for the next calendar year. Once this quantity is established, we are generally obligated to purchase at least 90% of this predetermined quantity during the subsequent year. We may terminate this agreement upon mutual agreement of the parties, a material breach by DCI or upon 30 days notice if the clinical development of Veronate is halted or terminated by the FDA or us.

In January 2005, we entered into a second supply agreement with another supplier of plasma. We currently cannot reasonably predict how much plasma this new supplier may supply us in the future, if any. This agreement has a ten-year term; however we may terminate the agreement upon mutual agreement of the parties, a material breach by the supplier, or upon 30 days notice that the clinical development of Veronate is terminated by the FDA or us. In addition to DCI and this new supplier, we believe there are additional suppliers of plasma for Veronate and we anticipate entering into supply agreements with other suppliers in the future, as necessary.

Manufacturing. We do not own or operate any manufacturing facilities. We currently outsource the manufacture of our product candidates to qualified contract manufacturers. We anticipate we will continue to rely on these or other qualified contract manufacturers for the foreseeable future. The manufacturing processes used to manufacture Veronate and Aurexis are vastly different, therefore we use different manufacturers for each of these product candidates.

The manufacturing process for Veronate is referred to as fractionation and purification. The fractionation process involves separating plasma into various components or fractions. Fractions are then purified form the appropriate fraction. This process has been used for over thirty years by major pharmaceutical companies to manufacture antibody-based products such as immune globulins. In December 2001, we entered into a ten-year contract manufacturing agreement with Nabi Biopharmaceuticals, Inc., or Nabi, to manufacture Veronate on our behalf. Nabi operates a FDA-approved facility in the United States, and is approved to manufacture its proprietary, as well as third-party, immune globulin products. Pursuant to our contract with Nabi, we must provide three-year forecasts as to how much Veronate we want it to manufacture on our behalf. As of December 31, 2004, our maximum purchase commitments under this agreement through December 31, 2007, were approximately $5.2 million. However, if we cancel or postpone the production of one or more batches of Veronate in accordance with the terms of this agreement, financial penalties would instead apply, which could be substantially less, and in no case more, than the minimum purchase commitments, depending on the length of the notice provided by us to Nabi. The amount of the cancellation penalty payable ranges from $25,000 per batch if we provide notice of cancellation more than twelve months in advance, to $425,000 per batch if we provide notice of cancellation less than 90 days in advance of the scheduled production date of the related batch. We believe Nabi is qualified and has the available capacity to manufacture Phase III clinical trial material and commercial quantities of Veronate. Nabi has manufactured five lots of Veronate to date. During the term of this agreement, we may not grant any rights allowing any other party to manufacture Veronate, and therefore we may not engage an alternative manufacturer until the agreement is terminated. We may terminate the agreement with Nabi if Nabi materially breaches the agreement, subject to a 20-day cure period, or if the clinical development of Veronate is halted or terminated. We do not have alternative manufacturing plans for Veronate at this time. If our agreement with Nabi were terminated for any reason, it may be difficult or impossible for us to find alternative manufacturers on commercially acceptable terms, if at all. Because Nabi is developing both a product to prevent S. aureus infections in VLBW infants and a staphylococcal vaccine, we consider Nabi to be a potential competitor.

We have also used a contract manufacturer, Avid Bioservices, Inc., or Avid, to produce clinical trial materials for Aurexis for use in our Phase I and II clinical trials. As of December 31, 2004, we have no long-term obligations under any of our prior agreements with Avid.

In November 2004, we entered into an agreement with Lonza Biologics PLC for the manufacture of Aurexis. Under the terms of the agreement, Lonza has agreed to perform numerous process development related services and manufacture two cGMP lots of Aurexis for our use in future clinical trials. As of December 31, 2004, our maximum purchase commitments under this agreement through June 30, 2008, were approximately 3.6 million pounds sterling or $6.7 million. However, prior to June 30, 2005 we can cancel the second cGMP lot without incurring any financial obligations associated with that lot, in which case our purchase commitments to Lonza would be reduced. At this time, we have not contracted with Lonza to manufacture any additional lots of Aurexis. A change in contract manufacturers for commercial lots may require further clinical trials for Aurexis.

Our industry is highly competitive and characterized by rapid technological change. Significant competitive factors in our industry include, among others, product efficacy and safety; the timing and scope of regulatory approvals; the government reimbursement rates for and the average selling price of products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual property and patent rights and their protection; and sales and marketing capabilities.

Any product candidates that we successfully develop and are approved for sale by the FDA or similar regulatory authorities in other countries may compete with existing products and products that may become available in the future. Many organizations, including large pharmaceutical and biopharmaceutical companies, such as Cubist Pharmaceuticals, Inc. and Vicuron Pharmaceuticals, Inc., as well as academic and research organizations and government agencies, continue to pursue the research and development of novel anti-infective therapies that target staphylococcal as well as other bacterial and fungal organisms. Many of these organizations have more substantial capital resources than we have, and greater capabilities and experience than we do in basic research, conducting preclinical studies and clinical trials, regulatory affairs, manufacturing, marketing and sales. As a result, we may face competitive disadvantages relative to these organizations should they develop or commercialize a competitive product. Therefore, we cannot assure you that any of our product candidates, if approved for sale, will compete successfully and that another organization will not succeed in developing and commercializing products that render our technology or product candidates non-competitive or obsolete.

Currently, we are not aware of any antibody-based products approved by the FDA specifically for the prevention or treatment of S. aureus, CoNS, candida or enterococcal infections in any patient population. However, we are aware of several biopharmaceutical companies developing antibody-based therapies directed towards the prevention or treatment of bacterial, and particularly staphylococcal, infections.

Nabi Biopharmaceuticals, Inc. is a publicly-held biopharmaceutical company that discovers, develops, manufactures and markets antibody-based therapies. Nabi has antibody-based product candidates and vaccines currently in clinical trials that are directed towards preventing or treating staphylococcal infections. One of these product candidates has received Orphan Drug status from the FDA. Nabi is our contract manufacturer for Veronate.

Biosynexus, Inc. is a privately-held biotechnology company that is developing a portfolio of protein-based products, including monoclonal antibodies, enzymes and peptides, for the prevention and treatment of staphylococcal infections.

NeuTec, PLC is a publicly-held biopharmaceutical company that is developing a portfolio of antibody-based therapeutic products designed to treat life-threatening infections, particularly hospital-acquired infections such as MRSA and candida.

We are licensed under 25 issued United States patents and over 25 pending United States patent applications, as well as corresponding international filings in the field of MSCRAMMs generally. We own seven pending United States patent applications and co-own two issued United States patents and three pending United States patent application, as well as corresponding international and foreign applications. The issued United States patents expire between 2009 and 2018. In addition to our patents and patent applications, we have registered trademarks for Inhibitex, MSCRAMM, Aurexis and Veronate.

Of the patents and applications in our portfolio, the following pertain directly to Veronate and Aurexis:


•	Our United States patent describing Veronate is directed to purified human immune globulin antibodies to S. aureus and S. epidermidis MSCRAMM proteins. This patent will expire in 2018 if not extended. Our pending United States Veronate patent application includes claims directed to methods used in preparing Veronate. Corresponding international applications are pending.

•	Our United States SdrG patent is directed to the nucleic acid sequence, or DNA, encoding the SdrG protein of S. epidermidis. The SdrG MSCRAMM protein is used in identifying donors for the preparation of Veronate. This patent will expire in 2018 if not extended. Our pending United States SdrG patent applications are directed to the SdrG protein and related methods. Corresponding international applications are pending.

•	Our two United States ClfA patents relate to both Veronate and Aurexis and are directed to the DNA and the ClfA MSCRAMM protein of S. aureus.These patents will expire in 2016 and 2014, respectively, if not extended. The ClfA protein is used in the identification of donors for the preparation of Veronate and is also the protein recognized by the Aurexis monoclonal antibody. There are no corresponding foreign rights available for the ClfA protein and nucleic acid sequences. Our pending United States ClfA patent application claims antibodies to the ClfA protein. Our pending United States ClfA monoclonal antibody patent application relates to Aurexis and claims a composition of matter for a monoclonal antibody to the ClfA protein. This US application has been allowed and will issue in the second quarter of 2005. Corresponding international applications are pending.

Patent rights and other proprietary rights are important in our business and for the development of our product candidates. We have sought, and intend to continue to seek patent protection for our inventions and rely upon patents, trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain a competitive advantage. In order to protect these rights, know-how and trade secrets, we typically require employees, consultants, collaborators and advisors to enter into confidentiality agreements with us, generally stating that they will not disclose any confidential information about us to third parties for a certain period of time, and will otherwise not use confidential information for anyone’s benefit but ours.

The patent positions of companies like ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any certainty. Our issued patents, those licensed to us, and those that may issue to us in the future may be challenged, invalidated or circumvented, and the rights granted thereunder may not provide us with proprietary protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies or duplicate any technology developed by us. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be approved for sale and commercialized, our relevant patent rights may expire or remain in force for only a short period following commercialization. Expiration of patents we own or license could adversely affect our ability to protect future product development and, consequently, our operating results and financial position.

We have filed two opposition proceedings with the European Patent Office, or EPO, to revoke or substantially narrow two patents issued to the Henry M. Jackson Foundation for the Advancement of Military Medicine relating to staphylococcal surface proteins. These patents have been licensed to Biosynexus. In the first opposition, on November 5, 2003 an oral proceeding took place in which the EPO

To date, we have entered into a number of license and collaborative agreements with various institutions to obtain intellectual property rights and patents relating to MSCRAMM proteins and our product candidates. We have also entered into an exclusive worldwide license and collaboration agreement with Wyeth with respect to their use of our MSCRAMM protein intellectual property to develop human staphylococcal vaccines and a joint development agreement with Dyax Corp. for the discovery, development, and commercialization of therapeutic products for the treatment of infections caused by enterococci. Our strategy includes possible future in-licensing of intellectual property or product candidates, as well as collaborations with companies to develop, co-develop, market and sell our product candidates in markets outside of the United States.

We have an exclusive royalty-bearing license from the Texas A&M University System, or Texas A&M, for an issued United States patent with claims directed toward the SdrG nucleic acid sequence and related pending United States divisional applications directed toward the SdrG protein and antibodies to it, as well as corresponding foreign applications. SdrG is the MSCRAMM protein that we target on S. epidermidis and is used in the manufacture of Veronate. We also have an exclusive royalty-bearing license to Texas A&M’s rights in an allowed United States patent application and foreign counterparts directed to the methods we use for screening and selecting donor plasma using MSCRAMMs for both SdrG and ClfA in the manufacture of Veronate. BioResearch Ireland/ Trinity College Dublin is a co-owner of these patents and applications. All of these licenses are subject to certain research rights retained by Texas A&M. Texas A&M may terminate the license if we fail to use commercially reasonable efforts to bring our products candidates to market. We may terminate the license without cause upon 60 days written notice. Otherwise, this agreement will terminate upon the expiration of all of the licensed patents. Currently, the latest to expire of the issued patents under the license agreement expires in 2019. We have agreed to pay Texas A&M a royalty based on net sales for any product sold utilizing these licenses.

In connection with these license agreements, in 1995 we entered into the first of several cooperative research agreements with Texas A&M. Pursuant to these agreements, we have the exclusive worldwide right to any discoveries resulting from this collaboration, subject to research rights retained by Texas A&M and certain rights of the United States government. We also have a right of first refusal to acquire the rights to and file patents on discoveries made by Texas A&M in the field of MSCRAMM proteins that are made outside of the scope of the collaboration. Texas A&M is entitled to a royalty on revenues that we receive for products that incorporate technology developed through the collaboration. We may terminate this collaboration upon 90 days written notice if the work is not performed satisfactorily.

Pursuant to these agreements, we have paid Texas A&M approximately $1.3 million through December 31, 2004. We have no future minimum royalty or milestone obligations pursuant to these agreements, but we currently pay Texas A&M approximately $350,000 in annual sponsored research payments. Our obligation to pay sponsored research payments ends in November 2005. If we do not continue to pay sponsored research payments beyond that time, we will be obligated to pay a minimum royalty of $25,000 annually.

We have obtained a royalty-bearing license from BioResearch Ireland, or BRI, under the United States SdrG patents and related applications licensed to us from Texas A&M, as described above. Scientists from both Texas A&M and BRI are co-inventors on these applications. We have an exclusive royalty-bearing license from BRI under two issued United States patents and a pending United States patent application directed to the ClfA nucleic acid and protein. The license also covers pending international applications relating to antibodies to ClfA. BRI may terminate the license if we fail to use commercially reasonable efforts to bring one or more products that use the licensed technology to market. Otherwise, this license will terminate upon the expiration of the licensed patents. We may terminate the license agreement as to any patent or patent application upon 90 days notice. Currently, the latest to expire of the issued patents under the license agreement expires in 2019.

Since 1996, we have entered into several cooperative research agreements with BRI for technologies relating to staphylococcal surface proteins. We have exclusive worldwide rights to, and are entitled to file patents on, any discoveries resulting from this collaboration. All licenses from BRI are subject to research rights retained by BRI. BRI is entitled to a royalty on any revenues that we receive from the sale of products that incorporate technology developed through the collaborative arrangement. We may terminate the collaboration agreement on two months written notice. BRI may terminate in the event of an uncured material breach by us.

Pursuant to these agreements, we have paid BRI approximately $382,000 through December 31, 2004. We have no future minimum royalty or milestone obligations pursuant to these agreements, but we currently pay BRI approximately $35,000 in annual sponsored research payments.

In August 2001, we entered into a license and development collaboration agreement with Wyeth for the development of human staphylococcal vaccines. Under the terms of this agreement, we granted Wyeth an exclusive worldwide license to our MSCRAMM protein intellectual property with respect to human vaccines against staphylococcal organisms. The development, manufacture and sale of any products resulting from the collaboration will be the responsibility of Wyeth. We may terminate this agreement if Wyeth fails to use reasonable commercial efforts to bring related products to market. Wyeth may terminate the agreement without cause on six months notice. Otherwise, this agreement will terminate upon the expiration of all of the licensed patents. Currently, the latest to expire of the issued patents under the license agreement expires in 2019.

Pursuant to this agreement, we have received $3.8 million in an upfront license fee and annual research support payments from Wyeth as of December 31, 2004. We are entitled to receive minimum research support payments of $500,000 per year until the first commercial sale of any product developed under this agreement. We are also entitled to receive milestone payments upon the filing of an Investigational New Drug application, or IND, the commencement of both Phase II and Phase III clinical trials, the filing of a BLA, and FDA approval of a licensed product. If all such milestones are achieved relative to one or more licensed products, we would be entitled to receive a minimum of $10.0 million in milestone payments from Wyeth. The maximum milestone payments we could receive with respect to all licensed products are $15.5 million. Finally, we are also entitled to royalties on net sales of licensed products manufactured, sold or distributed by Wyeth.

In October 2004, we entered into a collaboration agreement with Dyax Corp. to co-develop monoclonal antibodies to prevent or treat serious infections caused by enterococci. Under the terms of the agreement, we and Dyax have agreed to collaborate and share in the costs to perform preclinical research and development activities intended to identify and select a fully human monoclonal antibody, or antibodies,

against MSCRAMM proteins located on the surface of enterococci, that we would jointly advance into clinical development. During this preclinical phase, we and Dyax are responsible only for our respective internal development costs. Accordingly, neither party is responsible to make any upfront payments to the other party, nor is either party obligated to make future milestone or royalty payments to the other party at this time. Our internal development costs are expected to consist largely of salaries and other personnel-related costs associated with existing employees, certain supplies and other costs, such as travel and entertainment, associated with supporting existing employees. If at the end of the collaborative preclinical development activities, we mutually agree to advance one or more human monoclonal antibodies into clinical trials, we expect to continue to share in the clinical development costs of any such product candidates. The agreement also contemplates that we would share in the commercialization rights and profits from any approved and marketed products resulting from the collaboration. In the event that the parties mutually agree that the collaboration has been unable to identify a suitable monoclonal antibody to advance into clinical development, the collaboration agreement will immediately and automatically terminate without any further obligations to either party. Otherwise, this agreement can only be terminated during the initial preclinical development phase upon the mutual consent of both parties, or by one party in the event that the other party has committed a material breach, or filed for insolvency or bankruptcy.

The following four agreements relate to intellectual property associated with the production of monoclonal antibodies that we have in-licensed.

In November 2001, we entered into a research evaluation and worldwide non-exclusive license agreement with Lonza Biologics for intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis. Under the terms of the agreement, we agreed to pay an annual fee of up to 100,000 pounds sterling and a royalty on the net selling price of any products that we market that utilize the underlying technology. In the event we do not use Lonza to manufacture Aurexis, if and when it is approved by the FDA for sale, the annual payment would increase to 300,000 pounds sterling per year. We may terminate the agreement upon 60 days notice. The agreement terminates upon the expiration of the last valid patent or 15 years, whichever is longer. Currently, the latest to expire of the issued patents under the license agreement expires in 2016. Pursuant to this agreement, we have paid Lonza $693,000 as of December 31, 2004.

In June 2003, we obtained a non-exclusive, worldwide royalty-bearing license from Genentech for a patent, commonly known as the Cabilly patent, relating to the production of monoclonal antibodies for use in the manufacture of Aurexis. Under the agreement, we agreed to pay Genentech an up-front license fee and we are further obligated to pay a milestone payment due upon the approval of Aurexis and a royalty on the sale of any of our products that utilize the underlying technology. We may terminate this agreement without cause upon 90 days notice. Otherwise, this license will terminate upon the expiration of the patent, which will occur in 2018 if not extended. Pursuant to this agreement, we have paid $500,000 to Genentech as of December 31, 2004. Our aggregate future payments under this agreement are $5.0 million, which is payable if Aurexis is approved for sale by the FDA.

In July 2003, we obtained a non-exclusive, worldwide royalty-bearing license from the University of Iowa for patents, commonly known as the CMV promoter , or Stinski patents, relating to the expression of recombinant proteins used in the manufacture of Aurexis. Under this agreement, we paid the University of Iowa an up-front license fee of $35,000 and are obligated to make annual payments of $35,000 per year. We also agreed to pay a royalty on the sale of any of our products that utilize the underlying technology and milestone payments of $40,000 for each of the first four licensed products to receive FDA approval. We may terminate this agreement at any time. Otherwise, this license will terminate upon the expiration of the two licensed patents, which will be 2009 and 2012, respectively.

In March 2004, we obtained a non-exclusive, worldwide royalty-bearing license from the National Institutes of Health, or NIH, for patent applications relating to technology used in the humanization of monoclonal antibodies. Under this agreement we agreed to pay an up-front license fee, a minimum annual

In both the United States and foreign markets, the revenue associated with our products will depend largely upon the availability of reimbursement from third-party payers. Third-party payers include various government health authorities such as The Centers for Medicare and Medicaid Services, or CMS, which administers Medicare and Medicaid, managed-care providers, private health insurers and other organizations. Third-party payers are increasingly challenging the price and examining the cost-effectiveness of medical products and services, including pharmaceuticals. In addition, significant uncertainty exists as to the reimbursement status of newly approved pharmaceutical products. Our products may ultimately not be considered cost-effective, and adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to support a profitable operation or generate an appropriate return on our investment in product development.

The United States and foreign governments periodically propose and pass legislation designed to reduce the cost of healthcare. Accordingly, legislation and regulations affecting the pricing of pharmaceuticals may change before any of our product candidates are ever approved for marketing. Adoption of new legislation could further limit reimbursement for pharmaceuticals. In addition, an increasing emphasis on managed care in the United States has and will continue to increase the pressure on pharmaceutical pricing. The marketability of our products may suffer if the government and other third-party payers fail to provide adequate coverage and reimbursement rates for our product candidates.

We intend to obtain coverage and reimbursement for our products from these third-party payers, however we cannot assure you that we will be successful in obtaining adequate coverage, reimbursement, or pricing, if any.

The preclinical and clinical testing, manufacture, labeling, storage, distribution, promotion, sale and export, reporting and record-keeping of our product candidates are subject to extensive regulation by numerous governmental authorities in the United States, principally the FDA and corresponding state agencies, and regulatory agencies in foreign countries.

Non-compliance with applicable regulatory requirements can result in, among other things, fines, injunctions, seizure of products, total or partial suspension of product manufacturing and marketing, failure of the government to grant approval, withdrawal of marketing approvals and criminal prosecution.

Pursuant to FDA regulations, we are required to undertake a long and rigorous process before any of our product candidates may be marketed or sold in the United States. This regulatory process typically includes the following general steps:


•	the performance of satisfactory preclinical laboratory and animal studies under the FDA’s Good Laboratory Practices regulation;


•	the development and demonstration of manufacturing processes which conform to FDA-mandated current Good Manufacturing Practices, or cGMPs;

•	the submission and acceptance of an IND which must become effective before human clinical trials may begin in the United States;

•	obtaining the approval of Institutional Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials;

•	the successful completion of a series of adequate and well-controlled human clinical trials to establish the safety, purity, potency and efficacy of any product candidate for its intended use, which form to the FDA’s good clinical practice regulations; and

•	the submission to, and review and approval by the FDA of a Biologics License Application, or BLA, or for non-biologic pharmaceutical products, a New Drug Application, or NDA, prior to any commercial sale or shipment of a product.

This process requires a substantial amount of time and financial resources. We cannot assure you or be certain that this process will result in the granting of an approval for any of our product candidates on a timely basis, if at all. In 2002, the FDA announced a reorganization that has resulted in the shift of the oversight and approval process for certain therapeutic biologic drugs and the related staff from the Center for Biologics Evaluation and Research, or CBER, to the Center for Drug Evaluation and Research, or CDER. Our lead product candidate, Veronate, is being regulated through CBER, while Aurexis, and any other monoclonal product candidates that we may develop, are being regulated through CDER.

Preclinical tests generally include laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. We must submit the results of these preclinical tests, together with manufacturing information, analytical data and the clinical trial protocol, to the FDA as part of an IND, which must become effective before we may begin any human clinical trials. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within this 30-day time period, raises concerns or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. If one or more of our products is placed on clinical hold, we would be required to resolve any outstanding issues to the satisfaction of the FDA before we could begin, or continue clinical trials. Preclinical studies generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin.

In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the clinical protocol reviewed and approved by an independent IRB. The IRB considers, among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA’s Good Clinical Practices requirements.

Phase I. In Phase I clinical trials, a product candidate is typically introduced either into healthy human subjects, or patients with the medical condition for which the new drug is intended to be used. The main purpose of the trial is to assess a product candidate’s safety and the ability of the human body to tolerate the product candidate. Absorption, metabolism, distribution and pharmacokinetic trials are also generally performed at this stage.

Phase II. During this phase, a product candidate is studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended to be used in order to (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy or biologic activity of the product candidate for specific targeted diseases or medical

Phase III. If and when one or more Phase II trials demonstrate that a specific dose or range of doses of a product candidate is likely to be effective and has an acceptable safety profile, one or more Phase III trials are generally undertaken to further demonstrate clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase III trials will generally be designed to reach a specific goal or endpoint, the achievement of which is intended to demonstrate the product candidate’s clinical efficacy. The successful demonstration of clinical efficacy and safety in one or more Phase III trials is typically a prerequisite to the filing of a BLA or a NDA for a product candidate.

We cannot be certain that we will successfully complete the Phase I, Phase II or Phase III testing of our product candidates within any specific time period, if at all. Furthermore, we, the FDA or an IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health or safety risk.

Once our clinical trials have been completed, we must submit a BLA to the FDA in order to obtain approval for the marketing and sale of a product candidate. Among many other items, a BLA typically includes a description of the manufacturing process and quality control methods, as well as the results of preclinical and toxicology studies and clinical trials. The FDA must approve the BLA prior to the marketing and sale of the related product. The FDA may deny a BLA if all applicable regulatory criteria are not satisfied or may require additional data, including clinical, toxicology, safety or manufacturing data. It can take several years for the FDA to approve a BLA once it is submitted, and the actual time required for any product candidate may vary substantially, depending upon the nature, complexity and novelty of the product candidate. We cannot be certain that the FDA, or any other similar regulatory agency in other countries, will grant approval for any of our product candidates on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success in later stage clinical trials. Data obtained from preclinical and clinical activities is not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Even if such regulatory approval is granted, additional post-marketing, or Phase IV clinical trials, may be required that would add additional product development costs beyond those incurred through Phase III testing. Fast Track status products, such as Veronate and Aurexis are required to conduct Phase IV clinical trials.

Even if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery of previously unknown safety problems with a product may result in restrictions on its use or even complete withdrawal of the product from the market.

Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. Manufacturers of biologics must also comply with the FDA’s general biological standards. We cannot be certain that we, or our present or future contract manufacturers or suppliers, will be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure

If the FDA approves one or more of our product candidates, we and our contract manufacturers must provide the FDA with certain updated safety, efficacy, and manufacturing information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval.

The labeling, advertising, promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a Warning Letter directing the company to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution.

The FDA’s policies may change and additional government regulations may be enacted which could prevent or delay regulatory approval of our product candidates. Moreover, increased attention to the containment of health care costs in the United States and in foreign markets could result in new government regulations that could have a material adverse effect on our business. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.

Both Veronate and Aurexis have received Fast Track status as provided for under various FDA regulations. Veronate has also been designated as an Orphan Drug by the FDA, for the reduction of nosocomial bacteremia caused by staphylococci in VLBW infants. If our other product candidates meet the criteria, we may also apply for Orphan Drug and Fast Track status for such product candidates.

The FDA has developed “Fast Track” policies, which provide for the potential for expedited review of a BLA. However, there is no assurance that the FDA will, in fact, accelerate the review process for a Fast Track product candidate. Fast Track status is provided only for those new and novel therapies that are intended to treat persons with life-threatening and severely debilitating diseases, where there is a defined unmet medical need, especially where no satisfactory alternative therapy exists or the new therapy is significantly superior to alternative therapies. During the development of product candidates that qualify for this status, the FDA may expedite consultations and reviews of these experimental therapies. Further, an accelerated approval process is potentially available to product candidates that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses. The FDA can base approval of a marketing application for a Fast Track product on a clinical endpoint or on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may requires us as a condition of the approval of an application for certain Fast Track products on additional post-approval studies to validate the surrogate endpoint or confirm the effect on the clinical endpoint. Fast Track status also provides for the potential for a product candidate to have a “Priority Review.” A Fast Track status allows for portions of the BLA to be submitted to the FDA for review prior to the completion of the entire application, which could result in a reduction in the length of time it would otherwise take the FDA to complete its review of the BLA. Fast Track status may be revoked by the FDA at any time if the clinical results of a trial fail to continue to support the assertion that the respective product candidate has the potential to address an unmet medical need. In addition Fast Track status may be granted for a specific application of a drug candidate.

The FDA may grant Orphan Drug status to drugs intended to treat a “rare disease or condition,” which, in the United States, is generally a disease or condition that affects fewer than 200,000 individuals. If and when the FDA grants Orphan Drug status, the generic name and trade name of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Aside from guidance concerning the non-clinical laboratory studies and clinical investigations necessary for approval of the BLA, Orphan Drug status does not convey any advantage in, or shorten the duration of, the regulatory review and approval

Outside of the United States, our ability to market our product candidates will also be contingent upon receiving marketing authorizations from the appropriate foreign regulatory authorities whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally includes risks that are similar with the FDA approval process we have described herein. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals may vary widely from country to country and differ from that required for FDA approval.

As of December 31, 2004, we had 74 full-time employees, 58 of whom were engaged in research and development, clinical, regulatory, and quality assurance and control, and 16 of whom were engaged in administration, accounting, finance and business development. All of our employees have entered into non-disclosure agreements with us regarding our intellectual property, trade secrets and other confidential information. None of our employees is represented by a labor union or covered by a collective bargaining agreement, nor have we experienced any work stoppages. We believe that we maintain satisfactory relations with our employees.

Our offices and laboratory facilities are currently located in two separate leased properties in Alpharetta, Georgia, a northern suburb of Atlanta. We lease our office space, which is approximately 13,500 square feet, under a lease which expires in June 2005. We lease our laboratory facility, which is approximately 12,500 square feet, under a separate sub-lease which expires in December 2005. In December 2003, we entered into an agreement to lease a 51,000 square foot facility in Alpharetta, Georgia, which is being built to our specifications where we will relocate all personnel from both of our existing facilities. We anticipate that we will occupy this new facility during the second quarter of 2005, at which time we expect that our expense, including minimum lease obligations and the amortization of leasehold improvements paid by the lessor, for this facility will approximate $1.0 million per annum for the lease term of ten years.

In January 2003, Biosynexus commenced an action against us in the Superior Court of Fulton County, Georgia. The suit seeks injunctive relief and financial damages of $10.0 million on each of the three claims of (i) obtaining, (ii) converting and (iii) benefiting from alleged trade secrets, which we purportedly received through a large, nationally recognized third-party contract research organization.

In July 2003, the court denied Biosynexus’ request for an interlocutory injunction. The court’s ruling also stated that we made a preliminary showing that we did not misappropriate any Biosynexus information; that we are not using the information at issue; that our clinical trial protocol and approach to reporting adverse events, which were the alleged trade secrets, are substantially different than Biosynexus’; and that the alleged trade secrets are in fact not trade secrets but well known, widely-used and widely-reported concepts as applied to premature babies in a NICU. The court’s ruling also indicated that Biosynexus had not shown a substantial likelihood that it will ultimately prevail on the merits of its case at trial. Following this ruling, we notified Biosynexus, and its attorneys, of our intent to pursue an abusive litigation claim, as

The following table sets forth information concerning our executive officers and directors as of February 28, 2005:


(1)	Member of Compensation Committee.

(2)	Member of Audit Committee.

(3)	Member of the Nominating and Corporate Governance Committee.

William D. Johnston, Ph.D. has served as our President and Chief Executive Officer and a member of our board of directors since 1997. From 1991 to 1997, Dr. Johnston was Vice President and General Manager of the Gene Therapy Business Unit of Baxter Healthcare Corporation. From 1975 to 1991, Dr. Johnston held various executive positions at Baxter Healthcare Corporation, including Vice President of Applied Sciences, which was the central research and development unit of Baxter. Dr. Johnston currently serves as a director of ACTx, a privately held medical device company. Dr. Johnston is also a member of both the board of directors and the Emerging Companies Section Governing Body of the Biotechnology Industry Organization. Since 1999, Dr. Johnston has served on the board of the Georgia Biomedical Partnership; additionally, he is the chairman for the bioscience council executive committee for the Metro Atlanta Chamber of Commerce, and is an advisory member to the board of directors for the Georgia Department of Economic Development. Dr. Johnston received both a B.S. in Chemistry and a Ph.D. in Chemistry from Brigham Young University.

Seth V. Hetherington, M.D. has served as our Vice President, Clinical Development and Chief Medical Officer since June 2002. From 1995 to June 2002, Dr. Hetherington directed clinical programs in infectious diseases at GlaxoSmithKline. From 1984 to 2001, he held clinical appointments at various institutions, including the University of North Carolina, University of Tennessee, St. Jude Children’s Research Hospital in Memphis and Albany Medical College. Dr. Hetherington received a B.S. from Yale University and a M.D. from the University of North Carolina in Chapel Hill. Dr. Hetherington is board certified in pediatrics and infectious diseases.

Joseph M. Patti, M.S.P.H., Ph.D. is a co-founder of Inhibitex, Inc. and has served as our Vice President, Preclinical Development and Chief Scientific Officer since April 1998 and as a member of our board of

Russell H. Plumb has served as our Vice President, Finance and Administration and Chief Financial Officer since August 2000. From December 1999 to July 2000, Mr. Plumb served as Chief Financial Officer of Emory Vision, a healthcare company. From 1994 to November 1999, he served as Chief Financial Officer and Vice President, Finance of Serologicals Corporation, a publicly-held biopharmaceutical company. Mr. Plumb received both a B. Comm. and a M.B.A. from the University of Toronto. Mr. Plumb has received designations as a certified public accountant in Michigan and Georgia.

Robert T. Schweiger has served as our Vice President, Business Development since May 2001. From March 1999 to April 2001, Mr. Schweiger was Vice President, Business Development and Planning at UCB Pharma, a Belgian multinational pharmaceutical company. From August 1998 to February 1999, he was a consultant to various multinational pharmaceutical companies. Prior to that, Mr. Schweiger held various executive level positions with several large pharmaceutical companies, including 18 years with SmithKline Pharmaceuticals. Mr. Schweiger received a B.S. in Finance from Rider College and a M.B.A. from St. John’s University Graduate School of Business.

David M. Wonnacott, Ph.D. has served as our Vice President, Quality and Regulatory Affairs since May 2002. From May 2000 to March 2002, Dr. Wonnacott served as the Vice President of Regulatory Affairs at Aviron, Inc., a biopharmaceutical company. From 1988 to February 2000, he held several senior regulatory positions at Merck & Co. Inc. Prior to that, he held a quality operations position at Eastman Pharmaceutical, a division of Eastman Kodak. Dr. Wonnacott received a B.S. in Chemistry from Brigham Young University and a Ph.D. in Biochemistry from Utah State University.

Michael A. Henos has served as a member of our board of directors since July 1997 and as chairman of our board of directors since April 2001. Mr. Henos also served as chairman of our board of directors from July 1997 to January 2000. Since 1993, Mr. Henos has served as Managing General Partner of Alliance Technology Ventures, L.P., a venture capital firm. From 1991 to 2001, Mr. Henos also served as a General Partner of Aspen Ventures, a venture capital partnership. He currently serves as chairman of the board of directors of AtheroGenics, Inc., a publicly-held biopharmaceutical company. He is also a member of the board of directors of several privately-held biotechnology companies: Neuronyx, Inc., Genoptix, Inc., GlycoMimetics, Inc., and Sensys Medical, Inc.; as well as ValuBond, Inc., a company providing services to the brokerage industry. Mr. Henos received a B.S. in Economics and a M.B.A. in Finance from the University of California, Los Angeles.

M. James Barrett, Ph.D. has served as a member of our board of directors since February 2002. Since August 2001, Dr. Barrett has served as a general partner of NEA Partners 10, Limited Partnership, the general partner of New Enterprise Associates 10, Limited Partnership, a venture capital fund. From January 1997 to August 2001, he served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, Inc., a medical device company, which he founded in 1997 and continues to serve as the chairman of its board of directors. Dr. Barrett also serves on the boards of directors of two publicly-held biopharmaceutical companies: MedImmune, Inc. and Pharmion, Inc., as well as GlycoMimetics, Inc., Iomai Corporation, Peptimmune Inc., Nucleonics Inc., Eximias Pharmaceutical Corporation, Ruxson Pharma, Inc. and Targacept, Inc., which are privately-held life science companies. Dr. Barrett received a B.S. in Chemistry from Boston College, a Ph.D. in Biochemistry from the University of Tennessee and a M.B.A. from the University of Santa Clara.

Carl E. Brooks has served as a member of our board of directors since May 1999 and served as chairman from January 2000 to April 2001. Mr. Brooks is president of Brooks & Associates, a consulting firm for the biopharmaceutical and blood banking industries, which he founded in 1996. He previously served as the president of the Hyland division of Baxter Healthcare Corporation. He also serves as chairman of the

J. Douglas Eplett, M.D. has served as a member of our board of directors since February 2002. Since September 2000, Dr. Eplett has served as a general partner of Essex Woodlands Health Ventures, a venture capital firm. From July 2000 to August 2000, he worked as a private consultant. From May 1999 to June 2000, he served as a general partner of Pacific Horizon Ventures, LLC, a venture capital firm. From August 1998 to March 1999, he served as a consultant for Vanguard Venture Partners, a venture capital firm, and from 1995 to 1998, he directed medical affairs and business development activities at CardioGenesis Corp. Dr. Eplett serves on the boards of directors of St. Francis Medical Technologies, Inc. and Essentia Biosystems, Inc., which are privately-held medical device companies. He received a B.A. from the University of Vermont, a M.D. from Tufts University and a M.B.A. from Stanford University.

Russell M. Medford, M.D., Ph.D. has served as a member of our board of directors since July 1997. Since 1995, Dr. Medford has served as the President and Chief Executive Officer of AtheroGenics, Inc., a publicly-held biopharmaceutical company, and currently serves as a member of its board of directors. He also serves on the board of directors of SELSA (Southeastern Life Sciences Association), on the Biotechnology Industry Organization’s Emerging Companies Section Governing Body, and on the Biosciences Executive Committee for the Metro Atlanta Chamber of Commerce and is vice chairman of the board of directors of the Georgia Biomedical Partnership. He received a B.A. from Cornell University, and a M.D. and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine. Dr. Medford completed his residency in internal medicine at the Beth Israel Hospital, Boston, Massachusetts, and his fellowship in cardiology at the Brigham and Women’s Hospital, Boston, Massachusetts, and Harvard Medical School, where he also served on the faculty of medicine.

Arda M. Minocherhomjee, Ph.D. has served as a member of our board of directors since June 2000. Dr. Minocherhomjee is currently a partner at Chicago Growth Partners. Since 1998, he has served as a managing director of William Blair Capital Partners, LLC, a venture capital firm and prior to that, was a principal and senior healthcare analyst at William Blair & Co. He also serves on the board of directors of NuVasive Inc., a publicly-held medical device company, Favrille, Inc., a publicly-held oncology company, and several privately-held pharmaceutical and medical device companies, including CryoCor, Inc., Cypress Medical Products, LP, POINT Biomedical Corporation, and Targagen, Inc. Dr. Minocherhomjee received a M.Sc. in Pharmacology from the University of Toronto and a Ph.D. and a M.B.A. from the University of British Columbia and was a post doctoral fellow in pharmacology at the University of Washington Medical School.

Marc L. Preminger, FSA, MAAA, has served as a member of our board of directors since August 2003. From 1977 to September 2002, Mr. Preminger served in various capacities with CIGNA Corporation, a healthcare insurance company, the most recent of which was as its Senior Vice President and Chief Financial Officer of Cigna Healthcare. In 2004, he co-founded ACT II Ventures, LLC, a consulting firm. He also serves on the board of directors of Gifts of Love, a not-for-profit social services agency. Mr. Preminger received a B.S. in Economics from Lafayette College and a Masters of Actuarial Science from Georgia State University.

Louis W. Sullivan, M.D. has served as a member of our board of directors since August 2003. Dr. Sullivan is the founding Dean, Director and President Emeritus of the Morehouse School of Medicine. From 1993 until his retirement in June 2002 and from 1981 to 1989, Dr. Sullivan served as President of Morehouse School of Medicine. From 1989 to 1993, he served as Secretary, United States Department of Health and Human Services. Dr. Sullivan serves on the boards of directors of 3M Corporation, Bristol-Myers Squibb Company, CIGNA Corporation, Georgia-Pacific Corporation, Henry Schein, BioSante and United Therapeutics Corporation. He received a B.S. from Morehouse College and a M.D. from Boston University.

Our board of directors is divided into three classes, each of whose members serves for a staggered term. At each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2005 for the Class I directors, 2006 for the Class II directors and 2007 for the Class III directors.


•	Our Class I directors are Arda M. Minocherhomjee, J. Douglas Eplett and Russell M. Medford.

•	Our Class II directors are Louis W. Sullivan, Carl E. Brooks and Joseph M. Patti.

•	Our Class III directors are William D. Johnston, Michael A. Henos, Marc L. Preminger and M. James Barrett.

Our amended and restated certificate of incorporation and by-laws provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the total number of directors. Each officer serves at the discretion of the board of directors and holds office until his successor is elected and qualified or until his earlier resignation or removal. There are no family relationships among any of our directors or executive officers. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.

Our directors who are not employees receive an annual retainer of $25,000 and an additional $2,500 for serving on a committee of our board of directors for the year 2005. In 2004 the annual retainer was $10,000 with an additional $2,000 for serving on a committee of our board of directors. In addition to the foregoing $25,000 retainer, our chairman of the board, chairman of our audit committee, chairman of our compensation committee and chairman of our nominating and corporate governance committee will receive additional annual retainers of $20,000, $7,500, $5,000 and $5,000, respectively. Our non-employee directors are also eligible to participate in the 2004 Stock Incentive Plan, pursuant to which upon their election to our board, they will be entitled to an initial option grant to purchase 20,000 shares of common stock, as well as annual option grants to purchase 6,000 shares of common stock; provided that our chairman of the board is entitled to an annual option grant to purchase 18,000 shares of common stock. See the “Management — Employee Benefit Plans — 2004 Stock Incentive Plan” section for a further description of our 2004 Stock Incentive Plan. All of our non-employee directors are reimbursed for out-of-pocket expenses incurred in attending board and committee meetings.

Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and responsibilities described below. The board may also establish other committees from time to time to assist in the discharge of its responsibilities.

Audit Committee. Our audit committee oversees our corporate accounting and financial reporting process. Among other things, our audit committee monitors the qualifications, independence and performance of the independent auditors; determines the engagement and compensation of the independent auditors; approves the retention of the independent auditors to perform any proposed and permissible non-audit services; reviews our financial statements; reviews our critical accounting estimates; and discusses with management and the independent auditors the results of the annual audit and the review of our quarterly financial statements. Our audit committee also reviews the effectiveness of internal controls and the adequacy of our disclosure controls. In addition, our audit committee maintains procedures for the receipt of complaints and employee submissions of concerns regarding accounting or auditing matters. The members of our audit committee are Mr. Preminger, chairman, and Drs. Eplett, Medford, and Sullivan.

Mr. Preminger is our audit committee financial expert under the SEC rule implementing Section 407 of the Sarbanes-Oxley Act of 2002. We believe that the composition of our audit committee meets the standards for independence under the current applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations. Although Dr. Medford is not independent (as such term is defined under the rules of the Nasdaq National Market) due to the relationship between AtheroGenics, Inc., of which Dr. Medford is president and chief executive officer, as is described under “Certain Relationships and Related Party Transactions — Other Related Party Transactions,” our board of directors has determined, because of Dr. Medford’s experience as president and chief executive officer of a publicly-traded biopharmaceutical company and his familiarity with us and our business as one of our longest-standing board members, that his membership on the audit committee is in our best interests and the best interests of our stockholders, and is therefore permitted under the rules of the Nasdaq National Market. We believe that the functioning of our audit committee complies with the applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations.

Compensation Committee. Our compensation committee establishes, amends, reviews and approves our compensation and benefit plans with respect to our officers and employees, including reviewing the performance of and determining individual elements of total compensation of the Chief Executive Officer and other executive officers. The compensation committee also determines annual retainer, meeting fees, stock awards and other compensation for members of the board of directors and administers the issuance of stock options and other awards under our equity incentive plans. The current members of our compensation committee are Dr. Minocherhomjee, chairman, Messrs. Henos and Brooks and Dr. Barrett. We believe that the composition of our compensation committee meets the standards for independence under the current applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations. We believe that the functioning of our compensation committee complies with the applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations.

Nominating and Corporate Governance Committee. Our nominating and corporate governance committee develops and recommends to the board of directors corporate governance principles and procedures applicable to the Company, identifies individuals qualified to become board members, determines the director nominees for each annual meeting of the Company’s stockholders and ensures that the audit, compensation and nominating and corporate governance committees of the board of directors shall have the benefit of qualified and experienced independent directors. The current members of our nominating and corporate governance committee are Dr. Sullivan, chairman, and Dr. Barrett and Mr. Brooks. We believe that the composition of our nominating and corporate governance committee meets the standards for independence under the current applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations. We believe that the functioning of our nominating and corporate governance committee complies with the applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations.

None of our executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who serve on our board or compensation committee. None of the members of our compensation committee has ever been our employee.

We lease office and laboratory facilities in Alpharetta, Georgia from AtheroGenics, Inc. Michael A. Henos, a member of our compensation committee, is the chairman of the board of directors of AtheroGenics, Inc. This lease will expire on December 31, 2005. Current monthly lease payments to AtheroGenics pursuant to this lease are approximately $16,700. In addition to these lease payments, we are also currently paying AtheroGenics, Inc. $3,799 per month pursuant to a 7% promissory note in connection with certain leasehold improvements at our leased facility. As of December 31, 2004, the outstanding balance of the note was $43,906. The note expires in December 2005. See “Related Party Transactions” for information regarding shares of our common stock issued to entities affiliated with Alliance Technology Ventures, whose managing partner is Michael A. Henos.

In addition, Mr. Henos’s wife, Claudia Henos, purchased shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock in the private placement which took place in November 2004.

The following table sets forth the total compensation paid to or earned by our chief executive officer and each of our four other most highly compensated executive officers for the fiscal year ended December 31, 2004, who were serving as executive officers on December 31, 2004 and whose total annual cash compensation exceeded $100,000 for the year ended December 31, 2004. We refer to these individuals elsewhere in this prospectus as our “named executive officers.”


	(1)	We have omitted perquisites and other personal benefits that do not exceed the lesser of $50,000 or 10% of the executive officer’s annual salary and bonus disclosed in this table. We have also omitted information regarding group life and health insurance benefits that do not discriminate in favor of our directors or executive officers and are generally available to all salaried employees.

	(2)	Salaries and bonuses are reported as in the year paid.

	(3)	The amounts on the table under “All Other Compensation” represent supplemental insurance and 401(k) matching contributions, and in the case of Dr. Hetherington also represents relocation reimbursement of $77,050.

Stock Option Grants in 2004. The following table sets forth information concerning stock option grants made to each of the named executive officers during the fiscal year ended December 31, 2004. The potential realizable value is calculated based on the term of the option at the time of its grant, which is six years. Potential realizable values are net of exercise price, but before taxes associated with the exercise. This value is based on assumed rates of stock appreciation of 5% and 10% compounded annually from the date the options were granted until their expiration date. These numbers are calculated based on the requirements of the SEC and do not reflect our estimate of future stock price growth. Actual gains, if any,

Aggregated Option Exercises in Fiscal Year 2004 and Fiscal Year-End Option Values. The following table sets forth certain information regarding the number and value of unexercised options held by each of the named executive officers as of December 31, 2004. Amounts described in the following table under the heading “Value of Unexercised In-the-Money Options at Year End” are determined by multiplying the number of shares underlying the options by the difference between the closing price of $8.04 per share on December 31, 2004, and the per share option exercise price. The shares acquired on exercise of stock options, as set forth in the table below, were acquired prior to our initial public offering. Amounts under the table heading “Value Realized” are determined by multiplying the number of shares exercised by the difference between the initial public offering price of $7.00 per share, and the per share option exercise price.

William D. Johnston. Effective February 20, 2004, we entered into an employment agreement with William D. Johnston, our chief executive officer and president. The agreement has an initial term of one year and automatically renews on its anniversary date for an additional one-year term unless employment is terminated in accordance with the agreement. The agreement provides for an annual base salary of $350,000, subject to annual increases as approved by our compensation committee, and health and insurance benefits. Dr. Johnston is eligible for bonus and incentive (including stock option and other equity-based) compensation plans as established by our compensation committee, with a target bonus of up to 50% of base salary.

Under the agreement, we or Dr. Johnston may terminate his employment at any time. If we terminate Dr. Johnston without cause, or he resigns for good reason, he will be entitled, subject to execution of a release of Inhibitex, to receive severance payments representing 12 months of salary and health and

While employed by us and for a period equal to the greater of one year or the severance period, Dr. Johnston shall not directly or indirectly in the United States (i) render substantially similar services to any person or entity which competes with us; (ii) solicit for employment any person who was employed by us; or (iii) call on or solicit any of our customers or a potential customer with which we were in negotiations.

Executive Officer Employment Agreements. On December 11, 2002, we entered into employment agreements with each of our other named executive officers: Dr. Hetherington, Dr. Patti, Mr. Plumb and Dr. Wonnacott. All of these agreements were amended and restated as of February 20, 2004. Each of the employment agreements has an initial term of one year and automatically renews on its anniversary date for an additional one-year term unless employment is terminated in accordance with the agreement.

Each employment agreement provides for annual base salary, subject to annual increases as approved by our compensation committee, and health and insurance benefits. The 2005 annual base salary for Dr. Hetherington, Dr. Patti, Mr. Plumb and Dr. Wonnacott is $327,600, $232,500, $232,500, and $233,000, respectively. Each employment agreement also provides that these named officers are eligible for bonus and incentive compensation plans, including stock options and other equity-based compensation as established by our compensation committee, with a target bonus of up to 30% of base salary. In Dr. Hetherington’s case, his employment agreement also provided for a monthly automobile allowance of $600 per month and a monthly housing allowance of $1,970 per month, which allowances terminated in October 2004.

Under these agreements, we, or any of these named officers, may terminate his employment at any time. If we terminate one of these named executive officers without cause, or he resigns for good reason, such officer will be entitled, subject to execution of a release of Inhibitex, to receive severance payments representing 12 months of salary and health and insurance benefits. In addition, if within one year after a change in control of Inhibitex (or in contemplation of a change in control that is reasonably likely to occur), one of these named executive officers is involuntarily terminated for any reason other than for cause, or resigns for good reason, such executive officer will be entitled, subject to execution of a release of Inhibitex, to receive severance payments totaling 18 months of salary and health and insurance benefits. In addition, vesting of options to purchase shares of our common stock held by such named executive officers would accelerate upon a change in control.

While employed by us and for a period equal to the greater of one year or the severance period, an executive officer shall not directly or indirectly in the United States (i) render substantially similar services to any person or entity which competes with us; (ii) solicit for employment any person who was employed by us; or (iii) call on or solicit any of our customers or a potential customer with which we were in negotiations.

We adopted, and our stockholders approved, the 2002 Stock Incentive Plan in February 2002. We amended, restated and renamed it as the 2004 Stock Incentive Plan, or the Stock Incentive Plan, and our stockholders approved it as of February 20, 2004. The Stock Incentive Plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, deferred stock units, restricted stock awards, dividend rights, stock appreciation rights, cash payments and other forms of stock-based compensation,

Shares Reserved. As of March 31, 2005, 1,794,208 shares of common stock were reserved for issuance under the Stock Incentive Plan.

In addition, shares subject to stock awards granted under our Amended and Restated 1998 Equity Ownership Plan and our 2002 Non-Employee Directors Plan, as described later in this section, that expire, are forfeited or otherwise terminate without being exercised, will be available for re-issuance under the Stock Incentive Plan.

When a stock award expires, is settled in cash or is terminated before it is exercised or shares are not issued or are withheld upon the exercise of a stock award, the shares not acquired, not issued or withheld pursuant to the stock awards shall again become available for issuance under the Stock Incentive Plan. Similarly, any shares tendered to pay an exercise price or withheld in satisfaction of tax obligations shall again become available for issuance under the Stock Incentive Plan.

Administration and Exercise Price. Our compensation committee administers the Stock Incentive Plan. The compensation committee may delegate authority to perform certain functions under the Stock Incentive Plan to our executive officers. Subject to the terms of the Stock Incentive Plan, the compensation committee determines recipients, the numbers and types of equity awards to be granted, any applicable performance goals and the terms and conditions of the equity awards. The compensation committee determines the exercise price of option grants, the purchase price for rights to purchase restricted stock and the strike price for stock appreciation rights. Pursuant to the terms of the Stock Incentive Plan, each person who is elected for the first time to be a non-employee director will be granted an option to purchase 20,000 shares of common stock. Subsequently, each non-employee director will be granted an option to purchase 6,000 shares of common stock on February 1 of each year (18,000 shares in the case of our Chairman of the Board), provided, however, that each non-employee director who has been a non-employee director for less than 12 months at February 1 will receive an annual grant that has been pro-rated from the date of commencement of service as a non-employee director.

Vesting and Term. Stock awards granted under the Stock Incentive Plan to employees to date generally vest annually over four years. Annual stock awards under the Stock Incentive Plan to directors will vest in their entirety on the first anniversary of the date of grant and initial grants to directors upon joining our board will vest over three years after the date of grant at the rate of 33% for each completed year of service. The vesting and term of each stock award are set by the compensation committee, provided that no term can exceed ten years from the date of grant.

Transferability. Subject to certain exceptions, each of the awards under the Stock Incentive Plan may not be transferred other than by will or by the laws of descent and distribution. However, a participant may designate a beneficiary who may exercise the rights under the stock-based award following the participant’s death. The compensation committee, in its discretion, may provide for the transfer of stock awards granted under the Stock Incentive Plan to certain trusts and partnerships for the benefit of or held by immediate family members of the participant.

Effect of a Change in Control. Upon a change in control, as defined in the Stock Incentive Plan, under certain circumstances, vesting of options is subject to acceleration pursuant to a formula based upon the employee’s length of service so that, with respect to an employee who has been employed by us for two years, all such options would vest.

Termination of Service. A non-employee director whose service as a director ceases for any reason other than removal of such non-employee director for cause may exercise vested options for 12 months. In the case of removal for cause, the options shall terminate immediately upon such removal.

We adopted our 2002 Non-Employee Directors Stock Option Plan, or Director Plan, in February 2002. Upon our adoption of the 2004 Stock Incentive Plan in February 2004, no further options were authorized to be granted under or from the Director Plan. All options outstanding under the Director Plan will remain in full force and effect until they expire or are exercised. As of December 31, 2004, outstanding stock options to purchase a total of 66,804 shares of our common stock were held by participants under the Director Plan.

Administration and Exercise Price. Our compensation committee administers the Director Plan.

Vesting and Term. Awards granted under the Director Plan to date generally vest over three years after the date of grant at the rate of 33% for each completed year of service. Options granted under the Director Plan may be exercised, once vested, up to ten years from the date of grant.

Transferability. Awards granted under the Director Plan are generally not transferable, other than by will or by the laws of descent and distribution, and are exercisable during the life of the non-employee director only by the non-employee director or his or her guardian or legal representative. The compensation committee, in its discretion, may provide for the transfer of awards granted under the Director Plan to certain trusts and partnerships for the benefit of or held by immediate family members of the non-employee director.

In May 1998 our board of directors adopted our 1998 Equity Ownership Plan, or the 1998 Plan, which was amended and restated several times to increase the number of reserved shares, the last of which occurred in December 2000. Upon the adoption of the 2002 Stock Incentive Plan in February 2002, no further options were authorized to be granted under or from the 1998 Plan. All options outstanding under the 1998 Plan will remain in full force and effect until they expire or are exercised. As of December 31, 2004, options to purchase 188,262 shares of our common stock were outstanding under our 1998 Plan. The vast majority of the options granted under the 1998 Plan are intended to be ISOs.

Administration. Our compensation committee administers the 1998 Plan, and may delegate authority to perform certain functions under the 1998 Plan to our executive officers.

Vesting and Term. Options granted under the 1998 Plan generally vest over four years and terminate on the tenth anniversary of the date of grant.

Transferability. Unless otherwise provided in the 1998 Plan or in the individual stock option agreement, options granted under the 1998 Plan may not be transferred.

Our board of directors adopted, and our stockholders approved as of February 20, 2004, our 2004 Employee Stock Purchase Plan, or the Purchase Plan. The purpose of the Purchase Plan is to provide an opportunity for our employees to purchase a proprietary interest in us.

Administration. The Purchase Plan is administered by a committee appointed by the board of directors for such purpose. The board of directors has appointed our compensation committee to administer the Purchase Plan.

Shares Reserved. A total of 210,084 shares of common stock are authorized for issuance under the Purchase Plan as of December 31, 2004.

Eligibility. Employees who are customarily employed for more than 20 hours per week and for more than five months in any calendar year and have been so employed for a six-month period are eligible to participate in the Purchase Plan. Employees who would own 5% or more of the total combined voting power or value of all classes of our stock immediately after the grant may not participate in the purchase plan.

Purchase Periods. The Purchase Plan is intended to qualify under Section 423 of the Internal Revenue Code and provides for quarterly purchase periods.

Payroll Deduction; Purchase Limitations. The Purchase Plan permits participants to purchase common stock through payroll deductions of up to 25% of their eligible base salary. For any calendar year, a participant may not be granted rights to purchase shares to the extent the fair market value of such shares exceeds $25,000.

Amounts deducted and accumulated by the participant are used to purchase shares of our common stock at the end of each quarterly purchase period. The purchase price per share is 85% of the lower of the fair market value of our common stock at the beginning of a purchase period or at the end of a purchase period. An employee’s participation ends automatically upon termination of employment with us.

Nontransferability. A participant may not transfer rights to purchase our common stock under the Purchase Plan other than by will or the laws of descent and distribution.

Effect of a Change of Control. In the event of a change of control, no further shares shall be available under the Purchase Plan, but all payroll deductions scheduled for collection in that purchase period will be immediately applied to purchase whole shares of our common stock.

Additional Provisions. Our board of directors has the authority to amend or terminate the Purchase Plan, except that, subject to certain exceptions described in the Purchase Plan, no such action may adversely affect any outstanding rights to purchase stock under the Purchase Plan and the board of directors may not increase the number of shares available under the Purchase Plan, or amend the requirements as to the eligible class of employees, without stockholder approval.

We sponsor a 401(k) plan for the benefit of our employees that is a defined contribution plan intended to qualify under Section 401(a) of the Internal Revenue Code of 1986, as amended. Eligible employees may make pre-tax contributions to the 401(k) plan subject to the statutorily prescribed annual limit. Under the 401(k) plan, each employee is fully vested in his or her deferred salary contributions. The 401(k) plan permits us to make discretionary matching and profit-sharing contributions. During 2004 we matched 50% of an employee’s contributions, up to a maximum of 6% of that employee’s annual base compensation.

Our amended and restated certificate of incorporation contains certain provisions permitted under the Delaware General Corporation Law relating to the liability of directors. These provisions eliminate a director’s personal liability for monetary damages resulting from a breach of fiduciary duty, except in certain circumstances involving a breach of their duty of loyalty to our company or our stockholders, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law or any transaction from which the director derived an improper personal benefit.

These provisions do not limit or eliminate our rights or the rights of any stockholder to seek non-monetary relief, such as an injunction or rescission, in the event of a breach of a director’s fiduciary duty. These provisions also will not alter a director’s liability under federal securities laws. Our amended and restated certificate of incorporation and amended and restated by-laws also contain provisions indemnifying our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. We believe

We have entered into separate, but identical, indemnity agreements with each of our directors and executive officers and we expect to enter into similar indemnity agreements with persons who become directors or executive officers in the future. These indemnity agreements provide that we will indemnify our directors or executive officers, or the indemnitees, against any amounts that he or she becomes legally obligated to pay in connection with any claim against him or her based upon any act, omission, neglect or breach of duty that he or she may commit, omit or suffer while acting in his or her capacity as a director and/or officer of Inhibitex; provided that such claim: (i) is not based upon the indemnitee’s gaining any personal profit or advantage to which he or she is not legally entitled; (ii) is not for an accounting of profits made from the purchase or sale by the indemnitee of our securities within the meaning of Section 16(b) of the Exchange Act or similar provisions of any state law; and (iii) is not based upon the indemnitee’s knowingly fraudulent, deliberately dishonest or willful misconduct. The indemnity agreements also provide that all costs and expenses incurred by the indemnitee in defending or investigating any such claim shall be paid by us in advance of the final disposition thereof unless a majority of our directors who are not parties to the action, independent legal counsel in a written opinion, our stockholders or a court of competent jurisdiction in a final, unappealable adjudication determine that: (i) the indemnitee did not act in good faith and in a manner that he or she reasonably believed to be in or not opposed to our best interests or (ii) in the case of any criminal action or proceeding, the indemnitee had reasonable cause to believe his or her conduct was unlawful. Each indemnitee has undertaken to repay us for any costs or expenses so advanced if it shall ultimately be determined by a court of competent jurisdiction in a final, nonappealable adjudication that he or she is not entitled to indemnification under the indemnity agreements.

In addition, we maintain directors’ and officers’ liability insurance to provide our directors and officers with insurance coverage for losses arising from claims based on breaches of duty, negligence, error and other wrongful acts.

Other than employment agreements and other arrangements that are described in “Management” and the transactions described below, since January 1, 2002, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a party where the amount involved exceeded or will exceed $60,000 and in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of their immediate family had or will have a direct or indirect material interest.

We believe that we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third parties. It is the policy of the board that any and all future transactions between us and our executive officers, directors and principal stockholders and their affiliates, are approved by a majority of the board of directors, including a majority of the independent and disinterested members of the board of directors, and are on terms no less favorable to us than those that we could obtain from unaffiliated third parties.

The following is a summary of the participation of persons and entities who are our directors, executive officers or holders of 5% or more of any class of our capital stock in our preferred and common stock and warrant transactions since January 1, 2002. Upon the completion of our IPO in June 2004, each share of Series D and Series E preferred stock was converted into approximately 0.42 shares of our common stock based upon the 1-for-2.38 reverse stock split, which was effected on May 21, 2004.

In February, March and April 2002, we issued an aggregate of 11,420,794 shares of our Series D preferred stock at a price per share of $3.94 for a total purchase price of $44,997,928. We also issued warrants to purchase an aggregate of 2,855,200 shares of Series D preferred stock at an exercise price of $5.91 per share in connection with our Series D financing. The following table sets forth the number of shares of Series D preferred stock and related warrants sold to our 5% stockholders and their affiliates.


(1)	See “Principal Stockholders” for more detail on shares held by these purchasers and their affiliated entities.

(2)	Dr. M. James Barrett, a member of our board of directors, is a general partner of NEA Partners 10, Limited Partnership, the general partner of New Enterprise Associates 10, Limited Partnership.

(3)	Dr. J. Douglas Eplett, a member of our board of directors, is a general partner of Essex Woodlands Health Ventures V, L.P.

(4)	Michael A. Henos, the chairman of our board of directors, is the general partner or manager of the general partner of each of the entities affiliated with Alliance Technology Ventures III, L.P.

(5)	Dr. Arda M. Minocherhomjee, a member of our board of directors, is a managing director of William Blair Capital Partners VI, L.L.C., the general partner of William Blair Capital Partners VI, L.P.

On December 19, 2003, we issued an aggregate of 5,087,740 shares of our Series E preferred stock at a price per share of $3.94 for total proceeds of $20,045,696. We also issued warrants to purchase an

The following table sets forth the number of shares of Series E preferred stock and related warrants sold to our 5% stockholders and their affiliates.


(1)	See “Principal Stockholders” for more detail on shares held by these purchasers and their affiliated entities

(2)	Dr. M. James Barrett, a member of our board of directors, is a general partner of NEA Partners 10, Limited Partnership, the general partner of New Enterprise Associates 10, Limited Partnership.

(3)	Dr. Arda M. Minocherhomjee, a member of our board of directors, is a managing director of William Blair Capital Partners VI, L.L.C., the general partner of William Blair Capital Partners VI, L.P.

(4)	Michael A. Henos, the chairman of our board of directors, is the general partner or manager of the general partner of each of the entities affiliated with Alliance Technology Ventures III, L.P.

(5)	Dr. J. Douglas Eplett, a member of our board of directors, is a general partner of Essex Woodlands Health Ventures V, L.P. of Essex Woodlands Health Ventures V, L.P.

On November 10, 2004 we completed a PIPE financing in which we raised approximately $50 million in gross proceeds through the sale, at a price of $7.3775 per share, of 6,777,370 shares of our common stock and warrants to purchase 2,033,211 shares of our common stock. The warrants, which become exercisable on May 9, 2005 and expire November 10, 2009, have an exercise price of $8.81 per share. The following table sets forth the number of shares purchased in the private placement of common stock by our 5% stockholders and their affiliates.


(1)	See “Principal Stockholders” for more detail on shares held by these purchasers and their affiliated entities.

(2)	Includes 582,500 shares of common stock and warrants to purchase 174,750 shares of common stock purchased by New Enterprise Associates 10, Limited Partnership (“NEA 10”) and 1,355,470 shares of common stock and warrants to purchase 406,641 shares of common stock purchased by New Enterprise Associates 11, Limited Partnership (“NEA 11”). Dr. M. James Barrett, a member of our board of directors, is a general partner of NEA Partners 10, Limited Partnership, the general partner of NEA 10, and a manager of NEA 11 GP, LLC, which is the general partner of NEA Partners 11, Limited Partnership, the general partner of NEA 11.

(3)	Dr. Arda M. Minocherhomjee, a member of our board of directors, is a managing director of William Blair Capital Partners VI, L.L.C., the general partner of William Blair Capital Partners VI, L.P.

(4)	Michael A. Henos, the chairman of our board of directors, is the general partner or manager of the general partner of each of the entities affiliated with Alliance Technology Ventures III, L.P.


(5)	Dr. J. Douglas Eplett, a member of our board of directors, is a general partner of Essex Woodlands Health Ventures V, L.P.

(6)	Michael A. Henos, chairman of the Board, is married to Claudia Henos.

Under the terms of our prior certificate of incorporation, holders of shares of our Series C and Series D preferred stock were entitled to receive a cumulative annual dividend of 8% on their investment. The cumulative dividend accrued daily, whether or not declared. Upon the completion of our IPO in June 2004 and the adoption of our amended and restated certificate of incorporation, all preferred stock was converted into shares of common stock and therefore, dividends on these preferred shares ceased to accrue.

We lease office and laboratory facilities in Alpharetta, Georgia from AtheroGenics, Inc. Michael A. Henos, our chairman, and Russell M. Medford, a member of our board of directors, are chairman of the board of directors and the president and chief executive officer, respectively, of AtheroGenics, Inc. This lease will expire on December 31, 2005. Current monthly lease payments to AtheroGenics pursuant to this lease are approximately $16,700. In addition to these lease payments, we are currently paying AtheroGenics, Inc. $3,799 per month pursuant to a 7% promissory note in connection with certain leasehold improvements at our leased facility. As of December 31, 2004, the outstanding balance of the note was $43,906. The note expires in December 2005.

The following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of February 28, 2005 (except as indicated below), by:


•	each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our common stock (with respect to such stockholders, information is presented as of December 31, 2004);

•	each of our directors;

•	each of our named executive officers; and

•	all directors and executive officers as a group.

The column entitled “Percentage of Shares of Common Stock Beneficially Owned” is based on 25,170,626 shares of common stock outstanding after giving effect to the 6,777,370 shares issued in the private placement that closed on November 10, 2004 and assuming no further exercises of outstanding options or warrants. The warrants to purchase 2,033,211 shares of common stock that were issued in connection with the private placement have not been included as they are not exercisable until May 9, 2005.

Beneficial ownership is determined in accordance with the rules of the SEC. The information does not necessarily indicate beneficial ownership for any other purpose. For purposes of calculating each person’s or group’s percentage ownership, stock options and warrants exercisable within 60 days after February 28, 2005 are included for that person or group, but not the stock options or warrants of any other person or group.

Except as otherwise noted, the persons or entities in this table have sole voting and investing power with respect to all of the shares of common stock beneficially owned by them, subject to community property laws, where applicable.


	(1)	Includes 5,140,482 shares (including the 582,500 shares being sold in this offering) and 772,539 shares issuable under warrants but does not include 174,750 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005 beneficially owned by New Enterprise Associates 10, Limited Partnership and 1,355,470 shares being sold in this offering, but not 406,641 shares issuable under warrants exercisable as of May 9, 2005 beneficially owned by New Enterprise Associates 11, Limited Partnership. NEA Partners 10, Limited Partnership is the general partner of New Enterprise Associates 10, Limited Partnership. NEA 11 GP, LLC is the general partner of NEA Partners 11, Limited Partnership which is the sole general partner of New Enterprise Associates 11, Limited Partnership. Each of Stewart Alsop, James Barrett, Peter J. Barris, Nancy L. Dorman, C. Richard Kramlich, Thomas C. McConnell, Peter T. Morris, Charles W. Newhall III, Mark W. Perry, Scott D. Sandell and Eugene A. Trainor III, as a general partner of NEA Partners 10, Limited Partnership and as a manager of NEA 11 GP, LLC may be deemed to have shared voting and dispositive power over the shares held by New Enterprise Associates 10, Limited Partnership and New Enterprise Associates 11, Limited Partnership, and disclaims beneficial ownership of these shares except to the extent of his or her pecuniary interest therein. Each of New Enterprise Associates 10, Limited Partnership, and New Enterprise Associates 11, Limited Partnership is located at 1119 St. Paul Street, Baltimore, Maryland 21202.

	(2)	Includes 2,477,240 shares (including the 135,550 shares being sold in this offering) and 175,959 shares issuable under warrants but does not include 40,665 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005 beneficially owned by William Blair Capital Partners VI, L.P. William Blair Capital Partners VI, L.L.C. is the general partner of William Blair Capital Partners VI, L.P. Arda Minocherhomjee, as a member of the Board of Managers of William Blair Capital Partners VI, LLC, may be deemed to have voting and dispositive power over the shares held by William Blair Capital Partners VI, L.P. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. William Blair Capital Partners VI, L.P. is located at 227 W. Monroe Street, Suite 3500, Chicago, Illinois 60606.

	(3)	Includes 1,230,460 shares (including the 70,500 shares being sold in this offering) and 159,963 shares issuable under warrants but does not include 21,150 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005 beneficially owned by Alliance Technology Ventures III, L.P.; and 13,323 shares (including the 800 shares being sold in this offering) and 2,651 shares issuable under warrants but does not include 240 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005 beneficially owned by ATV III Affiliates Fund, L.P. Michael A. Henos as a manager of ATV III Partners, L.L.C., the general partner of Alliance Technology Ventures III, L.P. and ATV III Affiliates Fund, L.P. may be deemed to have voting and dispositive power over such shares and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Alliance Technology Ventures is located at 2400 Lakeview Parkway, Alpharetta, Georgia 30004.

	(4)	Includes 1,381,404 shares (including the 135,550 shares being sold in this offering) and 226,614 shares issuable under warrants but does not include 40,665 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005 beneficially owned by Essex Woodlands Health Ventures V, L.P. J. Douglas Eplett, James Currie, Martin Sutter and Immanuel Thangeraj may be deemed to have shared voting and dispositive power over the shares held by Essex Woodlands Health Ventures and disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein. Essex Woodlands Health Ventures is located at 190 S. LaSalle Street, Suite 2800, Chicago, Illinois 60603.

	(5)	Includes 1,704,270 shares (including the 704,270 shares being sold in this offering, which are held in the name of a nominee) but does not include 211,281 shares being sold in this offering issuable under warrants exercisable as of May 9, 2005. T. Rowe Price Associates, Inc. (“T. Rowe Price Associates”) serves as investment adviser with power to direct investments and/or sole power to vote the shares owned by T. Rowe Price Small-Cap Value Fund, Inc., as well as shares owned by certain other individual and institutional investors. T. Rowe Price Associates may be deemed to be the beneficial owner of all of the shares listed above; however, T. Rowe Price Associates expressly disclaims that it is, in fact, the beneficial owner of such securities. T. Rowe Price Associates is a wholly owned subsidiary of T. Rowe Price Group, Inc., which is a publicly traded financial services holding company located at 100 E. Pratt Street, Baltimore, MD 21202

	(6)	Includes 63,026 shares owned by Susan D. Johnston, 101,460 shares owned by Dr. Johnston directly and 215,606 shares issuable upon the exercise of stock options held by Dr. Johnston that are exercisable within 60 days of February 28, 2005.

	(7)	Represents 50,245 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.


	(8)	Includes 139,600 shares and 119,296 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

	(9)	Includes 39,391 shares and 55,151 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.


(10)	Includes 34,139 shares and 23,005 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

(11)	Dr. Barrett is a general partner of NEA Partners 10, Limited Partnership, the general partner of New Enterprise Associates 10, Limited Partnership and a manager of NEA 11 GP, LLC the general partner of NEA Partners 11, Limited Partnership, the general partner of New Enterprise Associates 11, Limited Partnership. In such capacities, he may be deemed to have voting and dispositive power with respect to the 5,140,482 shares and 772,539 shares issuable under warrants beneficially owned by New Enterprise Associates 10, Limited Partnership and the 1,355,470 shares beneficially owned by New Enterprise Associates 11, Limited Partnership. Dr. Barrett disclaims beneficial ownership of the shares held by each of New Enterprise Associates 10, Limited Partnership and New Enterprise Associates 11, Limited Partnership, except to the extent of his proportionate pecuniary interest therein.

(12)	Includes 26,916 shares and 20,546 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

(13)	Dr. Eplett is a general partner of Essex Woodlands Health Ventures V, L.P. In such capacity, he may be deemed to share voting and investment power with respect to the 1,381,404 shares and 226,614 shares issuable under warrants beneficially owned by Essex Woodlands Health Ventures V, L.P. Dr. Eplett disclaims beneficial ownership of the shares held by this fund, except to the extent of his proportionate pecuniary interest therein.

(14)	Includes 12,158 shares owned directly and 44,000 owned by Claudia Henos. In addition, Mr. Henos is a managing general partner of Alliance Technology Ventures, L.P., ATV/ GP Parallel Fund, L.P. and ATV/ MJF Parallel Fund, L.P., a manager of Alliance Associates II, L.L.C., the general partner of Alliance Technology Ventures II, L.P. and ATV II Affiliates Fund, L.P. and a manager of ATV III Partners, L.L.C., the general partner of Alliance Technology Ventures III, L.P. and ATV III Affiliates Fund, L.P. In such capacity, he may be deemed to have voting and dispositive power with respect to the 642,480 shares beneficially owned by Alliance Technology Ventures, L.P.; 178,024 shares beneficially owned by ATV/ GP Parallel Fund, L.P.; 48,689 shares beneficially owned by ATV/ MJF Parallel Fund, L.P.; 736,771 shares and 69,318 shares issuable under warrants beneficially owned by Alliance Technology Ventures II, L.P.; 1,230,460 shares and 159,963 shares issuable under warrants beneficially owned by Alliance Technology Ventures III, L.P.; 21,578 shares and 2,672 shares issuable under warrants beneficially owned by ATV II Affiliates Fund, L.P.; and 13,323 shares and 2,651 shares issuable under warrants beneficially owned by ATV III Affiliates Fund, L.P. Mr. Henos disclaims beneficial ownership of the shares held by this fund, except to the extent of his proportionate pecuniary interest therein.

(15)	Represents 26,007 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

(16)	Dr. Minocherhomjee is a managing director of William Blair Capital Partners VI, L.L.C., the general partner of William Blair Capital Partners VI, L.P. In such capacity, he may be deemed to have voting and dispositive power with respect to the 2,477,240 shares and 175,959 shares issuable under warrants beneficially owned by William Blair Capital Partners VI, L.P. Dr. Minocherhomjee disclaims beneficial ownership of the shares held by this fund, except to the extent of his proportionate pecuniary interest therein.

(17)	Includes 1,500 shares and 5,991 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

(18)	Represents 7,491 shares issuable upon the exercise of stock options exercisable within 60 days of February 28, 2005.

(19)	Includes 13,686,611 shares (including 1,409,716 shares issuable under warrants and 523,388 shares issuable upon the exercise of stock options) in aggregate; also includes the shares and warrants described in Notes (1) through (4) above.

The following description of our capital stock and provisions of our amended and restated certificate of incorporation and by-laws is a summary of all of the material terms and provisions of such instruments and is qualified by reference to our amended and restated certificate of incorporation and our amended and restated by-laws, copies of which have been filed with the SEC.

Our authorized capital stock consists of 75,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. All of these shares of preferred stock are undesignated.

As of December 31, 2004, there were 25,133,327 shares of our common stock outstanding held by 121 stockholders of record. In addition, as of December 31, 2004, 1,283,106 shares of our common stock were subject to outstanding options and 3,838,588 shares of our common stock were subject to outstanding warrants.

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Accordingly, holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.

In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to proportionately receive our net assets available for distribution after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Our board of directors is authorized, without further vote or action by the stockholders, to issue up to an aggregate of 5,000,000 shares of preferred stock in one or more series. Each series of preferred stock will have such number of shares, designations, preferences, voting powers, qualifications and special or relative rights or privileges as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, redemption and sinking fund provisions, liquidation preferences, conversion rights and pre-emptive rights.

The issuance of preferred stock, while providing desired flexibility in connection with possible acquisitions and other corporate purposes, could adversely affect the voting power or other rights of the holders of common stock, and could make it more difficult for a third party to acquire, or could discourage a third party from attempting to acquire, a majority of our outstanding voting stock. We cannot determine the actual impact or effect of the issuance of any of this preferred stock upon the rights of the holders of our common stock until the board issues or determines the specific rights of this preferred stock.

As of December 31, 2004, we have outstanding warrants to purchase 3,838,588 shares of common stock at exercise prices ranging from $0.286 to $14.07 per share with a weighted average exercise price of $11.12 per share. These warrants expire on dates ranging from February 2007 to May 2011. All of these warrants include a cashless exercise feature, and the holders are entitled to customary anti-dilution

As of December 31, 2004, we had outstanding options to purchase 1,283,106 shares of our common stock at a weighted average exercise price of $3.18 and 1,397,691 shares of common stock were reserved for issuance under the Stock Incentive Plan.

Under the terms of our amended and restated master rights agreement, the holders of 13,665,461 shares of common stock, including 1,837,029 shares issuable upon the exercise of warrants, or their transferees, have been granted rights to register these shares under the Securities Act of 1933, as amended, or the Securities Act. If we propose to register any of our securities under the Securities Act, either for our own account or for the account of other stockholders, the holders of these shares are entitled, under certain circumstances, to include in the registration statement, at our expense, their shares of common stock. In addition, the holders of these shares may require us, at our expense and on not more than two occasions at any time to file a registration statement under the Securities Act with respect to their shares of common stock, and we will be required to use our reasonable best efforts to effect the registration. Further, the holders of these shares may require us, at our expense, to register their shares on Form S-3 when we can avail ourselves of this form. These registration rights are subject to certain conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under certain circumstances. Holders of the foregoing registration rights waived such rights to register any shares as part of this registration.

Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and By-laws

We are subject to the provisions of Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A “business combination” is defined generally as a merger or asset sale involving the interested stockholder or other transaction resulting in a financial benefit to the interested stockholder. Subject to various exceptions, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within the past three years did own, 15% or more of a corporation’s voting stock. This statute could prohibit or delay the accomplishment of mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us.

In addition, certain provisions of our amended and restated certificate of incorporation and our amended and restated by-laws may have the effect of delaying, deferring or preventing a tender offer or takeover attempt that you, as a stockholder, might deem to be in your best interest. These provisions are designed to encourage persons seeking to acquire us to initiate such a transaction through arm’s-length negotiations with our board of directors. The existence of these provisions could adversely affect the prevailing price of our common stock or limit the price that others might be willing to pay in the future for shares of our common stock. These provisions include:

Stockholder Action; Special Meeting of Stockholders. Stockholders may not take action by written consent, but only at a duly called annual or special meeting of our stockholders. Special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer, or a majority of our board of directors, and in no event may stockholders call a special meeting. Thus, without

Advance Notice Requirements for Stockholder Proposals and Director Nominations. A stockholder seeking to bring business before an annual meeting of our stockholders, or to nominate candidates for election as directors at an annual meeting of our stockholders, must provide timely notice of his or her intention in writing. To be timely, a stockholder’s notice must be delivered to our secretary, at our principal executive offices, not less than 90 days nor more than 120 days prior to the first anniversary of the date of the previous year’s annual meeting of our stockholders. However, if no annual meeting of stockholders was held in the previous year or the date of the annual meeting of stockholders has been changed to be more than 30 calendar days from the time of the previous year’s annual meeting, then a proposal shall be received no later than the close of business on the tenth day following the date on which notice of the date of the meeting was mailed or a public announcement was made. Only our board of directors or a committee thereof may nominate candidates for election at a special meeting of our stockholders. Our by-laws also specify requirements as to the form and content of a stockholder’s notice. These provisions may preclude stockholders from bringing matters before an annual meeting of our stockholders or from making nominations for directors at an annual or special meeting of our stockholders.

Authorized but Unissued Shares. Our authorized but unissued shares of common and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the Nasdaq National Market. These additional shares may be utilized for a variety of corporate needs, including acquisitions and raising additional funds. The existence of authorized but unissued and unreserved common and preferred stock could discourage an attempt by third parties to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

Classification of Board Members. Our board of directors is classified into three different classes of members, as nearly equal in size as possible, with each class having its own three-year term. Any one or more, or all of the directors may be removed by the holders of at least a majority of the shares then entitled to vote at an election of directors only for cause. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of the board, may only be filled by vote of a majority of the directors then in office. This classification of our board of directors, and the limitations on the removal of directors and filling of vacancies, may have the effect of making it more difficult for a third party to acquire control of us, or of discouraging a third party from acquiring control of us because at least two annual meetings of stockholders, instead of one, generally will be required to change the majority of our board of directors.

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company.

On November 4, 2004, we entered into Stock and Warrant Purchase Agreements with the selling stockholders named below, pursuant to which we sold an aggregate of 6,777,370 shares of our common stock and issued warrants to purchase up to 2,033,211 shares of our common stock in a private placement transaction. This prospectus covers the sale by the selling stockholders of up the total number of shares of common stock issued to the selling stockholders pursuant to the Stock and Warrant Purchase Agreements plus the total number of shares of common stock issuable upon exercise of the warrants issued to the selling stockholders pursuant to the Stock and Warrant Purchase Agreements unless otherwise indicated. Throughout this prospectus, when we refer to the shares of our common stock registered on behalf of the selling stockholders, we are referring to the shares and the warrant shares. The warrants issued to the selling stockholders are exercisable at any time, in whole or in part, beginning May 9, 2005 and ending November 10, 2009 at an exercise price of $8.81 per share.

Selling stockholders have sold an aggregate of 6,400 shares of common stock pursuant to this prospectus. Accordingly, an aggregate of 6,770,970 shares of our common stock remain eligible for offer and sale, from time to time, pursuant to this prospectus.

We are registering the above-referenced shares to permit each of the selling stockholders and their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus to resell the shares in the manner contemplated under the “Plan of Distribution.”

The selling stockholders may sell some, all or none of their shares. We do not know how long the selling stockholders will hold the shares before selling them. We currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale of any of the shares. The shares offered by this prospectus may be offered from time to time by the selling stockholders, although the warrant shares will not be eligible to be offered pursuant to this prospectus until the related warrants become exercisable.

The following table sets forth the name of each selling stockholder, the number of shares owned (including warrant shares) by each of the respective selling stockholders, the number of shares that may be offered under this prospectus and the number of shares of our common stock owned by the selling stockholders after this offering is completed. The number of shares in the column “Number of Shares Being Offered” represents all of the shares that a selling stockholder may offer under this prospectus.

Except as otherwise disclosed below, none of the selling stockholders has, or within the past three years has had, any position, office or other material relationship with us.

Based on the information provided to us by the selling stockholders, except as set forth in the notes to the chart below, none of the selling stockholders are, or are affiliated with broker-dealers. Each of the selling stockholders has represented to us that it purchased its shares and warrants in the ordinary course of business, and at the time of such purchase, it had no agreements or understanding, directly or indirectly, with any person to distribute the securities.

Ownership is based upon information provided by each respective selling stockholder, Schedules 13G and other public documents filed with the SEC. Although the warrants held by the selling stockholders are not exercisable within 60 days of February 28, 2005, the shares of common stock issuable upon exercise of the warrants held by the selling stockholders are included in the table below since those shares of common stock are included in this registration statement. Unless otherwise noted, none of the share amounts set forth below represents more than 1% of our outstanding stock as of February 28, 2005, adjusted as required by rules promulgated by the SEC. The percentages of shares owned after the offering are based on 27,203,887 shares of our common stock outstanding as of February 28, 2005, including the shares of common stock offered in this prospectus.

The selling stockholders may have sold or transferred, in transactions exempt from the registration requirements of the Securities Act of 1933, some or all of their shares since the date on which the information in the table is presented. Information about the selling stockholders may change over time.


	*	Represents beneficial ownership or less than one percent of our common stock

	(1)	Assumes the exercise of all warrants to purchase common stock offered in this prospectus by the selling stockholders.

	(2)	Assumes the sale of all shares and warrant shares offered in the prospectus.


	(3)	Lindsay A. Rosenwald, M.D. is the chairmen and sole shareholder of Paramount BioCapital, Inc., an NASD member broker-dealer. Dr. Rosenwald is also is the Managing Member of Orion Biomedical GP, LLC, which is the general partner of each of Orion Biomedical Fund, LP and Orion Biomedical Offshore Fund, LP.

	(4)	John A Levin & Co, Inc is the investment manager of SR Capital Partners, L.P. and SR Capital Offshore, Ltd. Levco Securities, Inc., a registered broker-dealer, is a subsidiary of John A. Levin & Co., Inc.

	(5)	T. Rowe Price Investment Services, Inc., a registered broker-dealer, is a subsidiary of T. Rowe Price Associates Inc., the investment advisor to T. Rowe Price Small-Cap Value Fund, Inc.

	(6)	Consists of 91,650 shares of common stock offered by this prospectus, 1,159,960 additional shares of common stock and immediately exercisable warrants to purchase 159,963 shares of common stock held by Alliance Technology Ventures III, L.P.

	(7)	Consists of 1,040 shares of common stock offered by this prospectus, 12,523 additional shares of common stock and immediately exercisable warrants to purchase 2,651 shares of common stock held by ATV III Affiliates Fund L.P.

	(8)	Excludes with respect to each such selling stockholder, any shares of common stock held by the other selling stockholder. Michael A. Henos, a director of Inhibitex, as a manager of ATV III Partners, L.L.C., the general partner of Alliance Technology Ventures III, L.P. and ATV III Affiliates Fund, L.P. may be deemed to have voting and dispositive power over such shares and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

	(9)	Consists of 176,215 shares of common stock offered by this prospectus, 1,245,854 additional shares of common stock and immediately exercisable warrants to purchase 226,614 shares of common stock held by Essex Woodlands Health Ventures V, LP. J. Douglas Eplett, a director of Inhibitex, may be deemed to have shared voting and dispositive power over the shares held by Essex Woodlands Health Ventures and disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein.


(10)	Consists of 757,250 shares of common stock offered by this prospectus, 4,557,982 additional shares of common stock and immediately exercisable warrants to purchase 772,539 shares of common stock held by New Enterprise Associates 10 Limited Partnership and excludes any shares of common stock held by New Enterprise Associates 11, Limited Partnership. NEA Partners 10, Limited Partnership is the general partner of New Enterprise Associates 10, Limited Partnership. M. James Barrett, a director of Inhibitex, as a general partner of NEA Partners 10, Limited Partnership, may be deemed to have shared voting and dispositive power over the shares held by New Enterprise Associates 10, Limited Partnership and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(11)	Excludes any shares of common stock held by New Enterprise Associates 10, Limited Partnership. NEA Partners 11, Limited Partnership is the general partner of New Enterprise Associates 11, Limited Partnership. M. James Barrett, a director of Inhibitex, as a general partner of NEA Partners 11, Limited Partnership, may be deemed to have shared voting and dispositive power over the shares held by New Enterprise Associates 11, Limited Partnership and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(12)	William Blair & Co., a registered broker-dealer, is a member of William Blair Capital Partners VI, LLC, the general partner of William Blair Capital partners VI, LP.

(13)	Consists of 176,215 shares of common stock offered by this prospectus, 2,341,690 additional shares of common stock and immediately exercisable warrants to purchase 175,959 shares of common stock held by William Blair Capital Partners VI, L.P. William Blair Capital Partners VI, L.L.C. is the general partner of William Blair Capital Partners VI, L.P. Arda Minocherhomjee, as a member of the Board of Managers of William Blair Capital Partners VI, LLC, may be deemed to have voting and dispositive power over the shares held by William Blair Capital Partners VI, L.P. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(14)	LBI Group Inc. is a wholly-owned subsidiary of Lehman Brothers Inc, a registered broker-dealer and a wholly-owned subsidiary of Lehman Brothers Holdings Inc., a public reporting corporation. In the ordinary course of its business. Lehman Brothers, Inc. actively trades in our common stock for its own account and for the account of its customers and, accordingly, may at any time hold a long or short position in such securities.

The selling stockholders, which as used herein include donees, pledgees, transferees or other successors-in-interest, selling shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:


•	on The Nasdaq National Market (or any other exchange on which the shares may be listed);

•	on the over-the-counter market;

•	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

•	block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

•	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

•	an exchange distribution in accordance with the rules of the applicable exchange;

•	privately negotiated transactions;

•	short sales;

•	through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

•	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

•	a combination of any such methods of sale; and

•	any other method permitted pursuant to applicable law.

The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b) or under any applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.

In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may, in turn, engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-

The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants.

The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule.

The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have borne and will bear substantially all of the costs, expenses and fees in connection with the registration of the shares, other than any commissions, discounts or other fees payable to broker-dealers in connection with any sale of shares, which will be borne by the selling stockholder selling such shares of common stock. We have agreed to indemnify the selling stockholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.

In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

The selling stockholders may be subject to the anti-manipulation rules of Regulation M, which may limit the timing of purchases and sales of shares of our common stock by such selling stockholders.

We will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

We have agreed with each selling stockholder to keep the registration statement, of which this prospectus constitutes a part, effective with respect to its shares until the earlier of (1) the second anniversary of our issuance of shares and warrants to such selling stockholder, (2) the date on which all shares purchased from us by such selling stockholder may be sold pursuant to Rule 144 of the Securities Act without volume limitations and (3) such time as all of such selling stockholder’s shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement.

The validity of the common stock offered hereby has been passed upon for us by Swidler Berlin Shereff Friedman, LLP, New York, New York.

The financial statements of Inhibitex, Inc. at December 31, 2003 and 2004, and for each of the three years in the period ended December 31, 2004 and the period from inception (May 13, 1994) through December 31, 2004, appearing in this Prospectus and Registration Statement have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

We file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any document we file with the Securities and Exchange Commission at the public reference room maintained by the Securities and Exchange Commission at 450 Fifth Street, N.W., Washington, D.C. 20549. Copies may also be obtained from the Public Reference Section of the Securities and Exchange Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates. You may obtain information on the operation of the public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549 by calling the Securities and Exchange Commission at 1-800-SEC-0330. In addition, the Securities and Exchange Commission maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants who file electronically with the Securities and Exchange Commission. Our common stock is quoted on the Nasdaq National Market. Reports, proxy statements and other information concerning us may be inspected at the offices of the National Association of Securities Dealers, Inc. located at 1735 K Street, N.W., Washington, D.C. 20006.

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission. The registration statement contains more information than this prospectus regarding us and our common stock, including certain exhibits and schedules. You can obtain a copy of the registration statement from the Securities and Exchange Commission at the address listed above or from the Securities and Exchange Commission’s Internet site (http://www.sec.gov).

We have audited the accompanying balance sheets of Inhibitex, Inc. (a Development Stage Company) as of December 31, 2003 and 2004, and the related statements of operations, stockholders’ (deficit) equity and cash flows for each of the three years in the period ended December 31, 2004, and for the period from inception (May 13, 1994) through December 31, 2004. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Inhibitex, Inc. (a Development Stage Company) at December 31, 2003 and 2004, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2004, and for the period from inception (May 13, 1994) through December 31, 2004, in conformity with U.S. generally accepted accounting principles.

STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY



	Series A Preferred				Common Stock
	Stock				Subscription						Common Stock
															Additional
			Par					Par					Par		Paid-In
	Shares		Value		Shares			Value			Shares		Value		Capital

Balance at inception (May 13, 1994)		—	$	—		—		$	—			—	$	—	$	—
Issuance of subscriptions for common stock to founders at $.005 per share		—		—		44,258			44			—		—		483
Issuance of common stock at $1.00 per share		—		—		—			—			42,017		42		99,958
Net loss		—		—		—			—			—		—		—

Balance at December 31, 1994		—		—		44,258			44			42,017		42		100,441
Net loss		—		—		—			—			—		—		—

Balance at December 31, 1995		—		—		44,258			44			42,017		42		100,441
Issuance of Series A Preferred Stock at $2.50 per share, net of related costs of $18,641		216,000		216		—			—			—		—		521,143
Issuance of subscribed common stock at $.005 per share		—		—		(44,258	)		(44	)		44,258		44		—
Net loss		—		—		—			—			—		—		—

Balance at December 31, 1996		216,000		216		—			—			86,275		86		621,584
Issuance of common stock at $.05 per share, net of receivable from shareholder		—		—		—			—			129,960		130		15,335
Net loss		—		—		—			—			—		—		—

Balance at December 31, 1997		216,000		216		—			—			216,235		216		636,919
Issuance of common stock at $.05 and $.075 per share, net of receivable from shareholder		—		—		—			—			191,358		191		26,599
Net loss		—		—		—			—			—		—		—

Balance at December 31, 1998		216,000		216		—			—			407,593		407		663,518
Issuance of common stock at $.10 per share		—		—		—			—			1,787		2		423
Net loss		—		—		—			—			—		—		—

[Continued from above table, first column(s) repeated]


								Deficit
	Receivable							Accumulated			Total
	for			Common		Deferred		During			Stockholders’
	Purchase of			Stock		Stock		Development			(Deficit)
	Stock			Warrants		Compensation		Stage			Equity

Balance at inception (May 13, 1994)	$	—		$	—	$	—	$	—		$	—
Issuance of subscriptions for common stock to founders at $.005 per share		—			—		—		—			527
Issuance of common stock at $1.00 per share		—			—		—		—			100,000
Net loss		—			—		—		(54,088	)		(54,088	)

Balance at December 31, 1994		—			—		—		(54,088	)		46,439
Net loss		—			—		—		(266,491	)		(266,491	)

Balance at December 31, 1995		—			—		—		(320,579	)		(220,052	)
Issuance of Series A Preferred Stock at $2.50 per share, net of related costs of $18,641		—			—		—		—			521,359
Issuance of subscribed common stock at $.005 per share		—			—		—		—			—
Net loss		—			—		—		(248,510	)		(248,510	)

Balance at December 31, 1996		—			—		—		(569,089	)		52,797
Issuance of common stock at $.05 per share, net of receivable from shareholder		(3,867	)		—		—		—			11,598
Net loss		—			—		—		(508,304	)		(508,304	)

Balance at December 31, 1997		(3,867	)		—		—		(1,077,393	)		(443,909	)
Issuance of common stock at $.05 and $.075 per share, net of receivable from shareholder		(24,828	)		—		—		—			1,962
Net loss		—			—		—		(1,725,290	)		(1,725,290	)

Balance at December 31, 1998		(28,695	)		—		—		(2,802,683	)		(2,167,237	)
Issuance of common stock at $.10 per share		—			—		—		—			425
Net loss		—			—		—		(3,343,509	)		(3,343,509	)

STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY — (Continued)



	Series A Preferred				Common Stock
	Stock				Subscription				Common Stock
													Additional
			Par				Par				Par		Paid-In
	Shares		Value		Shares		Value		Shares		Value		Capital

Balance at December 31, 1999		216,000		216		—		—		409,380		409		663,941
Forgiveness of receivable from shareholders		—		—		—		—		—		—		—
Issuance of warrant for the purchase of common stock at $.06 per share		—		—		—		—		—		—		75
Exercise of stock Options		—		—		—		—		8,199		8		2,240
Cumulative effect of change in accounting principle		—		—		—		—		—		—		99,500
Preferred stock Dividends		—		—		—		—		—		—		—
Net loss		—		—		—		—		—		—		—

Balance at December 31, 2000		216,000		216		—		—		417,579		417		765,756
Issuance of warrant for the purchase of common stock at $.23 per share		—		—		—		—		—		—		3,450
Exercise of stock Options		—		—		—		—		48,181		48		12,426
Preferred stock Dividends		—		—		—		—		—		—		—
Net loss		—		—		—		—		—		—		—

Balance at December 31, 2001		216,000		216		—		—		465,760		465		781,632
Exercise of stock Options		—		—		—		—		47,438		48		18,258
Preferred stock Dividends		—		—		—		—		—		—		—
Accretion of Series D Preferred Stock to redemption value		—		—		—		—		—		—		—
Net loss		—		—		—		—		—		—		—

Balance at December 31, 2002		216,000		216		—		—		513,198		513		799,890
Exercise of stock Options		—		—		—		—		22,868		23		17,363
Preferred stock Dividends		—		—		—		—		—		—		—
Accretion of Series D and E Preferred Stock to redemption value		—		—		—		—		—		—		—
Deferred stock Compensation		—		—		—		—		—		—		980,545
Amortization of deferred stock compensation		—		—		—		—		—		—		—
Net loss		—		—		—		—		—		—		—

[Continued from above table, first column(s) repeated]


									Deficit
	Receivable								Accumulated			Total
	for			Common		Deferred			During			Stockholders’
	Purchase of			Stock		Stock			Development			(Deficit)
	Stock			Warrants		Compensation			Stage			Equity

Balance at December 31, 1999		(28,695	)		—		—			(6,146,192	)		(5,510,321	)
Forgiveness of receivable from shareholders		28,695			—		—			—			28,695
Issuance of warrant for the purchase of common stock at $.06 per share		—			—		—			—			75
Exercise of stock Options		—			—		—			—			2,248
Cumulative effect of change in accounting principle		—			—		—			—			99,500
Preferred stock Dividends		—			—		—			(460,600	)		(460,600	)
Net loss		—			—		—			(6,463,315	)		(6,463,315	)

Balance at December 31, 2000		—			—		—			(13,070,107	)		(12,303,718	)
Issuance of warrant for the purchase of common stock at $.23 per share		—			—		—			—			3,450
Exercise of stock Options		—			—		—			—			12,474
Preferred stock Dividends		—			—		—			(1,271,383	)		(1,271,383	)
Net loss		—			—		—			(8,106,341	)		(8,106,341	)

Balance at December 31, 2001		—			—		—			(22,447,831	)		(21,665,518	)
Exercise of stock Options		—			—		—			—			18,306
Preferred stock Dividends		—			—		—			(4,461,328	)		(4,461,328	)
Accretion of Series D Preferred Stock to redemption value		—			—		—			(1,164,476	)		(1,164,476	)
Net loss		—			—		—			(17,612,723	)		(17,612,723	)

Balance at December 31, 2002		—			—		—			(45,686,358	)		(44,885,739	)
Exercise of stock Options		—			—		—			—			17,386
Preferred stock Dividends		—			—		—			(4,871,217	)		(4,871,217	)
Accretion of Series D and E Preferred Stock to redemption value		—			—		—			(1,329,899	)		(1,329,899	)
Deferred stock Compensation		—			—		(980,545	)		—			—
Amortization of deferred stock compensation		—			—		176,235			—			176,235
Net loss		—			—		—			(22,333,021	)		(22,333,021	)

STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY — (Continued)



	Series A Preferred						Common Stock
	Stock						Subscription				Common Stock
															Additional
				Par					Par				Par		Paid-In
	Shares			Value			Shares		Value		Shares		Value		Capital

Balance at December 31, 2003		216,000			216			—		—		536,066		536		1,797,798
Exercise of stock options		—			—			—		—		309,965		310		255,657
Preferred stock dividends and accretion to redemption value		—			—			—		—		—		—		—
Deferred stock compensation		—			—			—		—		—		—		938,078
Amortization of deferred stock compensation		—			—			—		—		—		—		—
Conversion of preferred stock to common including dividends		(216,000	)		(216	)		—		—		11,936,438		11,936		93,871,724
Initial Public Offering of common stock		—			—			—		—		5,527,000		5,527		33,951,407
Exercise of warrants		—			—			—		—		46,488		47		207,593
Common Stock Warrants		—			—			—		—		—		—		—
PIPE Financing		—			—			—		—		6,777,370		6,777		42,166,488
Net loss		—			—			—		—		—		—		—

Balance at December 31, 2004		—		$	—			—	$	—		25,133,327	$	25,133	$	173,188,745

[Continued from above table, first column(s) repeated]


									Deficit
	Receivable								Accumulated			Total
	for		Common			Deferred			During			Stockholders’
	Purchase of		Stock			Stock			Development			(Deficit)
	Stock		Warrants			Compensation			Stage			Equity

Balance at December 31, 2003		—		—			(804,310	)		(74,220,495	)		(73,226,255	)
Exercise of stock options		—		—			—			—			255,967
Preferred stock dividends and accretion to redemption value		—		—			—			(2,823,160	)		(2,823,160	)
Deferred stock compensation		—		—			(938,078	)		—			—
Amortization of deferred stock compensation		—		—			473,289			—			473,289
Conversion of preferred stock to common including dividends		—		—			—			—			93,883,444
Initial Public Offering of common stock		—		—			—			—			33,956,934
Exercise of warrants		—		(47,927	)		—			—			159,713
Common Stock Warrants		—		6,113,749			—			—			6,113,749
PIPE Financing		—		5,490,146			—			—			47,663,411
Net loss		—		—			—			(25,911,495	)		(25,911,495	)

Balance at December 31, 2004	$	—	$	11,555,968		$	(1,269,099	)	$	(102,955,150	)	$	80,545,597

Inhibitex, Inc. (“Inhibitex” or the “Company”) was incorporated in the state of Delaware in May 1994. Inhibitex is a biopharmaceutical company committed to the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections. The Company’s primary activities since incorporation have been establishing its offices, recruiting personnel, conducting research, conducting pre-clinical and clinical trials, performing business and financial planning, and raising capital. Accordingly, the Company is considered to be in the development stage for financial reporting purposes.

The Company has incurred operating losses since inception and expects such losses to continue for the foreseeable future. These losses have largely been the result of research and development expenses related to Veronate, the Company’s lead product candidate, and to a lesser extent, Aurexis, its second product candidate. Veronate is being developed to prevent hospital-associated infections in very low birth weight infants. Aurexis is being developed to treat, in combination with antibiotics, serious, life-threatening Staphylococcus aureus (S. aureus) infections in hospitalized patients. Both Veronate and Aurexis are currently being evaluated in clinical trials. The Company plans to continue to finance its operations with equity and/or other financings or proceeds from potential future partnerships. The Company’s ability to continue its operations is dependent, in the near term, upon the successful execution of such financings and ultimately upon achieving profitable operations. There can be no assurance that funds will be available on terms acceptable to the Company or that the Company will become profitable.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimated.

Cash, Cash Equivalents and Short-Term Investments. Cash equivalents consist of short-term, highly liquid investments with original maturities of 90 days or less when purchased. Cash equivalents are carried at cost, which approximates their fair market value. Investments with original maturities beyond 90 days when purchased are considered to be short-term investments. These investments are accounted for in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, Accounting for Certain Investments in Debt and Equity Securities (“SFAS 115”). The Company is required to maintain a cash balance equal to two times the loan balance on deposit with a lender pursuant to a loan and security agreement as discussed in Note 7.

The Company has classified its entire investment portfolio as available-for-sale. These securities are recorded as either cash equivalents or short-term investments. Short-term investments are carried at estimated fair value based upon quoted market prices with unrealized gains and losses, if any, reported in other comprehensive income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest and other income (expense), net. Realized gains and losses are included in interest and other income (expense), net. The cost basis of all securities sold is based on the specific identification method.

Available-for-sale securities as of December 31, 2004, and 2003 consisted of commercial paper, agency obligations, corporate bonds, and money-market funds.

Property and Equipment, Net. Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives of the related assets:

The Company also capitalizes costs related to computer software developed for internal use in accordance with Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use. When assets are retired or sold, the assets and accumulated depreciation are removed from the respective accounts and any gain or loss is recognized in interest and other income (expense), net. Expenditures for repairs and maintenance are charged to expense as incurred.

Revenue Recognition. To date, the Company has not generated any revenues from the sale of products. Revenues relate to fees recovered for licensed technology, collaborative research and development agreements and a grant awarded to the Company by the FDA’s Office of Orphan Products Development. The Company follows the revenue recognition criteria outlined in Staff Accounting Bulletin (“SAB”) No. 101, Revenue Recognition in Financial Statements (“SAB No. 101”) as amended by SAB 104 Revenue Recognition, and Emerging Issues Task Force (“EITF”) Issue 00-21, Revenue Arrangements with Multiple Deliverables (“EITF Issue 00-21”). Accordingly, up-front, non-refundable license fees under agreements where the Company has an ongoing research and development commitment are amortized, on a straight-line basis, over the term of such commitment. Revenues received for ongoing research and development activities under collaborative arrangements are recognized as these activities are performed pursuant to the terms of the related agreements (see Note 12). Any amounts received in advance of performance are recorded as deferred revenue until earned. Revenue related to grant awards is recognized as related research and development expenses are incurred.

Accrued Expenses. As part of the process of preparing its financial statements, management is required to estimate expenses that the Company has incurred but for which it has not been invoiced. This process involves identifying services that have been performed on the Company’s behalf and estimating the level of services performed by third parties and the associated cost incurred for such services as of each balance sheet date. Examples of expenses for which the Company accrues based on estimates include fees for services, such as those provided by clinical research and data management organizations, investigators and fees owed to contract manufacturers in conjunction with the manufacture of clinical trial materials. In connection with such service fees, these estimates are most affected by management’s understanding of the status and timing of services provided relative to the actual levels of services incurred by such service providers. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed. Management makes these estimates based upon the facts and circumstances known to it at the time and in accordance with accounting principles generally accepted in the United States.

Prepaid Expenses and Other Current Assets. Prepaid expenses and other current assets consist primarily of license payments, insurance premiums and payments to clinical research organizations that the Company has made in advance.

Stock-based Compensation. The Company accounts for employee stock options using the intrinsic-value method in accordance with Accounting Principles Board (“APB”) Opinion No. 25, Accounting for Stock Issued to Employees (“APB No. 25”), and Financial Accounting Standards Board Interpretation (“FIN”) No. 44 (“FIN 44”), Accounting for Certain Transactions Involving Stock Compensation, an Interpretation

of APB No. 25, and Related Interpretations and has adopted the disclosure only provisions of SFAS No. 123, Accounting for Stock-Based Compensation (“SFAS No. 123”). The Company accounts for equity instruments issued to non-employees in accordance with the provisions of the SFAS No. 123, EITF Issue No. 96-18, Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. In December 2002, the Financial Accounting Standards Board issued SFAS No. 148, Accounting for Stock-Based Compensation — Transition and Disclosure (“SFAS No. 148”). SFAS No. 148 amends SFAS No. 123 to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 and APB No. 28, Interim Financial Reporting, to require disclosure in the summary of significant accounting policies of the effects of an entity’s accounting policy with respect to employee stock compensation on reported net loss. The Company has adopted the disclosure requirements of SFAS No. 148.

Under APB No. 25, if the exercise price of the Company’s employee and director stock options equals or exceeds the estimated fair value of the underlying stock on the date of grant, no compensation expense is recognized. In the event that stock options are granted with an exercise price below the estimated fair value of the Company’s common stock on the date of such grant, APB No. 25 requires that the difference between the estimated fair value and the exercise price be recorded as deferred compensation and amortized over the related vesting period. No stock compensation expense is reflected in the Company’s reported net loss in any period prior to December 31, 2002 as all options granted had an exercise price equal to the fair value of the underlying common stock on the date of grant.

The Company recorded deferred stock compensation of $980,545 and $938,078 for the year ended December 31, 2003 and 2004, respectively, which represents the difference between the exercise price per share and the fair value at the respective grant dates for options granted in 2003 and 2004. Deferred stock compensation is recognized and amortized on a straight-line basis over the vesting period of the related options, which for employees is generally four years. The amortization of deferred stock compensation related to stock options granted to the Company’s employees and directors was $176,235 and $473,289 for the years ended December 31, 2003 and 2004, respectively. The expected future amortization of deferred stock compensation related to the options granted in 2003 and 2004 is $496,755, $473,637, $262,762 and $35,945 for the years ended December 31, 2005, 2006, 2007 and 2008, respectively.

The option valuation models used to value options under SFAS No. 123 were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected volatility. Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in the Company’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

As a result, the Company has elected to continue to follow the intrinsic value method of accounting as prescribed by APB No. 25. The information regarding net loss as required by SFAS No. 123 has been determined as if the Company had accounted for its stock-based compensation under the fair value method of that Statement. The following table illustrates the effect on net loss attributable to common

stockholders and basic and diluted net loss per share attributable to common stockholders had the Company applied the fair value provisions of SFAS No. 123 to employee stock-based compensation:

The fair value of each stock option was estimated at the date of grant using the minimum value method through 2003 and the Black-Scholes method in 2004 with the following assumptions:

For purposes of pro forma disclosure, the estimated fair value of the options is amortized to expense over the vesting period of the related options.

Fair Value of Financial Instruments. The carrying amounts of the Company’s financial instruments, which include cash, cash equivalents, short-term investments, accounts payable, accrued expenses, and capital lease and debt obligations, approximate their fair values.

Concentrations of Credit Risk and Limited Suppliers. Cash and cash equivalents consist of financial instruments that potentially subject the Company to concentrations of credit risk to the extent recorded on the balance sheets. The Company believes that it has established guidelines for investment of its excess cash that maintains principal and liquidity through its policies on diversification and investment maturity.

The Company relies on certain materials used in its development process that are procured from a single source supplier as well as certain third-party contract manufacturers that make its product candidates. The failure of its supplier or a contract manufacturer to deliver on schedule, or at all, could delay or interrupt the development process and adversely affect the Company’s operating results.

Research and Development Expense. Research and development expense primarily consists of costs incurred in the discovery, development, and manufacturing of the Company’s product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to monitor and accumulate data related to the Company’s clinical trials, (ii) costs related to obtaining patents and license and research

agreements, (iii) the costs to procure and manufacture materials used in clinical trials, and (iv) salaries and related expenses for personnel. These costs are charged to expense as incurred.

Income Taxes. The Company utilizes the liability method of accounting for income taxes as required by SFAS No. 109, Accounting for Income Taxes (“SFAS No. 109”). Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. A valuation allowance is recorded to reduce the carrying amounts of net deferred tax assets to an amount the Company expects to realize in the future based upon the available evidence at the time.

Reclassifications. Certain reclassifications have been made to prior period amounts to conform to the current year presentation.

Recent Accounting Pronouncements. On December 16, 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123 (revised 2004), Share-Based Payment, which is a revision of SFAS No. 123. “SFAS 123(R)” supersedes APB Opinion No. 25, and amends SFAS No. 95, Statement of Cash Flows. Generally, the approach in SFAS 123(R) is similar to the approach described in SFAS 123. However, SFAS 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative.

SFAS 123(R) must be adopted no later than July 1, 2005. Early adoption will be permitted in periods in which financial statements have not yet been issued. We expect to adopt SFAS 123(R) on July 1, 2005. We anticipate adoption of this statement on July 1, 2005 could have a material effect on our results of operations.

Currently, the Company uses the Black-Scholes formula to estimate the value of stock options granted to employees and expects to continue to use this acceptable option valuation model upon the required adoption of SFAS 123(R) on July 1, 2005. Because SFAS 123(R) must be applied not only to new awards but to previously granted awards that are not fully vested on the effective date, and because the company adopted SFAS 123 using the prospective transition method (which applied only to award granted, modified or settled after the adoption date), compensation cost for some previously granted awards that were not recognized under SFAS 123 will be recognized under SFAS 123(R). However, had we adopted SFAS 123(R) in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net income and earnings per share in Note 2 to our financial statements. SFAS 123(R) also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after adoption.

The Company calculates net loss per share in accordance with SFAS No. 128, Earnings Per Share (“SFAS No. 128”) and SEC Staff Accounting Bulletin No. 98 (“SAB No. 98”). Under the provisions of SFAS No. 128 and SAB No. 98, basic net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and dilutive common stock equivalents then outstanding. Common stock equivalents consist of common shares issuable upon the conversion of preferred stock and upon the exercise of stock options, and the conversion of

preferred stock upon the exercise of warrants. Dilutive earnings per share is the same as basic earnings per share since common stock equivalents are excluded from the calculation, due to their effect being anti-dilutive.

The unaudited pro forma net loss per share attributable to common stockholders and the shares used to compute basic and diluted pro forma net loss per share attributable to common stockholders are calculated assuming all of the Company’s outstanding preferred stock was converted into common stock as of its date of issuance and the conversion of all cumulative preferred stock dividends as of the date they were accrued. This calculation excludes the assumed issuance of shares of common stock subject to the mandatory cashless exercise of warrants that were outstanding at December 31, 2003 and December 31, 2004.

The following table sets forth the computation of historical and pro forma basic and diluted net loss attributable to common stockholders per share:

The following table outlines potentially dilutive common stock equivalents outstanding that are not included in the above historical calculations as the effect of their inclusion was anti-dilutive.

Included in the property and equipment are assets recorded under capital leases with an accumulated cost of approximately $1,158,000, and $1,383,000 at December 31, 2003 and 2004, respectively. Amortization of the assets recorded under capital leases is included in depreciation expense. The accumulated amortization related to these assets under capital leases was approximately $421,000, and $737,000 at December 31, 2003 and 2004. Depreciation expense was approximately $772,000, $768,000, and $821,000 for the years ended December 31, 2002, 2003 and 2004, respectively.

Lease Commitments. The Company leases laboratory and office facilities in Alpharetta, Georgia under two operating leases, one of which is with a related party. The Company also leases office equipment under various non-cancelable operating leases. Future minimum lease payments under operating leases primarily relate to the laboratory and office facility leases. One of the these leases includes annual rent increases based upon increases in the Consumer Price Index, which are considered to be contingent rentals and are charged to expense when incurred. During the years ended December 31, 2002, 2003 and 2004, rent expense totaled approximately $270,000, $421,000 and $520,000, respectively.

Future minimum payments under these operating leases at December 31, 2004 are as follows:

In December 2003, the Company entered into an agreement to lease a new 51,000 square foot research and office facility to be built to its specifications. Under this agreement, the Company had a right to terminate the lease without any further obligation by March 31, 2004. The Company did not exercise this right, and expects to occupy this new facility upon its completion, which is anticipated to occur in the second quarter of 2005. The Company is not obligated to make rent payments related to this facility, and has not taken possession of or controls the physical use of the property until January 2005. The Company estimates that these expenses, including minimum rent payments and the amortization of leasehold improvements paid by the lessor, will approximate $1.0 million per year on average under this lease. In conjunction with this agreement the Company issued 21,009 common stock warrants at a price of $9.38 to the lessor. The table includes these estimated minimum payments under this operating lease as they are an obligation of the Company at December 31, 2004.

Purchase Commitments. In December 2001, the Company entered into a ten-year contract manufacturing agreement for Veronate with Nabi Pharmaceuticals, Inc. (“Nabi”). Pursuant to the terms of the agreement, the Company is obligated to pay Nabi on a per batch basis. The Company is required to provide Nabi with a three-year rolling forecast that outlines the number of batches it desires to be manufactured in each of the next three years. As of December 31, 2004, the Company’s purchase commitments under this agreement through December 31, 2008 were approximately $5.2 million. However, if the Company cancels or postpones the production of one or more lots of Veronate in accordance with the terms of this agreement, certain cancellation penalties would instead apply, which could be substantially less than the minimum purchase commitments, depending on the length of the notice provided to Nabi. The amount of the cancellation penalty payable per batch ranges from $25,000 per batch if Inhibitex provides notice of cancellation more than twelve months in advance, up to $425,000 per batch if notice of cancellation is provided less than 90 days in advance of the scheduled production date of the related batch. Specific prices per batch were established at the time of the agreement and are subject to increases based upon increases in certain cost of living indexes. The agreement may be terminated by either party in the event of a default by the other party, or upon mutual agreement.

In October 2002, Inhibitex entered into a ten-year plasma supply agreement with a supplier. Inhibitex is required to purchase a certain number of liters of plasma per year that shall be agreed upon by both

parties no later than 90 days prior to the beginning of such calendar year. The Company is generally obligated to purchase 90% of the agreed upon quantity in any given year. A price per liter was established at the time of the agreement and is subject to increases based upon increases in certain cost of living indexes and other adjustments. The agreement may be terminated by either party only in the event of a default by the other party, by the Company upon 30 days written notice if the clinical development of Veronate is halted or terminated, or upon mutual agreement. In the event that the supply agreement is terminated, Inhibitex is obligated to purchase the amount of plasma that the supplier had collected on Inhibitex’s behalf, but had not yet shipped, as of the date of termination. The Company has estimated that the amount of plasma subject to this termination obligation approximates 17% of the agreed upon quantity in any given year.

In November 2004, Inhibitex entered into an agreement with Lonza Biologics PLC for the manufacture of Aurexis. Under the terms of the agreement, Lonza has agreed to perform numerous process development related services and manufacture two cGMP lots of Aurexis for our use in future clinical trials. As of December 31, 2004, Inhibitex’s maximum purchase commitments under this agreement through June 30, 2008, were approximately 3.6 million pounds sterling or $6.7 million. However, prior to June 30, 2005 Inhibitex can cancel the second cGMP lot without incurring any financial obligations associated with that lot, in which case Inhibitex’s purchase commitments to Lonza would be reduced. At this time, Inhibitex has not contracted with Lonza to manufacture any additional lots of Aurexis. A change in contract manufacturers for commercial lots may require further clinical trials for Aurexis.

Capital Lease Obligations. In 2002, 2003 and 2004, Inhibitex entered into capital lease transactions related to the acquisition of certain laboratory and other equipment. The amortization of assets acquired under these capital leases has been recorded as depreciation expense. These capital leases bear interest at a rate of 10.2% and expire at various dates from March 2005 to November 2007. In connection with these capital leases, the lessor was granted warrants to purchase 5,071 common shares at exercise price ranges of $6.78 to $9.38 per share. These warrants were recorded at their weighted average estimated fair value of $4.86 per share, using the Black-Scholes method. This amount was recorded as interest expense.

Future payments under capital lease agreements as of December 31, 2004 are as follows:

Notes Payable. In January 1999, Inhibitex entered into a loan and security agreement (the “Security Agreement”) with a financial institution. Under the terms of the Security Agreement, Inhibitex could borrow up to $1,000,000 through December 31, 1999, evidenced by senior secured promissory notes (the “Senior Notes”). In February and June 1999, Inhibitex executed three Senior Notes in the aggregate amount of $447,584 under the Security Agreement. During 2003, two of the Senior Notes were repaid in

full. The outstanding balance of the Senior Notes at December 31, 2003 and 2004 was $15,244 and $0, respectively. The remaining balance was paid in full in April 2004. In conjunction with the Security Agreement, the financial institution received a warrant to purchase 20,000 shares of Series B Redeemable Convertible Preferred Stock at an exercise price of $1.50 per share. Using the Black-Scholes method, the warrant was recorded at its estimated fair value of $0.37 per share, assuming no dividend yield, expected life of four years, risk-free interest rate of 5.64% and volatility of 50%. The principal balance of the related promissory notes was discounted in an amount equal to such value.

In April 1999, the Company issued two promissory notes to a related party in connection with certain leasehold improvements. The notes bear interest at 7% per annum. One note was repaid in full in December 1999. Remaining monthly payments are $3,799 through December 2005, and the outstanding balance as of December 31, 2003 and 2004 was $84,852 and $43,906, respectively. In connection with these promissory notes, the Company issued a warrant to purchase 11,250 shares of Series B Redeemable Convertible Preferred Stock at an exercise price of $1.50 per share. Using the Black-Scholes method, the warrant was recorded at its estimated fair value of $0.59 per share, assuming no dividend yield, an expected life of three years, risk-free interest rate 5.97% and volatility of 50%. The principal balance of the related notes was discounted in an amount equal to such value.

In February 2003, Inhibitex entered into a loan and security agreement (the “Loan Agreement”) with a commercial bank. In June 2003, the Company borrowed $2.5 million under the Loan Agreement (“Term Note”) and paid two interest-only payments in June and July 2003. Beginning August 2003, the Company began to make the first of 36 equal monthly installments of principal of $69,444. The Term Note bears interest at 6.5% per year. The outstanding balance of the Term Note at December 31, 2003 and 2004 was $2,152,778 and $1,319,445, respectively. The Loan Agreement is secured by all unencumbered tangible assets of the Company.

Future minimum payments due under notes payable as of December 31, 2004 are as follows:

In December 2004, the Company entered into an interest-free $2.5 million credit facility with a local development authority for laboratory-related leasehold improvements at the Company’s new research and headquarters facility. As of December 31, 2004 no amounts were outstanding under this facility.

At December 31, 2003 and 2004, Inhibitex had available net operating loss (“NOL”) carry forwards of approximately $58.9 million, and $84.9 million, respectively, which will begin to expire in the year 2019. A portion of the Company’s existing NOL carryforwards relates to exercises of non-qualified stock options. The tax benefit of which; when utilized, will be recorded as an increase to shareholder equity. Inhibitex also has approximately $657,000 and $866,000 of research and development (“R&D”) tax credit carry forwards as of December 31, 2003 and 2004, respectively. The NOL and R&D tax credit carry forwards are available to offset future income taxes payable, if any. The Tax Reform Act of 1986 contains provisions that may limit NOL and R&D tax credit carry forwards available for use in any given year in the event of significant changes in ownership interests, as defined.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of Inhibitex’s deferred tax asset are as follows:

For financial reporting purposes, SFAS No. 109 requires that a valuation allowance be recorded to reduce the balance of deferred income tax assets if it is more likely than not that some portion or all of the deferred income tax assets will not be realized in the future. Inhibitex has established a full valuation allowance equal to the amount of its deferred tax asset due to uncertainties with respect to the Company’s ability to generate sufficient taxable income in the future. The valuation allowance increased by $10,034,300 from December 31, 2003 to December 31, 2004.

The following table outlines redeemable convertible preferred stock and related warrants as of December 31, 2002 and 2004, including its conversion to common stock as of June 3, 2004:

During 1997, the Company issued 644,340 shares of Series B Redeemable Convertible Preferred Stock (“Series B”) for $750,012 in cash. During 1998, the Company issued an additional 1,644,330 shares of Series B for $2,250,000 in cash.

In April and June 2000, the Company issued an aggregate of 2,300,329 shares of Series C Redeemable Convertible Preferred Stock (“Series C”) for total consideration of $6,555,938, which included the conversion of $2,000,000 in bridge loans, accrued interest of $124,576, and cash proceeds of $4,431,365. In October and November 2000, the Company sold an additional 3,275,911 shares of Series C for total cash consideration of $9,336,346.

In February, March and April 2002, the Company issued an aggregate of 11,420,794 shares of Series D Redeemable Convertible Preferred Stock (“Series D”) and warrants to purchase 2,855,200 shares of Series D for total cash consideration of $44,997,928. Net proceeds to the Company, after legal and other issuance costs, were $44,746,579. The total proceeds were allocated between Series D and the related warrants based on their relative fair values. The amount allocated to the warrants was $4,140,040, which was recorded as a discount to Series D. This discount is being accreted to the Series D on a straight-line basis through April 6, 2006, the date that Series D becomes redeemable. The accretion is recorded in the statement of operations to arrive at the net loss attributable to common stockholders.

In connection with the Series D financing, in February 2002 the Board of Directors approved three additional series of preferred stock Series B-1 Convertible Preferred Stock (the “Series B-1”), Series C-1 Convertible Preferred Stock (the “Series C-1”), and Series D-1 Convertible Preferred Stock (the “Series D-1”). The Company is authorized to issue up to 2,600,000 shares of Series B-1, 8,000,000 shares of Series C-1 and 17,500,000 shares of Series D-1. Series B-1, Series C-1 and Series D-1 have the same

rights and preferences as the Series B, Series C and Series D, respectively, except for certain provisions relating to anti-dilution rights and rights of first refusal with respect to additional issuances of equity securities. No shares of this series of preferred stock were outstanding as of December 31, 2002, 2003, and 2004.

In December 2003, the Company issued an aggregate of 5,087,740 shares of Series E Redeemable Convertible Preferred Stock (“Series E”) and warrants to purchase 1,271,930 shares of Series E for total cash consideration of $20,045,696. Net proceeds to the Company, after legal and other issuance costs, were $19,972,511. Of this amount, $1,499,997 was recorded as a subscription receivable at December 31, 2003, as these proceeds were not received by the Company until January 5, 2004. The total proceeds were allocated between Series E and the related warrants based on their relative fair values. The amount allocated to the warrants was $1,806,141, which was recorded as a discount to Series E. This discount is being accreted to Series E on a straight-line basis through April 6, 2006, the date the Series E becomes redeemable. The accretion is recorded in the statement of operations to arrive at the net loss attributable to common stockholders.

In connection with the Series E financing, in December 2003 the Board of Directors approved an additional series of preferred stock, Series E-1 Convertible Preferred Stock (the “Series E-1”). The Company is authorized to issue up to 9,600,000 shares of Series E and Series E-1. Series E-1 has the same rights and preferences as Series E, except for certain provisions relating to anti-dilution rights and rights of first refusal with respect to additional issuances of equity securities. No shares of this series of preferred stock were outstanding as of December 31, 2002, 2003 and 2004.

Voting Rights. All holders of redeemable convertible preferred stock have voting rights equal to the number of shares of common stock into which the respective preferred stock is convertible.

Dividends. Dividends on Series B are payable when and as declared by the Board of Directors. Dividends on Series C and D are cumulative and accrue at the rate of 8% per annum from the date of issuance through the earlier of: (i) the date on which the liquidation value is paid in connection with the liquidation of the Company or redemption of such shares; (ii) the date on which such shares are converted, or (iii) the date on which such shares are otherwise acquired by the Company. Dividends on Series C and D are also convertible into shares of Series C and D at their respective liquidation values per share. All dividends have been accrued and included in the carrying value of the respective redeemable convertible preferred stock in the accompanying balance sheets. As of December 31, 2003, the Company had accrued cumulative preferred stock dividends of $11,064,505, which were convertible into 1,354,279 of preferred stock, respectively. As of December 31, 2004 the outstanding shares of preferred stock, and accrued dividends thereon, were converted into common stock upon the initial public offering. No dividends have been declared by the Board of Directors, or paid by the Company.

Liquidation. Upon a liquidation event, which includes a liquidation, dissolution, winding-up of the Company, or a merger, consolidation or reorganization of the Company that results in the transfer of 50% or more of the outstanding voting power of the Company or a sale of substantially all the assets of the Company, the holders of Series B, Series C, Series D and Series E are entitled to, prior and in preference to any other stockholders, a liquidation preference distribution of their respective liquidation values plus all accrued but unpaid dividends or if greater, the amount per share as would have been payable had each share of preferred stock been converted in the Company’s common stock prior to a liquidation event. The liquidation value of Series B issued before July 2, 1998 and on or after July 2, 1998 is $1.164 and $1.50 per share, respectively. The liquidation value of Series C issued on or before June 8, 2000 and after June 8, 2000 is $5.70 and $2.85 per share, respectively. The liquidation value of Series D and E is

$3.94 per share. The following table summarizes the liquidations preferences of convertible redeemable preferred stock:

Conversion. The holders of Series B, Series C, Series D, and Series E may convert at any time shares of their preferred stock into common stock on a one-for-one basis subject to certain adjustments including dilutive issuances, adjustments or splits, as defined. Upon the effectuation of the 1-for-2.38 reverse stock split, the conversion ratio of Series B, Series C, Series D, and Series E was adjusted to approximately 0.42 shares of common stock for each share of redeemable convertible preferred stock. As of June 3, 2004 the outstanding shares of preferred stock were converted into common stock upon the initial public offering.

Redemption. At any time after April 6, 2006, the holders of Series B, Series C, Series D and Series E have the option to require Inhibitex to redeem any or all of their respective outstanding shares of redeemable preferred stock. If so elected, the redemption price for each share of preferred stock is the original purchase price paid for such stock as adjusted for stock splits, stock dividends, or other recapitalizations, plus all accrued but unpaid dividends. Prior to the Series E financing in December 2003, the holders of Series B, Series C and Series D could redeem their preferred stock at any time after April 6, 2005. As of June 3, 2004 the outstanding shares of preferred stock were converted into common stock upon the initial public offering.

Preferred Stock Warrants. The preferred stock issuable upon the exercise of outstanding warrants to purchase shares of the Company’s redeemable convertible preferred stock shall convert into common stock based upon a conversion rate of one to one, adjusted for the 1-for-2.38 reverse stock split. The warrants were converted to common stock warrants upon the Company’s initial public offering on June 3, 2004.

The following table outlines outstanding warrants to purchase preferred stock at December 31, 2003.

Warrants to purchase shares of redeemable preferred stock issued in connection with notes payable and capital leases are described in Note 7.

In connection with bridge loans provided to the Company in March and August 1999, the Company issued warrants to purchase a total of 170,000 shares of Series B at an exercise price of $1.50 per share. The warrants became exercisable on December 31, 1999 and expire on June 19, 2004. Using the Black-Scholes

method, the warrants have been recorded at their estimated fair value of $0.53 to $0.59 per share, assuming no dividend yield, risk-free rates ranging from 5.19% to 5.97%, expected life of three years and volatility of 50%.

In connection with another bridge loan provided to the Company in March 2000, the Company issued warrants to purchase a total of 40,000 shares of Series B at an exercise price of $1.50 per share. The warrants became exercisable on May 15, 2000 and expire on June 19, 2004. Using the Black-Scholes method, the warrants have been recorded at their estimated fair value of $0.69 per share, assuming no dividend yield, risk-free interest rate of 6.43%, expected life of four years and volatility of 50%.

In connection with the issuance of shares of Series D in February, March and April 2002, the Company issued warrants to purchase 2,855,200 shares of Series D at an exercise price of $5.91 per share. The warrants may be exercised at any time by the holders through February 7, 2007. The warrants have been recorded at their estimated fair value of $1.45 per share using the Black-Scholes method assuming no dividend yield, risk-free interest rate of 4.3%, expected life of five years, and volatility of 50%. The Series D was discounted by an amount equal to such value.

In connection with the issuance of Series E in December 2003, the Company issued warrants to purchase a total of 1,271,930 shares of Series E at an exercise price of $5.91 per share. The warrants may be exercised at any time through December 19, 2008. The warrants have been recorded at their estimated fair value of $1.42 per share using the Black-Scholes method assuming no dividend yield, risk-free interest rate of 3.7%, expected life of five years, and volatility of 50%. The Series E was discounted by an amount equal to such value.

During the years ended December 31, 2002, 2003 and 2004 the Company recorded aggregate accretion related to warrants and preferred dividends of $5,625,804, $6,201,116 and $2,823,160, respectively.

Convertible Preferred Stock. On January 3, 1996, the Company issued 216,000 shares of Series A Preferred Stock (“Series A”) for total consideration of $540,000, which included the conversion of a $220,000 bridge loan and $320,000 in cash consideration (the “Series A Financing”).

Series A is convertible into common stock at the option of the holder, or automatically upon the completion of a qualified initial public offering of the Company’s common stock. The initial conversion rate for Series A is one to one, which is to be adjusted in the event of a subdivision or combination of the stock or a reorganization, dividend, consolidation, merger or sale of the Company or sale of additional shares of common stock for consideration less than the original purchase price of the Series A. The Series A conversion rate was adjusted to 0.42 shares of common stock for each share of Series A, upon effectuation of the 1-for-2.38 reverse stock split. Dividends on Series A are payable when and as declared by the Board of Directors. In the event of a liquidation of the Company, the Series A stockholders are entitled to receive, prior to and in preference to the common stockholders, an amount equal to the Series A liquidation value. The liquidation value of Series A shares is $1.164 per share plus all declared and accrued but unpaid dividends. As of December 31, 2003 the liquidation value was $251,424. The holders of Series A have voting rights equal to the number of shares of common stock into which the shares are convertible. The holders of Series A and common stock (voting as a class) may elect one director. As of June 3, 2004, outstanding shares of Series A were converted into common stock upon the initial public offering.

Common Stock. As of December 31, 2003 and December 31, 2004, the Company is authorized to issue 43,100,000, and 75,000,0000 shares of common stock, respectively. Each holder of common stock is

entitled to one vote for each share of common stock held of record on all matters on which stockholders generally are entitled to vote.

Our Board of Directors adopted, and our stockholders approved as of February 20, 2004, our 2004 Employee Stock Purchase Plan, or the Purchase Plan. The purpose of the Purchase Plan is to provide an opportunity for our employees to purchase a proprietary interest in us. The Purchase Plan is administered by a committee appointed by the Board of Directors for such purpose. The Board of Directors has appointed our compensation committee to administer the Purchase Plan. A total of 210,084 shares of common stock are authorized for issuance under the Purchase Plan as of December 31, 2004. Employees who are customarily employed for more than 20 hours per week and for more than five months in any calendar year and have been so employed for a six-month period are eligible to participate in the Purchase Plan. Employees who would own 5% or more of the total combined voting power or value of all classes of our stock immediately after the grant may not participate in the purchase plan. The Purchase Plan is intended to qualify under Section 423 of the Internal Revenue Code and provides for quarterly purchase periods. The first such purchase period commenced on October 1, 2004 and will end on December 31, 2004. The Purchase Plan permits participants to purchase common stock through payroll deductions of up to 25% of their eligible base salary. For any calendar year, a participant may not be granted rights to purchase shares to the extent the fair market value of such shares exceeds $25,000. Amounts deducted and accumulated by the participant are used to purchase shares of our common stock at the end of each quarterly purchase period. The purchase price per share is 85% of the lower of the fair market value of our common stock at the beginning of a purchase period or at the end of a purchase period. An employee’s participation ends automatically upon termination of employment with us. A participant may not transfer rights to purchase our common stock under the Purchase Plan other than by will or the laws of descent and distribution. In the event of a change of control, no further shares shall be available under the Purchase Plan, but all payroll deductions scheduled for collection in that purchase period will be immediately applied to purchase whole shares of our common stock. Our Board of Directors has the authority to amend or terminate the Purchase Plan, except that, subject to certain exceptions described in the Purchase Plan, no such action may adversely affect any outstanding rights to purchase stock under the Purchase Plan and the Board of Directors may not increase the number of shares available under the Purchase Plan, or amend the requirements as to the eligible class of employees, without stockholder approval.

On June 3, 2004, Inhibitex completed an initial public offering (IPO) of five million shares of its common stock at an initial offering price to the public of $7.00 per share, resulting in net proceeds of $30.8 million after deducting underwriters’ commissions and related expenses. Upon the closing of the IPO, all outstanding shares of preferred stock, and accrued dividends thereon, were converted into 11,936,438 shares of common stock. On July 8, 2004 in connection with the underwriters’ exercise of the over-allotment option on the IPO, an additional 527,000 shares of common stock were issued at an initial offering price to the public of $7.00 per share, resulting in net proceeds of $3.0 million after deducting underwriters’ commissions and related expenses.

On November 10, 2004, the Company completed a private placement in public entity or PIPE financing in which it raised $47.7 million in net proceeds through the sale, at a price of $7.3775 per share, of 6,777,370 shares of its common stock and warrants to purchase 2,033,211 shares of its common stock. The warrants, which become exercisable on May 9, 2005 and expire November 10, 2009, have an exercise price of $8.81 per share. The shares and warrants were offered and sold only to institutional and accredited investors. The Company filed a registration statement with the SEC in order to register the sale and resale of the common stock issued in the PIPE, and issuable upon the exercise of the related warrants.

1998 Equity Ownership Plan. In May 1998, the Board of Directors approved the 1998 Equity Ownership Plan (the “Plan”), which provided for the grant of stock options to directors, officers, employees and consultants. Under the Plan, both incentive stock options and non-qualified stock options, among other equity related awards, could be granted. The Board of Directors determined the term and vesting dates of all options at their grant date, provided that such price shall not be less than the fair market value of the Company’s stock on the date of grant. Under the Plan, the maximum term for an option grant is 10 years from the grant date, and options generally vest ratably over a period of four years from the grant date. As of December 31, 2003 and 2004, there were 421,023 and 188,262 options outstanding under the Plan to purchase the Company’s common stock, respectively. Upon the adoption of the 2002 Stock Incentive Plan (“2002 Plan”) as discussed below, no additional grants of stock options or equity awards were authorized under the 1998 Equity Ownership Plan. All options outstanding under the Plan will remain in full force and effect until they expire or are exercised. However, future forfeitures of any stock options granted under the 1998 Equity Ownership Plan are added to the number of shares available under the 2002 Plan.

2004 Stock Incentive Plan and 2002 Non-Employee Directors Stock Option Plan. In February 2002, the Board of Directors approved the 2002 Plan, which provided for the grant of incentive stock options, non-qualified stock options and other equity related awards to employees, contractors and consultants of the Company. At that time, the Company also adopted the 2002 Non-Employee Directors Stock Option Plan (the “Director Plan”) which provided for the grant of non-qualified stock options and other equity related awards to non-employee members of the Board of Directors. On February 20, 2004, the Board of Directors amended the 2002 Plan and the Director Plan, whereby the 2002 Plan was renamed the 2004 Stock Incentive Plan (the “2004 Plan”). The 2004 Plan was further modified to provide for option grants to non-employee directors and 1,420,180 shares of common stock were added to the number of reserved shares. Upon the adoption of the 2004 Plan, no further options were authorized to be granted under the Director Plan.

The 2004 Plan and the Director Plan are administered by the compensation committee of the Board of Directors, which has the authority to select the individuals to whom awards are to be granted, the number of shares granted, and the vesting schedule. As of December 31, 2004, an aggregate of 2,476,463 shares of common stock were reserved for issuance under the 2004 Plan and the Director Plan, respectively. Under the 2004 Plan and Director Plan, the maximum term for an option grant is ten and six years from the grant date, respectively. Options granted under the 2004 Plan and Director Plan generally vest ratably over

a period of four years and three years, respectively, from the grant date. As of December 31, 2003, there were 867,007 outstanding options to purchase the Company’s common stock and 207,197 options available for grant under the 2004 Plan. As of December 31, 2004, there were 1,080,872 outstanding options to purchase the Company’s common stock and 1,395,591 options available for grant under the 2004 Plan. As of December 31, 2003 and 2004, there were 50,422 and 66,804 outstanding options to purchase the Company’s common stock and 54,622 and no options available for grant under the Director Plan, respectively.

The following is a summary of all stock option activity and related information related to all the Company’s stock option plans, and 35,000 shares issued outside these plans, from inception of such plans through the period ended December 31, 2004:

The following tables summarize information relating to outstanding and exercisable options as of December 31, 2004:

The Company applies the measurement principles of APB No. 25 in accounting for stock options granted to its employees and directors.

As of December 31, 2004 the Company has entered into a number of license and collaborative agreements with various institutions to obtain intellectual property rights and patents relating to MSCRAMM proteins, and its product candidates. Inhibitex has also entered into an exclusive worldwide license and collaboration agreement with Wyeth with respect to its use of the MSCRAMM proteins to develop staphylococcal vaccines. The significant arrangements are described further below.

Texas A&M University Health Science Center. Inhibitex has licensed, on an exclusive basis, from the Texas A&M University System a number of issued United States patents, related United States divisional applications and foreign counterpart applications directed to one of the MSCRAMM proteins that the Company’s lead product candidate, Veronate, targets. Texas A&M may terminate the license if the Company fails to use commercially reasonable efforts to bring product candidates to market. Inhibitex may terminate the license without cause upon 60 days written notice. Otherwise, this agreement will terminate upon the expiration of all of the licensed patents. Currently, the latest to expire of the issued patents under the license agreement expires in 2019. The Company has agreed to pay Texas A&M a royalty based on net sales for any products sold utilizing these patents. Pursuant to these agreements, the Company has paid Texas A&M approximately $1.3 million of sponsored research payments as of December 31, 2004. The Company has no future minimum royalty or milestone obligations pursuant to these agreements. However, if the Company does not continue to pay sponsored research payments to Texas A&M, it will be obligated to pay a minimum royalty of $25,000 annually. The Company’s obligation to pay sponsored research payments terminates in November 2005.

BioResearch Ireland (BRI)/Trinity College Dublin. Inhibitex has also obtained a license from BioResearch Ireland (“BRI”) under certain patents and related applications licensed to it from Texas A&M, as described above. Scientists from both Texas A&M and BRI are co-inventors on these applications. The license also covers pending international applications. BRI may terminate the license if Inhibitex fails to use commercially reasonable efforts to bring one or more products that use the licensed technology to market. Otherwise, this license will terminate upon the expiration of the licensed patents.

Currently, the latest to expire of the issued patents under the license agreement expires in 2019. BRI is entitled to a royalty on the net sales of products sold utilizing these patents. Pursuant to these agreements, the Company has paid BRI approximately $382,000 through December 31, 2004. The Company has no future minimum royalty or milestone obligations pursuant to these agreements.

Wyeth. In August 2001, Inhibitex entered into an exclusive worldwide license and development collaboration agreement with Wyeth for the development of staphylococcal vaccines for humans. Under the terms of this agreement, Inhibitex granted Wyeth an exclusive worldwide license to its MSCRAMM protein intellectual property with respect to human vaccines against staphylococcal organisms. The development, manufacture and sale of any products resulting from the collaboration are the responsibility of Wyeth. Inhibitex may terminate the agreement if Wyeth fails to use reasonable commercial efforts to bring related products to market. Wyeth may terminate the agreement, without cause, upon six months notice. Otherwise, this agreement will terminate upon the expiration of all of the licensed patents. Currently, the latest to expire of the issued patents under the license agreement expires in 2019.

Pursuant to this agreement, Inhibitex has received $3.8 million in an upfront license fee and annual research support payments from Wyeth as of December 31, 2004. The Company is also entitled to receive milestones upon the filing of an IND, the commencement of both Phase II and Phase III clinical trials, the filing of a BLA, and FDA approval of a licensed product. If all such milestones are achieved relative to one or more licensed products, the Company would be entitled to receive a minimum of $10.0 million in milestone payments from Wyeth. The maximum milestone payments the Company could receive with respect to all licensed products are $15.5 million. Finally, the Company is also entitled to royalties on net sales of licensed products manufactured, sold or distributed by Wyeth.

In October 2004, Inhibitex entered into a collaboration agreement with Dyax Corp. to co-develop monoclonal antibodies to prevent or treat serious infections caused by enterococci. Under the terms of the agreement, Inhibitex and Dyax have agreed to collaborate and share in the costs to perform preclinical research and development activities intended to identify and select a fully human monoclonal antibody, or antibodies, against MSCRAMM proteins located on the surface of enterococci, that Inhibitex and Dyax would jointly advance into clinical trials. During this preclinical phase, Inhibitex and Dyax are only responsible for our respective internal development costs. Accordingly, neither party is responsible to make any upfront payments to the other party, nor is either party obligated to make future milestone or royalty payments to the other party at this time. Inhibitex’s internal development costs are expected to consist largely of salaries and other personnel-related costs associated with existing employees, certain supplies; and other costs, such as travel and entertainment, associated with supporting existing employees. If at the end of the collaborative preclinical development activities, Inhibitex and Dyax mutually agree to advance one or more human monoclonal antibodies into clinical trials, Inhibitex and Dyax will continue to share in the clinical development costs of any such product candidates. The agreement also contemplates that Inhibitex and Dyax would share in the commercialization rights and profits from any approved and marketed products resulting from the collaboration. In the event that the parties mutually agree that the collaboration has been unable to identify a suitable monoclonal antibody to advance into clinical development, the collaboration agreement will immediately and automatically terminate without any further obligations to either party. Otherwise, this agreement can only be terminated during the initial preclinical development phase upon the mutual consent of both parties, or by one party in the event that the other party has committed a material breach, or filed for insolvency or bankruptcy.

Other Agreements. The following five agreements relate to intellectual property associated with the production of monoclonal antibodies that the Company has in-licensed.

In November 2001, Inhibitex entered into a research evaluation and worldwide non-exclusive license agreement with Lonza Biologics for intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis. Under the terms of the agreement, Inhibitex agreed to pay an annual fee and a royalty on the net sales of any products that it may sell that utilize this technology. Inhibitex may terminate the agreement upon 60 days notice. The agreement terminates upon the expiration of the last valid patent or 15 years, whichever is longer. Currently, the latest to expire of the issued patents under the license agreement expires in 2016. Pursuant to this agreement, the Company has paid Lonza $693,000 as of December 31, 2004.

In June 2003, Inhibitex obtained a non-exclusive, worldwide royalty-bearing license from Genentech for a patent relating to the production of monoclonal antibodies for use in the manufacture of Aurexis. Under the agreement, the Company agreed to pay Genentech an up-front license fee and it is further obligated to pay a milestone payment upon the approval of Aurexis and a royalty on the sale of any of its products that utilize the underlying technology. Inhibitex may terminate this agreement without cause upon 90 days notice. Otherwise, this license will terminate upon the expiration of the patent, which will occur in 2018 if not extended. Pursuant to this agreement, the Company has paid $500,000 to Genentech as of December 31, 2004. The Company’s aggregate future payments under this agreement are $5.0 million, of which most is payable if Aurexis is approved for sale by the FDA.

In July 2003, Inhibitex obtained a non-exclusive, worldwide royalty-bearing license from the University of Iowa for patents relating to technology used in the expression of recombinant proteins for use in the manufacture of Aurexis. Under this agreement, the Company has paid the University of Iowa an up-front license fee of $35,000 and it is obligated to make annual payments of $35,000 per year. The Company also agreed to pay a milestone payment of $40,000 for each of the first four license related products to receive FDA approval and a royalty on the sale of any of its products that utilize the underlying technology. The Company may terminate this agreement at any time. Otherwise, this license will terminate upon the expiration of the patents, which will be 2009 and 2012, respectively.

In March 2004, the Company obtained a non-exclusive, worldwide royalty bearing license from the National Institutes of Health (NIH) for patent applications relating to the humanization of monoclonal antibodies. Under this agreement, the Company agreed to pay an up-front license fee, a minimum annual royalty of $25,000 per year, milestone payments and a royalty on the sale of any of its products that would otherwise infringe any patent that may issue from the pending applications. For any product covered by this license, the milestone payments are based upon the filing of an IND, the first subject enrolled in a Phase II and Phase III trial, the filing of a BLA and upon the approval of a BLA by the FDA. The Company may terminate this agreement upon 60 days notice. Otherwise, this agreement terminates upon the expiration of the patent, which will occur in 2011 if not extended. Pursuant to this agreement, the Company has paid $259,000 to the NIH as of December 31, 2004. If Aurexis is approved for sale by the FDA, the Company’s total future payments to the NIH under this agreement related to the up-front license fee and milestone payments would be approximately $900,000 in the aggregate.

In April 2004, the Company obtained an exclusive, worldwide royalty bearing license from the Biostapro AB for patent applications relating to the staphylococcal proteins. Under this agreement, the Company agreed to pay an up-front license fee, a milestone payment, and a royalty on the net sale of products utilizing the underlying technology. The milestone payment is based on the marketing approval of a BLA by the FDA. The Company may terminate this agreement upon 90 days notice. Otherwise, this agreement terminates upon the expiration of the patent. Pursuant to this agreement, the Company has paid $350,000 to the Biostapro AB as of December 31, 2004. The Company’s aggregate future payments under this agreement are $800,000.

Inhibitex sponsors a 401(k) plan for the benefit of its employees that is a defined contribution plan intended to qualify under Section 401(a) of the Internal Revenue Code of 1986, as amended. Eligible employees may make pre-tax contributions to the 401(k) plan of up to 20% of their eligible earnings, subject to the statutorily prescribed annual limit. The 401(k) plan permits the Company to make discretionary matching and profit sharing contributions. The Company’s contributions to the plan were approximately, $112,000, $108,000 and $138,000 in 2002, 2003 and 2004, respectively. Under the 401(k) plan, each employee is fully vested in his or her deferred salary contributions. The Company’s contributions vest over a three-year period.

The following table presents unaudited quarterly financial data of the Company. The Company’s quarterly results of operations for these periods are not necessarily indicative of future results.

Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90 days from the date of acquisition. Inhibitex has invested in corporate notes and commercial paper, all of which have a minimum investment rating of A1/P1, and government agency notes. Inhibitex had no realized gains or losses from the sale of investments for the years ended December 31, 2004 and 2003. The cumulative unrealized (loss) gains were $(14,086) and $(1,579) at December 31, 2004 and 2003, respectively. The following table summarizes the estimated fair value of Inhibitex’s short-term investments:

All available-for-sale securities held at December 31, 2004 will mature during 2005.


Year Ending December 31, 2004:	High		Low

Second quarter (From June 4, 2004)	$	7.75	$	7.00
Third quarter	$	7.66	$	4.80
Fourth quarter	$	12.76	$	4.92


			Period
			from Inception
			(May 13, 1994)
			through			Years Ended December 31,
			December 31,
			2004			2000			2001			2002			2003			2004


			(In thousands, except per share data)
Statement of Operations Data:
Revenue			$	3,812		$	634		$	271		$	900		$	1,096		$	650
Operating expenses:
	Research and development			75,039			5,864			7,099			15,615			18,991			22,581
	General and administrative			16,303			1,121			1,847			3,328			4,581			4,040
	Amortization of deferred stock compensation			649			—			—			—			176			473

		Total operating expenses		91,991			6,985			8,946			18,943			23,748			27,094

		Loss from operations		(88,179	)		(6,351	)		(8,675	)		(18,043	)		(22,652	)		(26,444	)
Interest and other income (expense), net				1,606			(112	)		568			430			319			532

Net loss				(86,573	)		(6,463	)		(8,107	)		(17,613	)		(22,333	)		(25,912	)
Dividends and accretion to redemption value of redeemable preferred stock				(16,382	)		(461	)		(1,271	)		(5,626	)		(6,201	)		(2,823	)

Net loss attributable to common stockholders			$	(102,955	)	$	(6,924	)	$	(9,378	)	$	(23,239	)	$	(28,534	)	$	(28,735	)

Basic and diluted net loss attributable to common stockholders per share						$	(16.85	)	$	(21.17	)	$	(47.83	)	$	(54.19	)	$	(2.52	)

Pro forma basic and diluted net loss attributable to common stockholders per share (unaudited)(1)															$	(2.81	)

Weighted average shares used to compute basic and diluted net loss attributable to common stockholders per share							410,945			442,980			485,842			526,578			11,416,354

Pro forma weighted average shares used to compute basic and diluted net loss attributable to common stockholders per share (unaudited)(1)																10,145,137



	As of December 31,

	2000			2001			2002			2003			2004

Balance Sheet Data:
Cash and cash equivalents	$	7,982		$	1,404		$	28,658		$	26,649		$	71,581
Short-term investments		—			—			1,000			1,499			15,624
Working capital (deficit)		5,737			(1,360	)		25,838			23,529			79,560
Total assets		9,708			3,622			31,942			30,662			91,239
Long-term debt and capital leases, less current portion		387			572			459			1,795			807
Redeemable convertible preferred stock and warrants		19,276			20,558			70,934			95,608			—
Deficit accumulated during the development stage		(13,070	)		(22,448	)		(45,686	)		(74,220	)		(102,955	)
Total stockholders’ (deficit) equity		(12,304	)		(21,666	)		(44,886	)		(73,226	)		80,546



			Years Ended December 31,

			2002		2003		2004


			(In thousands)
Direct external costs:
	Veronate		$	6,277	$	7,620	$	8,851
	Aurexis			1,472		2,586		3,120
Unallocated costs and overhead				7,866		8,785		10,610

		Total research and development expenses	$	15,615	$	18,991	$	22,581



	December 31,

	2004		2003


	(In thousands)
Clinical and manufacturing related expenses	$	12,295	$	9,846
Personnel-related salaries and expenses		5,308		4,583
License fees and other expenses		3,496		3,070
Depreciation and facility related expenses		1,482		1,492

Total research and development expense	$	22,581	$	18,991


	Page

Prospectus Summary		1
Risk Factors		3
Special Note on Forward-Looking Statements		16
Use of Proceeds		17
Price Range of Common Stock		18
Selected Financial Data		19
Management’s Discussion and Analysis of Financial Condition and Results of Operations		21
Business		32
Management		52
Related Party Transactions		64
Principal Stockholders		67
Description of Capital Stock		70
Selling Stockholders		73
Plan of Distribution		76
Legal Matters		77
Experts		78
Where You Can Find More Information		78
Index to Financial Statements		F-1


•	complete the ongoing Phase III clinical trial and obtain regulatory approval for Veronate;

•	advance the development of Aurexis, in one or more indications, and our other preclinical product candidates;

•	establish a specialized, hospital-based sales force in the United States to sell Veronate and potentially our other product candidates;

•	utilize our expertise in MSCRAMM proteins to discover and develop additional first-in-class product candidates; and

•	expand our product portfolio through in-licensing and acquisitions.


	We depend heavily on the success of our lead product candidate, Veronate, which is still in clinical development. If we are unable to successfully develop or commercialize Veronate, or experience significant delays in doing so, our business could be materially harmed.


	*No antibody-based products that target MSCRAMM proteins have been developed or approved.*


	*If the clinical trials for our product candidates are unsuccessful or delayed, we could be delayed or precluded from further developing or ultimately selling our product candidates.*


	*We must comply with extensive government regulations in order to obtain and maintain marketing approval for our products in the United States and abroad.*


	If third-party vendors upon whom we rely to conduct our clinical trials do not perform or fail to comply with strict regulations, the clinical trials for our product candidates may be terminated, delayed, or unsuccessful.


	If third-party suppliers upon whom we rely or may rely to provide us with the critical raw material for Veronate do not perform or fail to comply with strict regulations, our clinical trials for, and the commercialization of, Veronate could be terminated, delayed, or adversely affected.


	If third-party contract manufacturers, upon whom we rely to manufacture our product candidates do not perform, fail to manufacture according to our specifications or fail to comply with strict regulations, our clinical trials and the commercialization of our products could be terminated, delayed, or adversely affected.


	Our third-party contract manufacturer for Veronate is a potential competitor. If we fail to maintain or renew our manufacturing agreement with this manufacturer, the development and commercialization of Veronate could be delayed or adversely affected.


	*We have experienced losses since our inception. We expect to continue to incur such losses for the foreseeable future and we may never become profitable.*


	*We may be forced to delay or curtail the development or commercialization of our product candidates if we are unable to obtain additional funding.*


	*We may be unable to successfully develop or commercialize product candidates that are the subject of collaborations if our collaborators do not perform.*


	If we are unable to attract and retain key employees, advisors or consultants, we may be unable to successfully develop and commercialize our product candidates or otherwise manage our business effectively and the price of our common stock may be adversely affected.


	Our industry is highly competitive and subject to rapid technological changes. As a result we may be unable to compete successfully or develop innovative products, which could harm our business.


	Most of our product candidates target Orphan Drug indications. If we fail to obtain approval for an Orphan Drug indication before one of our competitors does, we may be prevented from selling our products for a period of time.


	*If our products do not gain meaningful acceptance in their intended markets, we are not likely to generate significant revenues or become profitable.*


	*If we are unable to adequately protect our intellectual property, our business prospects could be harmed.*


	If a third party claims we are infringing on its intellectual property rights, we could incur significant litigation or licensing expenses, or be prevented from further developing or commercializing our products.


	If we fail to establish marketing and sales capabilities or fail to enter into effective sales, marketing and distribution arrangements with third parties, we may not be able to successfully commercialize our products.


	*If government and third-party payers fail to provide coverage and adequate reimbursement rates for our products, our revenues and potential for profitability will be harmed.*


	Veronate is a blood product derived from human plasma. The administration of blood products could result in the transmission of infectious diseases that could prevent us from selling Veronate or expose us to liability.


	*If a product liability claim is successfully brought against us for uninsured liabilities or exceeds our insurance coverage, we could be forced to pay substantial damage awards.*


	*Our revenues, expenses and results of operations will be subject to significant fluctuations, which will make it difficult to compare our operating results from period to period.*


	*If we succeed in implementing our strategy, we may encounter difficulties in managing our growth and expanding our operations successfully.*


	*If our use of hazardous materials results in contamination or injury, we could suffer significant financial loss.*


	*Our common stock price has been highly volatile, and your investment could suffer a decline in value.*


•	changes in accounting principles; and

•	general economic conditions.


	*If we raise additional capital in the future, your ownership in us could be diluted.*


	*Future sales of shares of our common stock may cause our stock price to decline, even if our business is doing well.*